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Infections with the bacterial pathogen Chlamydia trachomatis are a critical public health 
problem. Chlamydia remains the number one cause of preventable blindness worldwide and the 
leading cause of bacterial sexually transmitted infections in the United States. In humans, 
repeat and persistent infections with Chlamydia result in severe inflammation. Inflammation in 
the conjunctiva can result in blindness, while inflammation in the genital tract can result in pelvic 
inflammatory disease, ectopic pregnancy or infertility. In order to curb the increasing incidence 
of Chlamydia infections worldwide it will be necessary to develop a protective vaccine that 
affords long-term protection and prevents pathologies. To better inform vaccine development we 
must understand the mechanisms that drive long-term immunity in the genital tract and 
elucidate critical interactions between Chlamydia and host cells to uncover potential 
mechanisms of immune evasion.  
This dissertation is focused on understanding interactions between Chlamydia 
trachomatis and its host while leveraging those finding for future therapeutic intervention. First, 
using a novel infection model I characterized mechanisms that afford long-lived protection in the 
genital mucosa following C. trachomatis infection. These studies identified that CD4+ T cells are 
necessary and sufficient to protect mice from C. trachomatis infection. I further examined the 
migration of CD4+ T cells to the genital mucosa and discovered that the integrin α4β1 and the 
chemokine receptors CXCR3 and CCR5 are all required for the efficient recruitment of 
Chlamydia-specific T cells to the genital mucosa to mediate protection. Because immunity to 
Chlamydia in humans has been shown to be short-lived I next characterized how Chlamydia 
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may actively evade the host immune response. Using both proteomic and genomic approaches 
I identified hundreds of human proteins that are altered during Chlamydia infection. Using gain-
of-function and loss-of-function approaches I next identified host pathways and proteins that are 
also required for efficient intracellular Chlamydia development and can be targeted by small 
molecules. Together the approaches described here characterize mechanisms that drive long-
lived protective immunity in the genital mucosa, and elucidate virulence strategies employed by 
the Chlamydia to avoid clearance. These findings can now be used to better inform vaccine 
development and eradicate this costly disease.  	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The balance of host-pathogen interactions 
 Interactions with the world around us have strongly influenced human evolution (1). 
Nowhere is this more apparent than in studies examining the influence of bacteria on 
fundamental human processes (2). Bacteria outnumber cells in the human body by ten-fold, 
which alone highlights the constant interactions between people and microbes (3). Recent 
studies suggest that the proper balance of commensal bacteria is critical for the acquisition of 
nutrients, immune development, and more (4, 5). Unfortunately, while the majority of bacteria 
are relatively harmless to humans, history has shown that pathogenic bacteria, which disrupt the 
normal balance of host interactions, can lead to devastating diseases (6).  
When humans encounter bacterial pathogens, it is the job of the immune system to 
sense these dangers, to activate the proper defenses, and to clear the infections with the least 
harm to the host. This results in the development of memory, which protects against future 
infections. Our standard view of infections and immunity usually is associated with acute 
pathogens (7). Infection with acute pathogens normally results in one of two outcomes. Either 
the pathogen is cleared completely, and the host develops long-lived immunity or the pathogen 
wins evades the immune system and the host succumbs to the infection.  
Unlike acute infections, several bacterial pathogens cause persistent infections that 
infect a single host and can survive for extended periods of time without clearance (8). From an 
immunological standpoint, persistent infections by definition are the result of failures in the 
immune response (9, 10). These failures ultimately lead the host to be unable to cope with the 
bacterial pathogen. What drives this failure of immunity is a central question we must answer in 
order to develop protective vaccines or antibiotics that help the host detect, and destroy these 
pathogens, even when bacteria are in a quiescent state. Many chronic pathogens have tropism 
for a narrow host range allowing them to evolve directly in response to those particular hosts 
immune mechanisms over time (8, 11). The success of these diseases is startling. For example, 
over one-third of the world’s population is infected with the bacterial pathogen Mycobacterium 
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tuberculosis, with many unaware that they are infected (12, 13). These types of pathogens put a 
massive burden on public health and drive up healthcare costs (14, 15). In order to address this 
unmet clinical need and identify methods that skew hosts towards long-lived protective immunity 
that prevents future infections successfully, we must better understand the interactions between 
these chronic pathogens and their hosts to elucidate mechanisms of immune evasion. This 
dissertation is focused on understanding interactions between the chronic pathogen Chlamydia 
trachomatis and its mammalian host. Through the characterization of mechanisms that drive 
long-lived protective immunity, in conjunction with understanding virulence strategies employed 
by the pathogen to support growth and avoid clearance, we will be better equipped to prevent 
these infections in the future. 
 
Chlamydia trachomatis epidemiology 
Chlamydia trachomatis is a gram-negative obligate intracellular pathogen that infects the 
mucosal epithelium (16). While several species of Chlamydia exist, each has very limited host 
tropism and has evolved closely within their host environment (17). Therefore Chlamydia 
species are superbly adapted to survive within their specific host niche, but are rapidly cleared 
from host species of a broader range (11).  
Chlamydia trachomatis is a growing public health concern in humans, which costs 
millions of dollars in treatment each year (18, 19). In developing countries, C. trachomatis is the 
causative agent of blinding trachoma and is the leading cause of preventable blindness 
worldwide (20). Furthermore, C. trachomatis is the number one cause of bacterial sexually 
transmitted disease in the United States, with infection rates continuing to rise (16). Infections 
with Chlamydia can lead to the development of immune sequelae at the infection site (21). 
Infections of the conjunctiva lead to the development of inflammation in the eye leading to 
corneal damage. In the genital tract, C. trachomatis infections can lead to pelvic inflammatory 
disease, and result in complications such as ectopic pregnancy and infertility. Infections with 
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Chlamydia are rapidly cleared with antibiotics such as azithromycin, however, the majority of 
infections are asymptomatic, complicating diagnosis and treatment. Ultimately, a protective 
vaccine that prevents both infection and immunopathologies will be required to curb the impact 
of Chlamydia burden worldwide. 
Chlamydia trachomatis serovars are sub-divided into three major groups defined by their 
infection route and disease course (22). Serovars A-C infect the conjunctiva of the ocular tract 
and are highly prevalent in developing countries, particularly in the region of sub-Saharan Africa 
(22). Serovars D-K infect the columnar epithelial cells of the cervix (16). These infections are 
known to ascend to the upper genital mucosa, where they can persist over time. The third 
serovar group, L1-L3, infect through the genital mucosa and tend to cause systemic infections 
following spread to the draining lymphnodes, causing a condition known as lymphogranuloma 
venereum (17, 20, 23). These infections are more aggressive than those caused by other C. 
trachomatis serovars (17, 23). The focus of this dissertation will be on the genital serovars of 
Chlamydia trachomatis and their influence on immunity and pathology within the upper genital 
mucosa. 
 
Chlamydia intracellular development 
Chlamydia trachomatis is an obligate intracellular pathogen that must complete a unique bi-
phasic developmental cycle in order to infect, replicate, and productively infect new cells. C. 
trachomatis enters host epithelial cells as a metabolically inactive elementary body (EB) (24). 
Once EBs enter host cells they are maintained in a membrane bound vacuole known as an 
inclusion. In the inclusion, EBs differentiate into reticulate bodies (RBs) that are the more 
metabolically active, replicative form of C. trachomatis. RBs divide by binary fission and 
replicate 100-1000 fold inside a single human cell. RBs are non-infectious, and lysing cells that 
contain solely RBs will halt infection completely (24). Once replication is complete, due to 
signals that are entirely undescribed, RBs then re-differentiate into EBs in order to prepare for 
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further infection of new host cells. Chlamydia is then released from infected host cells via one of 
two mechanisms, lysis or extrusion, and infectious EBs then contact new host cells to begin the 
developmental cycle anew (24, 25). Because C. trachomatis is closely associated with host 
cells, infection triggers a wide-ranging immune response that is designed to sense, activate and 
protect against Chlamydia infections in the genital mucosa (16). 
 
Innate immunity and C. trachomatis 
Upon exposure to C. trachomatis, the mucosal barrier is the first line of defense to prevent 
against infection. The endometrial epithelium in the upper genital tract is unique in that turns 
over rapidly in line with the estrous cycle, which directly influences C. trachomatis infectious 
capacity (26, 27). Furthermore, mucin, defensins, and antimicrobial peptides are likely to be 
secreted into the lumen of the genital mucosa and are predicted to play a protective role (28-
30). However, detailed mechanistic insight into the importance of these proteins remains limited. 
 Once Chlamydia invades the epithelial layer in the genital mucosa, infected cells initiate 
early immune responses (31, 32). Studies have shown that epithelial cells can sense microbial 
products through the action of toll-like receptors (TLRs) and nod-like receptors (NLRs) and 
produce cytokines that recruit innate cells such as neutrophils, macrophages and NK cells (31, 
32). While Chlamydia contains several pathogen associate molecular patterns (PAMPs), studies 
have shown that the activation of TLR2 drives several aspects of the host immune response 
(33-36). Infection of epithelial cells with Chlamydia leads to the secretion of specific pro-
inflammatory cytokines such as interleukin 8 (IL-8), IL-1, and GM-CSF (37, 38). These cytokines 
initiate the immune response and attract adaptive immune cells to the site of infection. 
Ultimately, responding immune cells secrete interferon-γ (IFNγ), an essential cytokine that can 
directly restrict Chlamydia replication (39, 40). Mice deficient in IFNγ are unable to efficiently 
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clear Chlamydia infections in the genital mucosa, suggesting a critical role for this cytokine in 
limiting infection (40-42).  
 IFNγ restricts bacterial growth through several mechanisms that together lead to 
clearance. In general, IFNγ increases phagocytosis, upregulates important immunity genes such 
as MHC Class II, and activates other immune functions (39, 43-45). In human cells, IFNγ can 
also directly restrict bacterial growth through the induction of nitric oxide produced by 
upregulated inducible nitric oxide synthase (iNOS) (43, 44). Furthermore, IFNγ induces the 
enzyme indolamine 2-3-dioxygenase (IDO) which in turn depletes intracellular stores of 
tryptophan and increases the concentration of immunoregulatory metabolites known as 
kynurenines (46-48). Unlike humans, murine epithelial cells do not robustly initiate IDO 
dependent restriction. Instead of IDO, mice possess a family of p47 IFNγ -inducible GTPases 
(IRGs) that restrict bacterial growth both in vivo and in primary cells (49-51). Recent studies 
suggest that direct localization of these GTPases at the inclusion membrane disrupts the 
intracellular niche required for Chlamydia replication (52).  
 Interestingly, while the murine IRG system efficiently restricts human serovars of C. 
trachomatis, Chlamydia strains originally isolated from mice (such as Chlamydia muridarum) are 
largely resistant to this response (50, 51). Because of this resistance, infections of the murine 
genital mucosa with C. muridarum have increased duration and magnitude when compared 
directly to human strains (26, 31, 42, 53, 54). C. muridarum recapitulates many aspects of acute 
Chlamydia infection seen in humans and is used as an alternative tool to examine immunity 
development in the genital mucosa. However, because C. muridarum is not a human pathogen 
and uses different virulence mechanisms than C. trachomatis, its use is ultimately limited (41, 
50, 51). Even so, understanding mechanistic differences between human and mouse IFNγ 
responses will allow the development of infection models that more closely recapitulate the 
human disease course (11). 
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Adaptive immunity and C. trachomatis 
The initiation of the innate immune response during C. trachomatis infection leads to the 
activation, expansion and development of long-term immunity afforded by the adaptive immune 
compartment. While all major branches of the adaptive immune response are activated during 
Chlamydia infection, their importance in long-lived immunity differs dramatically. Through 
human clinical studies and mechanistic experiments in mice, we are beginning to understand 
what drives protective immunity in the genital mucosa to C. trachomatis.  
 
B cell responses to C. trachomatis infection  
 B cells are adaptive immune cells that detect soluble extracellular antigens in an antigen 
specific manner (55). Even though Chlamydia is predominantly found inside host cells during 
infection, EBs are exposed to the extracellular environment between rounds of replication. This 
affords an opportunity for B cells and the antibodies they produce to target exposed bacteria. 
Antibody binding to extracellular Chlamydia can directly inhibit invasion of host cells as well as 
opsonize Chlamydia particles for uptake by professional antigen presenting cells (APCs). This 
enhances the presentation of Chlamydia antigens to activate a robust T cell response, which will 
be discussed later.  
 In human patients, antibodies can be detected against several Chlamydia antigens, but 
predominantly against the Major Outer Membrane protein (MOMP) (56). Early studies showed 
that protection correlated with the presence of Chlamydia antibodies, and that antibodies could 
inhibit infection in vitro (57, 58). Unfortunately, later studies showed that Chlamydia antibodies 
are strain specific, which is caused by high variability of the MOMP proteins between strains 
(59). Because of this variability, antibodies are not anticipated to be broadly protective against 
further Chlamydia infections in humans. 
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 The importance of B cells in vivo has been confirmed using murine models of genital 
Chlamydia infection. Experimentally, mice deficient in B cells cleared primary Chlamydia 
infections similar to wild type mice (60). Further studies also showed B cells are not required for 
the recall response in the genital tract, although clearance was slightly delayed (61). Another 
study has shown that transfer of protective antibodies in vivo can partially protect mice from 
infection, but they do so rather weakly (62). Together, these data suggest that B cells are not 
the main drivers of protective immunity against C. trachomatis, and that antibodies play a limited 
role in Chlamydia clearance. Therefore, vaccine strategies that promote high antibody titers 
against Chlamydia may not provide true protection. Rather, vaccine strategies should be 
focused on developing robust cell mediated immunity. 
 
T cell mediated Immunity 
While it is clear that antibodies specific for Chlamydia are produced during infections, they do 
not appear to be necessary or sufficient for protection. Furthermore, mice infected previously 
with Chlamydia show strong resistance to re-infection, suggesting that the T cell compartment 
mediates protection against infection since B cells are not important for this resistance (26, 40).  
 T cells are characterized by the expression of protein heterodimers known as the T cell 
receptor (TCR), which defines T cell antigen specificity (55). There are two main classes of T 
cells that differ in their function and protective capacity, αβ T cells, which are the main focus of 
this dissertation, and γδ T cells which remain relatively uncharacterized during Chlamydia 
infections (63). During T cell development specific rearrangement events in the TCR, known as 
VDJ recombination, give rise to a broad range of antigen specificities. Specific steps during 
thymic selection ensure that T cells that enter the periphery can detect MHC molecules (positive 
selection) and do not cross-react with self-antigens (negative selection) (55, 64). This gives rise 
to a pool of naïve T cells that each detect unique foreign antigens such as invading pathogens. 
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In order for T cells to become activated and respond to infection, they must be able to find 
foreign antigens through a process known as antigen presentation. Distinct pathways of antigen 
presentation lead to the activation of distinct T cell populations. 
 
CD8+ T cell Responses during C. trachomatis Infection 
 The TCR does not recognize full-length proteins, but rather binds to short peptides that 
are produced through proteolytic cleavage. How peptides are processed and presented to T 
cells is dependent upon the MHC molecule. There are two major classes of MHC molecules, 
Class I and Class II (55). MHC class I molecules bind to peptides that are typically 8-10 amino 
acids in length, which are produced in the cytosol of host cells (65). These cytosolic peptides 
can be produced through proteasomal degradation as well as by other proteases in the cytosol. 
Peptides are then transported into the endoplasmic reticulum via Transporter associated with 
antigen processing (TAP) where they are then loaded into MHC class I molecules (65). Pre-
loaded class I molecules are trafficked to the surface of the host cell, where they can stimulate 
CD8+ T cell immunity. Upon detecting an antigen via TCR signaling, CD8+ T cells become 
activated and secrete a range of important cytokines, including IFNγ that can mediate protection 
(66). Furthermore, activated CD8+ T cells upregulate bioactive molecules such as perforin, 
FasL, or granzyme B, which can directly lyse or induce death of cells presenting the particular 
peptide (55). In this way CD8+ T cells can directly detect and destroy cells that are infected with 
intracellular pathogens such as C. trachomatis, removing the intracellular niche entirely (67, 68). 
Importantly, MHC class I expression occurs in almost all cell types, giving CD8+ T cells a broad 
capacity to protect regardless of cell type.   
 During infections of the genital mucosa with C. trachomatis, antigen specific CD8+ T 
cells are activated and recruited to the site of infection (68). In infected human patients, cervical 
samples show the presence of Chlamydia specific CD8+ T cells that secrete IFNγ (68, 69). In 
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mice, the presence of antigen specific T cells can also be found in the upper genital tract 
following Chlamydia infection. CD8+ T cells mostly recognize cytosolic proteins and C. 
trachomatis is maintained in a membrane vacuole intracellularly protecting most Chlamydia 
antigens from the MHC Class I pathway (70-72). However Chlamydia is known to secrete 
bacterial virulence proteins directly into the cytosol that can be processed and presented in 
MHC class I molecules to stimulate CD8+ T cell responses. Several Chlamydia proteins have 
been identified as CD8+ T cell antigens, however, their role in the cytosol generally remains 
unknown (70-72).  
 Since CD8+ T cells are stimulated and recruited to the genital tract investigators tested 
whether they are necessary and sufficient for protection. Transfer of Chlamydia specific CD8+ T 
cells cultured in vitro robustly protected mice from Chlamydia infection (73, 74). However, using 
depletion studies or genetic knockout-mice, investigators see a limited role for CD8+ T cells 
during primary infection or in response to secondary infection (75). In fact, it has been 
suggested that the CD8+ T cell memory response is blunted following Chlamydia infection. 
Inhibition of T cell memory prevents a robust recall response from the CD8+ T cell compartment 
and may influence the progression of disease and the development of immunopathologies (74). 
This suggests perhaps that Chlamydia has developed virulence mechanisms to directly 
influence the development of CD8+ T cell immunity during infection, preventing robust memory 
development and long-lived protective immunity. 
   
CD4+ T cell responses during Chlamydia infection 
Unlike MHC class I that normally binds peptides processed in the host cytosol, MHC class II 
molecules bind peptides derived from antigens initially found outside of host cells (55). 
Professional APCs, such as dendritic cells, phagocytose foreign antigens into an endosomal 
compartment that matures, accumulates proteases, and processes the antigens into peptides 
that are 12-15 amino acids in length. Eventually these intracellular compartments fuse with 
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vesicles where the cleaved peptides are loaded onto MHC class II and trafficked to the surface 
of the host cell (76). Once on the surface, loaded class II molecules can stimulate antigen-
specific CD4 + T cell responses that promote pathogen clearance. The exact cytokines and 
activation profile of CD4+ T cells is variable and depends on the APC presenting the antigen, the 
cytokine milieu and other signals that are not entirely characterized. There are three main sub-
types of activated CD4+ T helper (Th) cells, Th1, Th2, and Th17 that secrete distinct cytokines 
and serve different purposes during immunity (55, 77). Th1 responses, characterized by the 
secretion of cytokines like IFNγ and TNFα, are activated during infections with intracellular 
pathogens while Th2 responses are characterized by the production of IL-4 and are associated 
with resolving helminth infections efficiently (78). Finally, Th17 immunity develops to control 
extracellular bacteria and fungal infections, and also is implicated in many autoimmune 
diseases, such as rheumatoid arthritis (78). Together these CD4+ subsets can tune immune 
responses to effectively clear pathogens with broad tropism or multi-cellularity. CD4+ T cells are 
initially activated by professional APCs that constitutively express MHC class II molecules on 
their surface (79). However, the induction of MHC Class II molecules on other cells types, such 
as epithelial cells, is known to occur, but the understanding of the functional implications of 
CD4+ T cell interactions with these cell types remains limited (79).    
 In the context of C. trachomatis infection, CD4+ T cells are proposed to play the largest 
role in providing long lasting protective immunity. Chlamydia specific CD4+ T cells are activated 
through APCs that have engulfed free extracellular EBs or infected cells (80). In human 
patients, cervical samples from infected individuals showed the presence of Chlamydia specific 
CD4+ T cells (81). The activation of these T cells is predominantly skewed towards a Th1 
response, which is not surprising given the restrictive effects of IFNγ on C. trachomatis growth. 
However even though robust CD4+ responses are activated and limit pathogen growth, one 
recent study suggested these CD4+ T cells wane over time and do not develop into long-lasting 
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memory cells (81). This may be one mechanism responsible for the high rates of re-infection 
with C. trachomatis.  
 In murine models of Chlamydia infection CD4+ T cells are considered the primary 
indicators of effective immunity. During infection in the murine genital mucosa CD4+ T cells are 
recruited and secrete high levels of IFNγ (80, 82, 83). Studies using TCR transgenic mice to 
track Chlamydia-specific CD4+ T cells during infection showed that CD4+ T cells are initially 
primed in the iliac lymph node that drains the genital mucosa (84). These T cells proliferate in 
the lymph node and then traffic to the genital tract to mediate protection. Mice depleted of CD4+ 
T cells are unable to efficiently control primary or secondary infections with the mouse adapted 
species C. muridarum (82). Mice previously infected with C. muridarum show strong resistance 
to re-infection in a CD4 dependent manner beyond six months, suggesting the development of 
long-lived protective immunity. Furthermore, transfer of Chlamydia-specific CD4+ T cells limited 
bacterial growth during systemic routes of C. trachomatis infection (85). However, one recent 
study suggested that immunity to infections of the murine genital tract with the human strains of 
C. trachomatis were not driven by CD4+ T cells (54). This result was confounding based on the 
literature, and warranted further investigation to understand the mechanisms responsible for 
these conclusions. Chapter 2 in this dissertation will examine this discrepancy in the literature to 
determine the role of CD4+ T cells in providing protective immunity in the genital mucosa during 
infections with C. trachomatis. 
 
T cell Trafficking to the Genital Mucosa 
In order for T cells to impart their protective capacity at the genital mucosa during Chlamydia 
infection, they must first traffic to the mucosal tissue. As described above, Chlamydia specific 
CD4+ T cells initially become activated in the iliac lymph node that drains from the genital tissue 
(84). Following activation, these T cells must exit the lymphatic system and traffic directly into 
the genital mucosa, where the protective cytokines produced by CD4+ T cells can mediate 
	   13 
clearance. CD4+ T cells home to the genital mucosa through the coordinated action of 
chemokine receptors, integrins, and selectins. It is known that different combinations of homing 
molecules promote trafficking to specific tissues. For example, a combination of the integrin 
α4β7 and the chemokine receptor CCR9 direct T cells to the intestines (86).  There is great 
interest in characterizing the trafficking “area-code” for pathogen-specific T cells in the genital 
mucosa following infection with Chlamydia, yet few studies have pursued these experiments 
and no (86)studies have used antigen specific methods for characterization. In the limited 
published reports, investigators suggest that the chemokine receptor CCR5 may be required for 
efficient lymphocyte recruitment to the genital mucosa since CCR5-/- mice are unable to 
efficiently clear infections with C. muridarum (87). In separate studies examining integrin 
expression, one group describes the enrichment of T cells expressing α4β1 in the genital 
mucosa while a second group suggests α4β7 is the critical mediator of T cell trafficking (88, 89). 
However, all these studies examined the expression of receptors on bulk pools of T cells, and 
did not examine the influence of receptor expression on the protective capacity of the T cells. 
Because of the lack of strong evidence supporting the mechanisms of T cell recruitment to the 
genital tract, this dissertation will begin to characterize these processes in mice in chapters 3 
and 4.  
 
Failures of adaptive immunity to Chlamydia  
Although murine models of Chlamydia infection recapitulate several aspects of human disease, 
there are limitations to their use in the context of persistent infections. It is clear that C. 
trachomatis infections of the murine genital tract stimulate a robust protective T cell response 
that results in sterile immunity that is long lasting (42). However, in humans immunity appears 
short-lived and non-protective, resulting in multiple infections in a single patient (81). Clinical 
data also shows that some patients who are culture negative still shed Chlamydia DNA and 
	   14 
RNA, suggesting persistent infections with Chlamydia occur in vivo (90, 91).  The discrepancies 
in the outcome of infection and immunity between mice and humans with Chlamydia are likely 
due to distinct differences in the disease course and the subsequent immune response between 
hosts. As described previously, C. trachomatis has a host tropism limited to humans and 
therefore has developed specific mechanisms that subvert human immune processes. By 
introducing C. trachomatis into a host environment that contains different immune effectors 
relative to humans and within which the pathogen is not evolved to survive, we may activate 
alternative immune processes that are not relevant in humans or prevent virulence mechanisms 
that are relevant in humans (11). Therefore, it is critical that we not only understand 
mechanisms that drive long lasting protective immunity, but also that we characterize virulence 
strategies used by C. trachomatis in human cells to promote growth, replication, evade the 
immune response and persist in the human genital mucosa. The following sections will detail 
known virulence mechanisms used by C. trachomatis to support growth and alter host immunity. 
 
Bacterial mechanisms used to subvert host cells and support intracellular growth. 
Chlamydia trachomatis has a relatively small genome that contains roughly 1MB of DNA and 
1000 open-reading frames (ORFs) (92). Based on bioinformatics studies this small genome size 
suggests that Chlamydia species have undergone reductive evolution that limits the host range 
of C. trachomatis infections (23). Transcriptional analysis of Chlamydia genes during infection 
has shown that there is tight regulation of bacterial genes that are broken down into three 
groups, the early, middle and late genes (93). Early genes are transcribed quickly following 
inclusion formation and primary differentiation into RBs. Middle genes begin to be transcribed 
12-18 hours following infection, and late genes are activated after 20 hours post-infection. It is 
hypothesized that the timing of the distinct gene clusters in Chlamydia is initiated by unknown 
signals, and prepares Chlamydia for all stages of growth, including the final re-differentiation 
into EBs that is required for productive infection. Recent proteomic studies that examined the 
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Chlamydia proteome in purified EBs or RBs showed that EBs, although metabolically limited, 
are pre-loaded with a variety of virulence proteins that drive invasion and promote infection (94). 
Unfortunately, due to the obligate intracellular nature of C. trachomatis, it has remained difficult 
to use standard genetic techniques to knockout bacterial genes and to elucidate the function of 
individual virulence determinants. This has led investigators to develop different tools to 
understand the role of specific gene products (95, 96). The following sections will examine how 
these studies have informed our understanding of the virulence mechanisms used by 
Chlamydia to invade cells, acquire nutrients and subvert immunity.  
 
The Chlamydia type III secretion system 
Like many gram-negative pathogens, Chlamydia uses a specialized type III secretion system to 
translocate effector proteins directly into the host cell cytoplasm (97). Bioinformatic studies 
predict that Chlamydia secretes over 100 unique virulence factors into the host cell where they 
manipulate host cell processes to the benefit of the pathogen, yet the function of most effectors 
remains entirely unknown (98). Type III secretion systems are essentially a needle-and-syringe-
like structure, which protrudes from the bacterial surface and makes contact directly with host 
membranes. This creates a conduit for proteins within Chlamydia to translocate directly into host 
cells. Studies using yeast-two hybrid assays have begun to tease apart the important structural 
components of the Chlamydia type III secretion apparatus (99). These have defined the proteins 
that make up the basal body, or the base, of the secretion apparatus that spans both the inner 
and outer membrane of Chlamydia. Again, due to a lack of tractable genetics it has remained 
difficult to directly test the role of each protein in the overall structure and function of the type III 
secretion system. However, using chemical inhibitors that prevent type III secretion in other 
gram-negative pathogens, it is clear that a functional type III secretion system is required for 
productive bacterial growth and survival (100, 101).   
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Host cell adhesion and invasion 
 C. trachomatis is able to invade and infect most cultured cells, suggesting that the 
mechanisms of invasion are not cell type specific. Therefore, individual receptors that influence 
invasion are most likely ubiquitously expressed on many different cell types. It is hypothesized 
that initial binding and invasion occurs in a two-step process (102). First, there is a reversible 
binding that is mediated primarily by charge interactions. This is followed by a second 
irreversible step that is mediated by the binding of Chlamydia to secondary receptors. RNAi 
studies in drosophila cells that examined host factors required for initial entry of Chlamydia 
showed an unexpected role of growth factors and their receptors in initial Chlamydia binding 
and invasion (103, 104). These studies identified the PDGF receptors and FGFR as critical to 
initial invasion and to promote further rounds of Chlamydia replication. One recent study using a 
haploid cell line trap screen identified that the overall sulfation of cells, is an essential factor that 
influences the infectivity of host cells (105). Several bacterial factors including MOMP, OmcB, 
and PMPs have been suggested to influence these initial binding interactions, but it has 
remained difficult to understand the influence and mechanisms of each interaction in the 
absence of targetable genetic techniques (102).  
 Chlamydia enters non-phagocytic cells through a process mediated by both host and 
bacterial products. The invasion of C. trachomatis is driven by a rearrangement of actin through 
the action of host small GTPases (102, 106). C. trachomatis EBs are preloaded with specific 
effector proteins that are poised to be secreted into host cells upon contact. The best 
characterized of these factors is the Chlamydia protein TARP. TARP is a multifunctional 
virulence determinant that can directly polymerize actin to promote uptake of Chlamydia, and is 
phosphorylated by host tyrosine kinases such as ABL to influence invasion (107, 108). One 
study showed microinjection of TARP antibodies directly into host cells prior to infection could 
inhibit efficient invasion, giving direct evidence that TARP mediates infection (109). These data 
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suggest that Chlamydia uses a subset of secreted effectors to directly mediate uptake into host 
cells to initiate the infectious cycle.  
 
Inclusion development and localization 
Upon entering host cells, EBs maintained in the inclusion are diverted from the endolysosomal 
pathway, preventing lysosomal fusion (110). In a microtubule dependent fashion, inclusions are 
trafficked from the cellular periphery to the Peri-Golgi region, where both host and bacterial 
proteins are recruited to the inclusion membrane (110, 111). While the mechanistic details 
remain unknown, it is hypothesized that several Chlamydia proteins actively promote this 
transport in a dynein dependent fashion. Chlamydia is known to secrete several effector 
proteins known as Incs that possess a bi-lobed hydrophobic domain, allowing their insertion 
directly into the inclusion membrane (112). These Inc proteins have been shown to recruit and 
interact with several host trafficking proteins, such as Rabs and SNAREs that may promote 
acquisition of nutrients from the host through vesicle fusion with the inclusion (113-115). In 
support of this concept, several Inc proteins such as IncA contain similarities to eukaryotic 
SNARE proteins that may drive these processes in host cells. Together these previous findings 
suggest that active reorganization of the inclusion membrane is an essential step in the 
Chlamydia developmental cycle and is driven primarily by secreted effector proteins. 
 
Nutrient acquisition by Chlamydia in the host cell 
One of the primary goals of Chlamydia is to acquire the necessary nutrients to replicate robustly 
and survive in the intracellular niche. It has become clear that lipid acquisition is a critical 
component of Chlamydia virulence strategies. Lipid acquisition is required for efficient 
replication and for successful completion of the entire developmental cycle of Chlamydia. Early 
work by Hackstadt and colleagues suggested that Chlamydia is able to intercept host 
sphingomyelin and cholesterol for growth (116). More recent studies suggest that Chlamydia 
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also recruits lipids through non-vesicular trafficking mechanisms. For example two reports have 
shown a requirement for the host Ceramide transfer protein (CERT) to be recruited to the 
inclusion, and it is hypothesized that Ceramide may be directly converted to sphingomyelin at 
the inclusion (117, 118). CERT was shown to interact directly with the Chlamydia effector IncD, 
suggesting lipid acquisition is actively promoted by Chlamydia for survival.  
Studies have also shown that infection with Chlamydia leads to Golgi fragmentation, 
which is predicted to enhance nutrient acquisition in the inclusion (119). Initial studies suggested 
this process was mediated by the Chlamydia protease CPAF, however subsequent 
investigations showed this might be an artifact of post-lysis activity of the protease (120). 
Therefore, our understanding of which Chlamydia effectors mediate this host alteration remains 
unclear.  Beyond these mechanisms, Chlamydia has also been shown to actively recruit lipid 
droplets to the inclusion as an alternative source of nutrients. One report showed that lipid 
droplets co-fractionate with the secreted effector IncA, suggesting that this process is actively 
mediated by Chlamydia (121). Finally, close association of inclusions with mitochondria and 
lysosomes suggests a potential resource for essential amino acids that are required for efficient 
Chlamydia replication (122, 123). However, the mechanisms responsible or the importance of 
these pathways remains to be elucidated. 
 Beyond nutrient acquisition, Chlamydia infection directly interferes with normal host cell 
processes such as cell cycle progression. Work has shown that infection with Chlamydia directly 
leads to the cleavage of CyclinB1 halting cell cycle progression (124). Further work showed that 
infection with Chlamydia leads to abnormal spindle formation, centrosome amplification, and 
segregation defects (125-127). In combination with a recent study that showed that infection 
with Chlamydia leads to massive rearrangement of chromatin and DNA damage in host cells, it 
is tempting to speculate that infection with Chlamydia may also lead to a cancerous state (128). 
Future studies will need to better elucidate the long-term implications of Chlamydia infection on 
cancer development. 
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Inhibition of innate immune responses during Chlamydia infection. 
Because Chlamydia is entirely dependent on host cells for replication and survival, Chlamydia 
has evolved specific mechanisms that alter the initial innate immune response to promote 
infection. Our lab identified that Chlamydia encodes two specific deubiquitinating/deneddylating 
enzymes, ChlaDub1 and ChlaDub2, that can directly remove ubiquitin chains from proteins 
targeted for proteasomal degradation (129). One report has suggested that ChlaDub1 can 
prevent the activation of the NF-κB pathway by preventing the proteasomal degradation of the 
IκBα (130). This would prevent robust activation of the NF-κB cascade, which in turn would 
inhibit the secretion of proinflammatory cytokines that initiate an immune response to C. 
trachomatis. Other studies have shown that Chlamydia infection leads to the destruction of 
RelA, a subunit of the NF-κB complex (131). It is hypothesized that this inactivation plays a 
similar role to ChlaDub1 by preventing strong activation of the pathways needed to initiate host 
responses to infection. However, the exact bacterial factors that are responsible for this 
phenotype remain controversial. Future studies are needed to clarify the role of NF-κB inhibition 
during Chlamydia infection, particularly in vivo.  
When cells are infected with pathogens, one way in which the host can activate the 
immune response is through the induction of apoptosis, thereby removing the intracellular niche 
required by Chlamydia for survival.  Apoptotic cells can then be phagocytosed by professional 
APCs, resulting in the activation of a robust immune response (55). Because of this, Chlamydia 
has developed mechanisms that prevent premature apoptosis or cell death to ensure the 
developmental cycle can be completed without interruption. One mechanism by which this can 
occur is through the degradation of proapoptotic proteins such as the BH3-only proteins Bad, 
Bim and Puma (131-133). A separate mechanism by which this can occur is through the 
stabilization of inhibitors of apoptosis such as IAP2 and Mcl-1, which promotes cell survival 
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during Chlamydia infection (134-136). By directly manipulating innate immune signaling 
pathways and host survival pathways, Chlamydia ensures the intracellular replicative niche 
remains intact for the duration of infection, allowing it to complete the entire developmental cycle 
and to infect new cells. 
 
Chlamydia trachomatis subverts the IFNγ  response in epithelial cells. 
As discussed earlier, Chlamydia clearance is dependent on IFNγ, as mice deficient in IFNγ are 
unable to efficiently clear infections (40). However, epithelial cells in mice and humans differ in 
their response to IFNγ (11). In mice, IFNγ induces the IRG response, which is almost entirely 
absent in humans. In human cells, IFNγ leads to the robust upregulation of IDO, which in turn 
depletes intracellular stores of tryptophan (137). Upon the depletion of tryptophan, C. 
trachomatis transitions from actively replicating RBs into a quiescent noninfectious “persistent” 
form (138). These aberrant or persistent forms can remain in cells undetected for extended 
periods of time. This is possible because human strains of C. trachomatis contain a partial 
Tryptophan operon that can use exogenously found indole, most likely produced by 
commensals in the lower genital mucosa, to produce tryptophan and survive in cells even under 
high expression of IDO (139). This is the major mechanism that is hypothesized to promote 
chronic infections with C. trachomatis in humans. 
 Unfortunately, modeling of this persistent response to IFNγ has remained difficult in vivo 
due to distinct differences between mice and men, as addressed previously. One recent study 
examined whether loss of the IRG regulators would lead to the induction of persistent 
Chlamydia infection in the murine genital mucosa (41). Interestingly, this study found that loss of 
the IRG system resulted in robust growth of Chlamydia similar to IFNγ knockout mice early 
during infection, but it was later resolved through a compensatory CD4+ T cell response that 
was sufficient to mediate protection. Therefore, it seems that some level of restriction is 
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necessary for Chlamydia to persist. Because IDO is not induced robustly in murine epithelial 
cells, it is hypothesized that humanizing mice to allow robust IDO expression in murine epithelial 
cells in the absence of IRGs may lead to a model of Chlamydia persistence. However, this 
remains to be tested and will be a major focus of in vivo Chlamydia research in the future. 
 
Chlamydia infection directly alters antigen presentation in infected cells 
Another mechanism by which C. trachomatis has been shown to actively alter immune 
responses is by inhibiting antigen presentation. Studies by Zhong and colleagues suggest that 
during infection Chlamydia downregulates the surface expression of MHC molecules. One 
mechanism by which this occurs is through the degradation of host transcription factors RFX5 
and USF-1, which are responsible for MHC induction (140, 141). Through this process, 
Chlamydia is hypothesized to prevent efficient presentation of bacterial peptides to the immune 
system, thereby inhibiting robust activation. Initially, these phenotypes were associated with the 
Chlamydia protease CPAF, but recently these findings have been questioned (120). Therefore, 
it will be important to understand bacterial factors outside of CPAF that may be responsible for 
altering the expression of MHC molecules and to determine how this impacts subsequent 
immunity and memory development.  
 
Chlamydia infection leads to a blunted CD8+ T cell response limiting memory potential 
As discussed previously, the fact that Chlamydia trachomatis can cause persistent infections 
suggests there is a failure of the adaptive immune response to efficiently detect and eradicate 
infection. One area that has puzzled investigators is that CD8+ T cells do not appear to be 
important for mediating Chlamydia clearance. Chlamydia is an infection of epithelial cells, 
similar to many viruses in which CD8+ T cells are absolutely required for clearance. 
Furthermore, CD8+ T cells have the capacity to directly lyse Chlamydia infected cells, removing 
the intracellular niche and halting infection prior to re-differentiation into EBs (67, 71). It seems 
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that although CD8+ T cells can be protective when activated and supplied independently of 
Chlamydia infection, those CD8+ T cells produced during natural infection are deficient in some 
way. Several studies have shown repeatedly that CD8+ T cells do not play a major role during 
primary or secondary challenge in the genital mucosa (82, 142). Recent studies have begun to 
examine factors that may prevent a robust CD8+ T cell response during Chlamydia infection. 
Work in our lab has shown that following initial infection with Chlamydia, the CD8+ T cell 
memory response to Chlamydia infections is blunted (74). Normally, a recall T cell response 
should be faster and amplified in comparison to primary infection. However, in mice infected 
with Chlamydia, pathogen specific CD8+ T cells do not expand robustly, and appear to have 
exhausted T cell phenotypes. Furthermore, co-infection of Chlamydia with Listeria, which 
normally induces a robust secondary response, prevents efficient recall responses to both 
pathogens, suggesting that Chlamydia uses active mechanisms to alter immunity. However, the 
mechanistic details responsible for these observations remain to be elucidated and will be the 
focus of future work.   
 
Summary 
In this thesis I describe interdisciplinary approaches that I used to characterize immunity and 
host-pathogen interactions of the intracellular bacterium C. trachomatis. The first part of this 
dissertation presents findings that elucidate mechanisms of host immunity that drive protection 
in the murine genital mucosa. These studies identified that CD4+ T cells are necessary and 
sufficient for protection from C. trachomatis infection. Furthermore, I identified mechanisms that 
promoted the recruitment of Chlamydia-specific CD4+ T cells to the genital mucosa, where they 
were required for protection. In the second part of this dissertation I investigated how infection of 
human cells with C. trachomatis directly alters the host proteome. By using layered proteomic 
and genomic approaches, I uncovered broad host protein networks that were altered in their 
stability independently of changes in host transcription. In addition, I demonstrated that several 
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of these host-pathogen interactions are required for the intracellular development of C. 
trachomatis. Leveraging these findings, I showed that therapeutic approaches that use small 
molecules to alter the host pathways that are required for the survival of C. trachomatis have 
great potential. By characterizing mechanisms of host immunity that promote protection, as well 
as identifying critical host-pathogen interactions needed for Chlamydia propagation, we are 
better equipped to develop a protective vaccine that promotes long-term protective immunity 
without inducing immune pathologies. 
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Chapter 2: CD4+ T cells are necessary and sufficient to 
confer protection against C. trachomatis infection in the 
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The obligate intracellular bacterial pathogen Chlamydia trachomatis causes significant 
morbidity throughout the world (1). The major complications of C. trachomatis genital tract 
infections arise primarily in women, and include pelvic inflammatory disease (PID), which can 
result in fallopian tube scarring, infertility, and ectopic pregnancy(2, 3).  Better understanding of 
the interaction of C. trachomatis and the mammalian host is critical for the development of a 
vaccine to combat the prevalent human diseases caused by this pathogen. 
Human infection with C. trachomatis stimulates multiple elements of the immune system, 
but these responses often fail to clear the organism or prevent subsequent re-infection (4-6).  
The inability to clear chronic C. trachomatis infections suggests a failure in adaptive immunity – 
specifically the memory responses that should provide long-lasting protection. Studies have 
shown that mice intravaginally infected with human strains of C. trachomatis clear infection 
quickly and without the inflammation and pathology associated with human disease (7-9).  
Following genital infection with human C. trachomatis, CD4+ T cells become activated, 
proliferate, and are recruited to the genital mucosa (9-15). These CD4+ T cells exhibit a 
characteristic Th1 response, secreting the high amounts of IFNγ required for bacterial 
clearance. (9, 16). Infection of CD4-/- mice with C. trachomatis leads to higher pathogen load 
during primary infection, and a diminished ability to be protected from secondary infection (9).  
However, studies examining the protective quality of the CD4+ T cell memory cells induced 
following C. trachomatis infection have been contradictory (8, 9). One investigation examined C. 
trachomatis infection of wild type and µMT mice demonstrating a requirement for CD4+ T cells in 
protective immunity to secondary infection (17).  In contrast, a recent study where antibody was 
used to deplete CD4+ cells suggested that prior infection of mice with C. trachomatis does not 
yield strong protective immunity, and that CD4+ T cells are not critical for the clearance of 
human strains (8). These contradictory reports highlight the limited understanding of the 
dynamics of the CD4+ memory T cell response to C. trachomatis, particularly in tracking antigen 
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specific T cell responses over time. One possible reason for the limited data examining CD4+ T 
cell memory responses is that current small animal models do not accurately recapitulate 
human infections. 
In pursuing mouse models of host defense against Chlamydia, investigators have had to 
choose between infecting mice with C. trachomatis, the human pathogen, or Chlamydia 
muridarum, a pathogen isolated from a natural mouse infection.  C. muridarum has been an 
attractive option in that infections with this organism persist several days longer than infections 
with C. trachomatis, and are characterized by higher bacterial loads, ascending infections into 
the upper genital tract, and the development of pathologies such as hydrosalpinx and infertility 
(18-21). The use of the C. muridarum model has increased our knowledge about Chlamydia 
pathogenesis and immunity however, there are limitations to its use, specifically in the 
identification of antigens for use in a vaccine to protect against C. trachomatis (22-26). To date, 
there have been no published T cell epitopes shared between C. trachomatis and C. 
muridarum(6, 27, 28). Furthermore, C. muridarum only models acute phases of human C. 
trachomatis infection and not the chronic phases that are responsible for pathology in humans 
(5, 6). By identifying new protective T cell antigens and tracking C. trachomatis-specific 
responses to those antigens we may be able to differentiate responses that lead to protective 
immunity versus those that cause deleterious pathologies (6). 
We hypothesized that in the standard vaginal inoculation method of C. trachomatis 
infection, the organism does not reach the upper genital tract and therefore is unable to 
stimulate robust adaptive immunity, similar to human infections.  Here, we describe a model of 
mouse infection with C. trachomatis where the cervical barrier is bypassed.  Using this 
transcervical infection model we are able to directly infect the upper genital tract of mice with C. 
trachomatis, colonizing the clinically relevant site.  Compared to vaginal inoculation with C. 
trachomatis, transcervical inoculation allowed for more efficient colonization and stimulated a 
more robust and inflammatory antigen specific T cell response in the upper genital tract while 
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also allowing for the consistent development of pathology.  Using this model, we characterized 
the induction of antigen specific memory CD4+ T cells and show that they are necessary and 
sufficient for protection against re-infection of the murine genital mucosa.  This study 
demonstrates a novel inoculation method that will allow investigators to build on each other’s 
research results by using C. muridarum or C. trachomatis interchangeably.  These data move 
the field significantly forward with a model system that stimulates immunity, is highly 
reproducible, and causes disease at the site biologically relevant for human C. trachomatis (29).  
This model system will accelerate our understanding of Chlamydia pathogenesis in vivo, help to 
uniformly define the immune components needed for protection, and enhance the ability to test 





Transcervical inoculation of C. trachomatis allows robust and consistent murine upper 
genital tract infection. 
Our primary objective in this study was to compare murine models of Chlamydia genital 
infection on the induction of CD4+ T cell responses.  More specifically, we examined the 
differences between the intravaginal inoculation method and a newly-developed transcervical 
(intrauterine) inoculation method using both C. trachomatis and C. muridarum. The transcervical 
infection model uses a thin flexible probe (NSET device) to bypass the cervix and inject the 
bacteria directly into the lumen of the uterus. To understand how the bacterial burden in the 
upper genital tract changes with infection route or Chlamydia species, mice were given 106, 
4.5x105, or 103 IFU of C. trachomatis or C. muridarum by either the intravaginal or transcervical 
method. Three days after infection with 106 IFU of C. trachomatis transcervically (gray bars) or 
C. muridarum intravaginally (white bars), the murine uteri harbored similar levels of bacteria, 
(Figure 2-1).  In stark contrast, vaginal inoculation with 106 IFU of C. trachomatis resulted in two 
logs less bacterial burden in the upper genital tract (black bars). These results suggest that 
when the physical barrier of the cervix is bypassed, the human-adapted C. trachomatis can 
colonize the murine upper genital tract as efficiently as the murine-adapted C. muridarum. 
We next examined changes in Chlamydia burden over the course of primary 
infection.  For C. trachomatis given via the transcervical route, bacterial load remained constant 
from 3 to 6 days after infection, followed by a precipitous decrease on day 9 and 15 (Figure 2-
1).  Infection with C. muridarum intravaginally resulted in infection levels at day 3 comparable to 
that observed with C. trachomatis transcervical infection.  By day 6 the C. muridarum level had 
increased 10-fold and then decreased somewhat at days 9 and 15. Infection with either 
pathogen or route becomes undetectable 21-28 days following infection (data not shown). We 















Figure 2-1. Transcervical infection of the genital mucosa with C. trachomatis leads to 
efficient colonization and pathology in the upper genital tract. Wildtype mice were infected 
by either intravaginal or trancervical inoculation with (A) 106 (B) 5x104  or (C) 103 IFU of C. 
trachomatis or C. muridarum. At the indicated time points following infection, genomic DNA was 
isolated from the upper genital tract. Quantitative PCR was used to calculate the levels of 
Chlamydia 16s DNA relative to levels of host GAPDH. Shown is a box-and-whisker plot from 




Although there is an even higher load 3 days post-infection (3000 pg/ng), the bacterial burden 
was similar to intravaginal inoculation for the remainder of the time-course (data not shown). 
Therefore, we only used intravaginal inoculation of C. muridarum for the remainder of the study. 
When C. trachomatis was inoculated via the vaginal route, there was no consistent infection of 
the upper genital tract.  These results show that both C. trachomatis and C. muridarum are 
capable of colonizing the upper genital tract, but that C. trachomatis must be inoculated across 
the cervix for colonization to occur.  
We also examined the impact of infectious dose on the course of infection (Figure 2-
1).  Lowering the initial dose led to a corresponding decrease in bacterial burden on day three 
for both transcervical infections with C. trachomatis and vaginal inoculation with C. 
muridarum.  As was seen with the higher dose (106 IFU), each of the lower doses (5x104 IFU, 
103 IFU) resulted in similar burdens of organisms at day 3 using the two models. Regardless of 
the initial dose of C. muridarum, the amount of this organism rises to a similar high level by day 
six after infection, and the resolution of infection then follows a similar course, again regardless 
of inoculation dose. Therefore, transcervical delivery of C. trachomatis allows more robust initial 
infection compared to C. trachomatis intravaginal delivery but it never rises to the level seen 
following infection with C. muridarum. 
We next examined whether transcervical infection leads to pathology in the upper genital 
mucosa.  Mice were infected intravaginally with C. trachomatis or C. muridarum or infected 
transcervically with C. trachomatis.  Twenty-five days after infection, the genital tract was 
removed and examined for gross pathology.  Overall, pathology was seen in mice infected both 
intravaginally with C. muridarum and transcervically with C. trachomatis but never in mice 
infected intravaginally with C. trachomatis. Mice infected with C. muridarum showed severe 
oviduct hydrosalpinx similar to what has been described previously (Figure 2-2) (30).  Mice 
infected transcervically with C. trachomatis showed major nodes of inflammation ascending the 
length of the upper genital tract (Figure 2-2).  These data indicate that the transcervical model of 
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infection allows the formation of gross pathologies similar to what has been observed with C. 
muridarum.  While there have been reports of pathology following C. trachomatis infection of 
innate immune-deficient mice strains, consistent pathology has never been described in 
wildtype C57Bl/6 mice – a strain restrictive for C. trachomatis growth.  Furthermore, the 
pathology in C. trachomatis infected mice extends the length of the uterine horn, similar to rare 
cases described recently following C. muridarum infection (31).  
Because there was no gross pathology observed on the ovary’s following transcervical infection, 
we subjected several mice infected with C. trachomatis transcervically to histopathology in order 
to determine whether inflammation ascends the entire length of the upper genital tract as 
previously described for C. trachomatis infections in humans. The majority of mice examined 
following transcervical infection with C. trachomatis had severe oophoritis (inflammation of the 
uterine horn, oviduct, and ovary), examples of which can be seen in Figure 2-2. Evidence of 
large neutrophil and macrophage recruitment to the upper genital tract can be seen, as well as 
fibrin/mucus suggesting fluid buildup in these tissues. Importantly, we observed massive 
inflammation of the oviduct, a hallmark of murine infections with C. muridarum. Taken together, 
our transcervical model of C. trachomatis infection occurs throughout the upper genital tract and 
yields pathology similar to C. muridarum as well as human infection with C. trachomatis.  
 
IFNγ restricts the initial growth of C. trachomatis in the murine upper genital tract 
following transcervical infection. 
It is well accepted that the IFNγ response between mice and humans is quite different and that 
C. muridarum has adapted to evade this response in its murine host (22, 25).  In contrast, the 
human pathogen C. trachomatis is highly susceptible to the murine IFNγ response (22, 25).  We 
therefore tested whether the differential effect of IFNγ could explain why the level of C. 
muridarum increased 10-fold from day three to day six, whereas the level of C. trachomatis 



















Figure 2-2. Transcervical infection leads to the development of immunopathologies in the 
upper genital tract. (Top) 25 days following infection the upper genital tract was isolated, 
photographed, and scored for pathology. Arrow heads indicate nodes of inflammation. Shown 
are representative images from 25 experimental mice per group from two independent 
experiments. (Bottom) Histological sections of the upper genital tract from mice infected 
transcervically with C. trachomatis were stained with hematoxylin and eosin. Shown are 
representative images of the inflammation seen in the uterine horn, oviduct, and ovary following 
transcervical infection.  
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shown in figure 2, we challenged wild type or IFNγ-/- mice transcervically with C. trachomatis 
and compared the bacterial burden to that obtained through vaginal inoculation with C. 
muridarum.  In the mice lacking IFNγ, transcervical infection with C. trachomatis led to an 
expansion of organisms by day 6 that closely resembled the expansion of organisms observed 
in wild type mice infected with C. muridarum. These results suggest that IFNγ restricts the initial 
growth of C. trachomatis rapidly following infection of the upper genital tract.  Since this rapid 
restriction is prior to the peak infiltration of T cells (10), it also leaves open the possibility of other 
sources of IFNγ capable of restricting C. trachomatis growth - such as NK cells resident in the 
cervical tissues (32). We suspected that the primary effectors of this IFNγ mediated restriction of 
C. trachomatis in mice were the immunity related GTPases (IRGs).  When we examined the 
peak burden of C. trachomatis after transcervical infection of IRGm1/m3 deficient mice, we 
found a higher level of bacteria on day six compared to wild type mice, a level identical to what 
we observed using IFNγ-/- mice (Figure 2-3).  These data indicate that even though the human 
adapted C. trachomatis is still constrained in its ability to grow due to innate responses 
mediated by a rapid induction of IFNγ and the murine IRG system, removal of Irgm1/m3 alone 
allows C. trachomatis to become resistant to the murine-specific IFNγ response and to grow 
similarly to C. muridarum. 
 
Transcervical inoculation of C. trachomatis leads to a robust primary immune response 
Previous reports have shown that CD4+ T cells specific for C. trachomatis can protect against 
systemic infection (11, 16).  However, a recent report by Morrison et al. suggests that CD4+ T 
cells are dispensable for protection against genital infection with C. trachomatis.  In their 
experiments, Morrison et al. inoculated mice in the vaginal vault, a method which we have now 
shown does not promote efficient infection of the upper genital tract by C. trachomatis.  This led 
us to suspect that Morrison’s finding resulted from a lack of colonization of the target tissue 























Figure 2-3. IFNγ restricts C. trachomatis rapidly following infection of the upper genital 
mucosa. Wild-type, IFNg-/- or Irgm1/m3-/- mice were infected transcervically with 106 IFU of C. 
trachomatis. A separate group of wild-type mice were infected with 106 IFU of C. muridarum. 
Three and six days following infection, genomic DNA was isolated from the upper genital tract. 
Quantitative PCR was used to calculate the levels of Chlamydia 16s DNA relative to levels of 




used to directly infect the upper genital tract with C. trachomatis we would observe a significant 
role for CD4+ T cells in immunity to this organism. To test this we used antigen specific CD4+ T 
cells to directly compare T cell proliferation, activation, cytokine secretion, and recruitment to the 
genital mucosa between mice infected with C. trachomatis intravaginally or transcervically.  
We first wanted to determine whether antigen-specific CD4+ T cells are activated following 
transcervical or intravaginal infection. We transferred CFSE-labeled C. trachomatis-specific 
CD4+ TCR transgenic T cells into naïve mice, which were then challenged with C. trachomatis 
either by the transcervical or vaginal route of infection.  As demonstrated in Figure 2-4, these C. 
trachomatis-specific T cells were capable of recognizing the infecting bacteria and proliferated 
to a similar degree regardless of the route of infection (93% vs. 89% becoming CFSE-low).  
However, the proliferation of Chlamydia specific T cells was more robust when infected 
transcervically than intravaginally, as seen by the marked difference in their accumulation 
following division.  We also examined the phenotype of these pathogen specific T cells based 
on activation markers CD44 and CD62L, and found that there was no difference in the activation 
state of T cells stimulated by the two routes of infection (Figure 2-4). 
Recent evidence from multiple studies using mice, non-human primates, and humans has 
shown convincingly that the quality of a T cell response is a critical factor in defining protective 
immunity (33).  To examine if there is a difference in the quality of the T cell response following 
different routes of infection, we compared the ability of pathogen-specific T cells to produce 
multiple cytokines following either transcervical or intravaginal infection with C. trachomatis.  We 
transferred C. trachomatis-specific CD4+ TCR transgenic T cells into naïve mice, which were 
then challenged with C. trachomatis either by the transcervical or vaginal route of infection.  
Seven days after infection, we examined the ability of the pathogen specific cells to produce 
multiple cytokines by flow cytometry.  Transcervical inoculation induced over 50% of antigen-
specific CD4+ T cells into a “triple producer” phenotype - capable of robustly producing TNFα, 










Figure 2-4. Transcervical infection with C. trachomatis leads to the accumulation of  
cytokine secreting pathogen specific CD4+ T cells. Wildtype mice were infected by either 
intravaginal or trancervical inoculation with 106 IFU of C. trachomatis or C. muridarum.  Wild-
type CD90.1+ transgenic CD4+ T cells were CFSE labeled and transferred into CD90.2 hosts 
one day before they were inoculated transcervically or intravaginally with 106 IFU of C. 
trachomatis. Seven days following infection the draining lymph nodes were harvested and cells 
were prepared for flow cytometry. Antigen specific CD4+ T cells (CD90.1+ CD4+) were analyzed 
for CFSE dilution (A) and the surface levels of the activation markers CD62L and CD44 (B).  (C) 
Wild-type CD90.1+ transgenic CD4+ T cells were isolated seven days following infection, re-
stimulated in vitro, and prepared for intracellular cytokine staining. Gray or Black dots indicate 
whether cells are positive or negative for TNFa repectively.  (D) Wild-type CD90.1+ transgenic 
CD4+ T cells were transferred into CD90.2 hosts one day before they were inoculated 
transcervically or intravaginally with 106 IFU of C. trachomatis. Seven days following infection 
the draining lymph nodes and the genital tract were isolated and prepared for flow cytometry. 
The absolute number of Chlamydia-specific CD4+ T cells in each tissue was enumerated. 
Shown are representative plots from three independent experiments. 
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associated with enhanced protection in other infection models (33). Interestingly, Chlamydia-
specific T cells from mice infected intravaginally did not contain a high proportion of “triple 
producing” T cells (black dots vs. gray dots in Figure 2-4).   This suggests that transcervical 
infection yields a higher quality immune response when compared directly to intravaginal 
infection. 
Our CFSE proliferation data suggested that transcervical infection leads to more 
proliferation and accumulation of antigen specific T cells (Figure 2-4). We next wanted to 
directly quantify the accumulation of Chlamydia-specific T cells in the draining lymph node and 
genital mucosa. We transferred C. trachomatis-specific CD4+ TCR transgenic T cells into naïve 
mice, and then challenged them with C. trachomatis either by the transcervical or vaginal route 
of infection.  Seven days after infection, we measured the absolute number of pathogen-specific 
T cells in the draining lymph nodes and the genital mucosa.  We identified five-fold more 
Chlamydia-specific CD4+ T cells in the draining lymph node (p<0.03) and upper genital tract 
(p<0.02) when mice were infected transcervically compared to intravaginally (Figure 2-4).  
These data indicate that transcervical infection leads to enhanced recruitment of antigen 
specific cells to both the site of activation (the draining lymph node) and the target tissue (the 
genital mucosa) when compared directly to intravaginal inoculation.  Together these data 
suggest that although vaginal infection of mice with C. trachomatis elicits a pathogen-specific 
immune response, the quality of the response is minimal and the pathogen-specific CD4+ T cells 
are not robustly activated. Conversely, when the physical barrier of the cervix is bypassed using 
transcervical inoculation, C. trachomatis-specific CD4+ T cells are stimulated, the response of 
those T cells is more potent, and the cells accumulate in the both the draining lymph node and 
genital mucosa to promote clearance.  
 
CD4+ T cells are necessary and sufficient to confer protection against C. trachomatis 
infection in mice 
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As shown above, transcervical inoculation of C. trachomatis leads to higher bacterial loads in 
the upper genital tract throughout infection, causes the development of gross pathology, and 
induces a higher quality Chlamydia-specific CD4+ T cell response when compared to the vaginal 
route of inoculation.  With these data we clearly show that intravaginal inoculation of mice with 
C. trachomatis is a poor model of human infection.  Therefore, as we continued these studies 
we used only the transcervical infection model to directly examine the role of CD4+ T cells in 
protection against C. trachomatis.  Morrison et al. showed that following intravaginal inoculation 
the depletion of CD4+ T cells during the primary immune response did not result in enhanced 
disease (8).  This is in contrast to previous work from our lab showing that depletion of CD4+ T 
cells during primary infection leads to increased bacterial loads (34).  To rectify the disparity in 
these findings, we examined whether protection from a secondary challenge with C. trachomatis 
would require a competent CD4+ T cell compartment.  Mice were either infected with 106 IFU of 
C. trachomatis transcervically or C. muridarum intravaginally, rested for greater than 4 weeks to 
allow clearance of the initial infection, then re-challenged with the same pathogen.  Before re-
challenge, the mice were divided into groups treated with either antibody to deplete CD4+ T cells 
or an isotype control IgG (Figure 2-5).  After secondary challenge of the group infected with C. 
trachomatis, we examined the level of organisms present in the genital tract.  The immune mice 
were protected 100-fold more than the naïve control group (p<0.01).  Immune mice that were 
depleted of CD4+ T cells did not exhibit any protection and the bacterial burden of C. 
trachomatis was similar to that of naïve mice.  In comparison, the bacterial burden in immune 
mice challenged with C. muridarum exhibited a nearly 1000-fold level of protection as compared 
to the naïve control.  This protection was completely eliminated if C. muridarum immune mice 
were depleted of CD4+ T cells before secondary challenge.  These results demonstrate that 
CD4+ T cells are necessary for protection in the genital tract, whether mice are infected with C. 

































Figure 2-5. CD4+ T cells protect the genital mucosa from re-infection with C. trachomatis. 
Wildtype mice were infected transcervically with 106 IFU of C. trachomatis or intravaginally with 
106 IFU of C. muridarum. Five weeks after primary infection mice were injected with anti-CD4 or 
isotype control antibody. Naïve and immune mice were then infected with 106 IFU of C. 
trachomatis or C. muridarum. Six days after challenge genomic DNA was isolated from the 
upper genital tract. Quantitative PCR was used to calculate the levels of Chlamydia 16s DNA 
relative to levels of host GAPDH. Shown is a box-and-whisker plot from one of three 




We next addressed if pathogen specific CD4+ T cells are sufficient to confer protection.  Our 
previous studies have indicated that transfer of 107 TH1-skewed antigen-specific cells could 
confer protection against C. trachomatis if the mice were challenged either intravenously (16) or 
transcervically (10, 34).  However, these studies involved transfer of larger numbers of CD4+ T 
cells, than we use here, and therefore might not have accurately reflected the behavior of 
endogenous antigen-specific cells (35). We wanted to determine the minimum number of 
transferred pathogen-specific CD4+ T cells capable of conferring protection against C. 
trachomatis. C. trachomatis-specific T cells were first pre-activated and skewed towards the 
TH1 phenotype.  Cells were then transferred into mice in numbers ranging from 104-107. One 
day after the transfer of T cells, the mice were infected transcervically with C. trachomatis.  As 
demonstrated in Figure 2-6, all doses of TH1-skewed pathogen-specific T cells were capable of 
conferring protection.  However, the level of protection provided by those cells was dose 
dependent, with any number greater than 105 transferred cells conferring similar protection 
typical of an immune mouse (Figure 2-5).  It has been well-described that following transfer of 
transgenic T cells, only 10-15% of the transferred population takes hold in the new host (35).  
Therefore, these data suggest that only 104 pathogen-specific CD4+ T cells are sufficient to 
confer protection against C. trachomatis in the genital mucosa.  For the first time this allows us 
to estimate the lower limit of antigen specific CD4+ T cells needed to protect the host from 
infection with C. trachomatis.  By knowing this lower limit, future vaccines can be designed that 
offer protection, but where immunopathology can be limited. 
 
C. trachomatis infection stimulates the activation and memory development of 
endogenous C. trachomatis-specific CD4+ T cells  
Many of the experiments described above depend on the response of TCR transgenic 
cells transferred into mice.   As yet, there is no published report examining the endogenous 
































Figure 2-6. Antigen-specific TH1 cells are sufficient to protect the genital mucosa from 
infection with C. trachomatis. Wild type Chlamydia specific CD4+ T cells were skewed in vitro 
to the TH1 phenotype for 5 days. These pre-activated T cells were then transferred into 
IFNg-/- host mice. The following day the mice were challenged transcervically with 106 IFU C. 
trachomatis.  Six days after infection, the genital tract was harvested and genomic DNA was 
isolated. We used quantitative PCR to compare the levels of Chlamydia 16s DNA to host 
GAPDH. Shown is a box-and-whisker plot from one representative experiment of three 





biological relevance of the TCR transgenic transfer system.   To address the capacity of C. 
trachomatis to elicit a response of endogenous pathogen specific CD4+ T cells in mice, we used 
a MHC class-II tetramer, which recognizes T cells with the same epitope specificity as the T 
cells from the C. trachomatis-specific TCR transgenic mice.  Using the MHC class-II tetramer, 
we isolated endogenous C. trachomatis-specific CD4+ T cells from the peripheral lymphoid 
tissues of 1) naïve mice, 2) mice responding to a primary infection with C. trachomatis, and 3) 
mice that had recovered from infection and therefore harbored populations of memory T 
cells.  For comparison, we also purified endogenous C. trachomatis-specific CD8+ T cells from 
the same groups of mice using a tetramer that binds CrpA-specific T cells.  As demonstrated in 
figure 6a, our tetramers were capable of identifying endogenous C. trachomatis specific CD4+ 
and CD8+ T cells.  The number of antigen specific cells purified by the tetramer was enumerated 
in naïve mice, at the peak of primary infection, and during late memory development (Figure 2-
7).  The endogenous epitope- specific CD8+ T cells vastly outnumbered the epitope-specific 
CD4+ T cells at all time points.  However, a similar trend was observed with both CD4+ and 
CD8+ tetramer+ cells in which there was a 100-1000 fold expansion of the cell population during 
the primary immune response followed by a contraction, leaving a memory population which 
was 5-10 fold higher than the initial naïve population (p < 0.05). These experiments are the first 
to examine the expansion and contraction of endogenous pathogen-specific T cells following a 
genital infection.  Interestingly, the absolute number of Class II tetramer-positive cells identified 
during the peak of infection is similar to the minimum number of transgenic T cells needed for 
protection (Figure 2-6).  Therefore using two complimentary techniques we can show that 
between 5000 and 10000 antigen specific CD4+ T cells are necessary for protection in the 
genital mucosa. Collectively, these data indicate that endogenous CD4+ T cell immunity is 
primed following transcervical infection with C. trachomatis and a memory CD4+ T cell pool 









































Figure 2-7. Endogenous T cell response to C. trachomatis infection.  T cells specific for C. 
trachomatis were isolated from naïve, infected, or memory mice via magnetic isolation and 
tetramer pull down.  A) Representative plot for isolation of tetramer specific and negative control 
at the peak of primary infection.  The axis identifies CD4+ and CD8+ T cells specific for CTA-1 
and CrpA, respectively. B) Absolute number of pathogen specific tetramer positive CD4+ and 







Understanding adaptive immunity to C. trachomatis is key to the development of an 
effective vaccine against this pathogen. Following vaginal infection in humans, the bacteria can 
ascend to the upper genital tract where persistent infection results in inflammation and tissue 
damage.  In contrast to human infection, vaginal infection of mice with C. trachomatis does not 
result in significant upper genital tract infection or pathology (28).  The mouse specific 
Chlamydia species, C. muridarum, is able to ascend from the vagina to the upper genital tract, 
causing robust inflammation but not persistent infection (36).  Deciphering any differences in 
how the immune system responds to these organisms will allow both to be used in studies of 
disease pathogenesis and to develop vaccines.  
Here we sought to compare the ability of the mouse to mount a CD4+ T cell response 
against both Chlamydia species and measure the level of protection provided by that immunity. 
One of the most significant differences between the two species is the inability of C. trachomatis 
to ascend from the vagina/ectocervix to the upper genital tract in mice. This deficiency may 
prevent C. trachomatis from stimulating robust protective immunity in the vaginal vault as 
previous reports have suggested that the lower genital tract is an immune suppressive 
environment (37, 38). We hypothesized that the cervix is the primary physical barrier to upper 
genital tract infection with C. trachomatis, and that if we bypassed this restriction we might allow 
for an immune response to this human-adapted pathogen. We show there is a marked 
difference in the infection and the resulting immune response between transcervical and vaginal 
delivery of C. trachomatis.  Transcervical infection also led to gross pathology in roughly 15% of 
animals while intravaginal inoculation of C. trachomatis led to no obvious pathology (Figure 2-2). 
This is the first fully immune competent mouse model to consistently demonstrate gross 
pathology after C. trachomatis infection (39).   One important consideration with this study is the 
use of the LGV strain of C. trachomatis. Future studies will need to broadly examine the 
transcervical infection model with other genital strains of C. trachomatis that are of high public 
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health interest. These studies will allow us to begin examining the characteristics of both antigen 
specific cells and bystander cells that promote the induction of pathology across several 
clinically relevant strains of C. trachomatis; studies that have been difficult up to this point. 
Our infection timecourse showed that bypassing the cervix alone does not lead to 
pathogen burden similar to the C. muridarum. The 10-fold increase in bacterial burden from day 
3 to day 6 following C. muridarum infection was not seen with C. trachomatis. We next 
examined whether the lack of expansion was due to the suppression of C. trachomatis growth 
by the murine IFNγ response, as previous reports have shown that the absence of IFNγ leads to 
higher burden and longer duration of C. trachomatis infection (40, 41). IFNγ -mediated 
restriction of C. trachomatis is predominantly driven through the activity of the IRG family of 
GTPases (22, 25, 42).  In contrast to C. trachomatis, C. muridarum is thought to evade IRG-
mediated growth restriction due to the expression of a cytotoxin, which undermines this 
restriction mechanism (25).  When mice deficient in either IFNγ or IRGs (Irgm1/m3) are infected 
with C. trachomatis, we observe a burst of bacterial growth from day 3 to day 6. These 
enhanced bacterial loads are identical, whether it is IFNγ -KO mice or IRGm1/m3-KO mice 
infected transcervically with C. trachomatis, or wildtype mice infected with C. muridarum (Figure 
2-3).  Thus, bypassing the physical restriction of the cervix, in combination with the lack of IRGs, 
leads to a C. trachomatis infection model system where loads and pathologies are comparable 
to that observed with C. muridarum vaginal infection. Both C. trachomatis transcervical 
infections and C. muridarum intravaginal infections are highly inflammatory as measured by the 
significant influx of neutrophils and the response of CD4+ T cells that ultimately are able to clear 
infection with either species (data not shown and (34, 43)). Importantly, neither mouse model 
allows the development of the chronic infections observed in humans (34, 40). One explanation 
for the lack of persistent infection in mice is that mice and humans have different cell-
autonomous mechanisms of responding to IFNγ. Humans lack an IFNγ-inducible IRG response, 
and instead respond to IFNγ by upregulating the expression of indolamine dioxygenase (IDO) 
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(7, 44).  IDO induces tryptophan catabolism, resulting in a persistent form of C. trachomatis that 
does not grow rapidly and is not cleared. It is this critical difference in the response to IFNγ that 
may prevent C. trachomatis and C. muridarum from causing persistent infections in a murine 
model of genital infections.  We are now examining whether transcervical infection of mice in 
which Irgm1 and Irgm3 are knocked out, and human IDO is knocked in might allow infection 
with C. trachomatis that more closely models the persistent infections seen in humans. 
It is well accepted that the primary source of IFNγ seen during infection is the CD4+ T 
helper cell. However, one recent report called into question the role, if any, CD4+ T cells play in 
the resolution of, and protection against, C. trachomatis during murine infection.  Morrison et al. 
showed that clearance of vaginal C. trachomatis genital infection is unaltered by depletion of 
CD4+ T cells in mice deficient for innate immunity (8). The authors concluded that genital 
infection with C. trachomatis in mice does not stimulate an adaptive immune response and are 
not protected from subsequent infection.  We hypothesized that the lack of adaptive immunity 
observed using their model was due to the inability of C. trachomatis to access the upper genital 
tract. Transcervical infection resulted in a significant enhancement in the ability of C. 
trachomatis to prime pathogen-specific T cells and recruit them to the upper genital mucosa 
(Figure 2-4).  Transcervical infection with C. trachomatis also stimulated a robust CD4+ memory 
response that was essential for protection following re-infection of the genital tract (Figure 2-
5).  We further characterized the protective capacity of CD4+ T cells, showing that pathogen 
specific cells skewed towards TH1 are sufficient to protect naïve mice from C. trachomatis in a 
dose dependent manner (Figure 2-6).  For the first time we were able to show that only 1000 
Chlamydia specific T cells is the lower limit needed for significant protection (Fig 2-6). Finally, 
we tested whether transcervical inoculation was capable of stimulating endogenous C. 
trachomatis-specific T cells.  Using a MHC-II tetramer for the first time to track T cells during a 
genital tract infection, we demonstrated clonal expansion and memory development of 
endogenous epitope-specific CD4+ T cells (Figure 2-7).  These results showed that during the 
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peak of infection, >1000 antigen specific T cells are induced, similar to the lowest transfer dose 
in our protection experiments (Figure 2-6). By quantifying the lower limit needed for protection 
we now have a baseline that allows us to tune the infiltration of different cell types to reduce 
pathology while still promoting protection.  Together our studies illustrate our unique ability to 
examine physiological levels of Chlamydia specific T cell responses using a combination of TCR 
transgenic T cells and Class-I and Class-II tetramers.  To date, there is lack of data using TCR 
transgenic T cells or MHC-II tetramers to determine the extent to which Chlamydia-specific 
CD4+ T cells are recruited to the genital mucosa following C. muridarum infection. This 
shortcoming in the literature has made it impossible to know whether the T cells responding to 
C. muridarum infection are antigen-specific or whether many of them are bystander cells that 
merely follow the chemokine/cytokine gradients resulting from inflammation.  Studying total 
CD4+ T cell infiltration may not reflect the antigen-specific immune response generated by C. 
trachomatis and C. muridarum infections.  Only by differentiating antigen specific and bystander 
immune responses can we determine the role of these populations in development of the 
immune pathologies seen clinically. 
This study demonstrates that infection of the upper genital tract with either C. 
trachomatis or C. muridarum stimulates protective immune responses as well as gross 
pathology.  Immunity to both species is dependent on CD4+ T cells, and only 1000 Chlamydia 
specific CD4+ T cells are sufficient to confer protection.  Importantly, in the absence of the 
murine IRG or IFNγ response, C. trachomatis and C. muridarum colonize the murine upper 
genital tract at similar levels yet neither species causes persistent infections.  The novel 
transcervical inoculation technique described here will provide a technically easy, non-invasive, 
highly reproducible, biologically relevant system for vaccine development (29).  The model 
allows investigators to transcend discussions of relevant model system and focus on issues of 
pathology vs. protection following infection.  These discussions are a critical step in defining the 
factors that drive Chlamydia specific pathogenesis and host defense.   
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Methods and Materials: 
Mice 
C57BL/6, B6.PL-Thy1a (CD90.1 congenic), and B6.129S7-IFNγtm1Agt (IFN-γ−/−) were 
purchased from The Jackson Laboratory. Irgm1/m3(-/-) and NR1 mice were described 
previously (11, 34) and are maintained and cared for within the Harvard Medical School Center 
for Animal Resources and Comparative Medicine (Boston, MA). All mice were treated with 
2.5mg of medroxyprogetrone subcutaneously seven days prior to infection in order to normalize 
the murine estrous cycle. All experiments were approved by Institutional Animal Care and Use 
Committee. In all experiments four or five mice per group were used. 
Growth, isolation and detection of bacteria.  
C. trachomatis serovar L2 (434/Bu) or C. muridarum was propagated within McCoy cell 
monolayers grown in Eagle’s MEM (Invitrogen, Grand Island NY) supplemented with 10% FCS, 
1.5 g/L sodium bicarbonate, 0.1 M nonessential amino acids, and 1 mM sodium 
pyruvate.  Infected monolayers were disassociated from plates using sterile glass beads and 
sonicated to disrupt the inclusion.  EBs were purified by density gradient centrifugation as 
described previously (10). Aliquots were stored at -80°C in medium containing 250 mM sucrose, 
10 mM sodium phosphate, and 5 mM L-glutamic acid and thawed immediately prior to use. To 
quantify the levels of C. trachomatis or C. muridarum we used quantitative PCR with 16s 
primers specific for Chlamydia as done previously (REF). For titering directly from the genital 
tract, at the given timepoints the upper genital tract was isolated, homogenized by mechanical 
disruption, and placed in six-well plates pre-seeded with 5x105 McCoy cells and incubated for 
36 hours to allow the developmental cycle to finish. Cells were then lysed as described above 
and titered into 96-well plates containing 1x104 McCoy cells. Thirty hours post-infection the cells 
were fixed with methanol and stained using a Chlamydia culture diagnostic kit (Roche). 
Inclusions were then quantified by fluorescence microscopy.  
Skewing of NR1 cells and protection assay.  
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CD4+ T cells were purified from NR1 mice using a mouse CD4 negative isolation kit (Invitrogen) 
per the manufacturer’s directions.  The T cells were cultured in RPMI-1640 (Invitrogen) 
supplemented with 10% FCS, L-glutamine, HEPES, 50 µM 2-mercaptoethanol, 50 U/ml 
penicillin, and 50 ug/ml streptomycin.  To stimulate the T cells, irradiated feeder splenocytes 
were pulsed with 5 µM of Cta1 133-152 peptide and cocultured with the CD4-enriched NR1 cells 
at a stimulator to T cell ratio of 4:1. To polarize T cells towards the Th1 phenotype cells were 
incubated with 10 ng/ml of IL-12 (Peprotech, Rocky Hill NJ) and 10 µg/ml of anti-IL4 
(Biolegend). Cells were stimulated for five days then 106 cells were transfered into naïve 
CD90.2+  IFNγ-/- host mice. Twenty-four hours following transfer, mice were challenged in the 
uterus with 106 IFU of C. trachomatis L2. 
Flow cytometry 
Tissues were mechanically disaggregated and immediately stained for activation markers or 
stimulated for 5 h with 50 ng/ml PMA (Alexis Biochemical) and 500 ng/ml ionomycin 
(Calbiochem) in the presence of brefeldin A (GolgiStop; BD Biosciences) for intracellular 
cytokine staining. Cells were preincubated with anti-FcRγ (Bio X-Cell) before staining with anti-
CD4 Pacific Blue (Biolegend) and anti-CD90.1 peridinin chlorophyll-a protein (BD Bioscience). 
For activation marker analysis, we examined anti-CD44 PE-CyChrome 7 (Biolegend), anti-
CD62L allophycocyanin-Alexa 750 (Ebioscience), and anti-CD25 allophycocyanin (BD 
Bioscience). For intracellular staining, the following antibodies were used: anti-IFN-γ PE, anti-
IL2- allophycocyanin, anti-IL17 fitc, and anti-TNF-α PE-CyChrome 7 (BD Biosciences). Cells 
were permeabilized with the Cytofix/Cytoperm Plus kit according to the manufacturer’s 
instructions (BD Bioscience). The absolute cell numbers in each sample was determined using 
accucheck counting beads (Invitrogen). Data were collected on a modified FACSCalibur (Cytek 
Development) or an LSRII (BD Bioscience) and analyzed using Flow Jo (Tree Star). 
T cell depletion 
 64 
For CD4+ T cell depletion experiments, mice were infected with 106 IFU C. trachomatis or C. 
murdidarum then rested for greater than four weeks. Starting three days prior to secondary 
challenge, immune mice were intraperitoneally injected with 200µg/mouse anti-CD4 (clone 
GK1.5) or isotype control (clone LTF-2) everyday.  Mice were sacrificed five days after 
challenge and their lymphocytes were assessed in the spleen, lymph nodes, and uterus.  In 
addition, the bacterial load was determined by quantitative PCR. 
Tetramer production, enrichment 
Chlamydia trachomatis predicted periplasmic protein Cta1 133-152 
(KGIDPQELWVWKKGMPNWEK) Biotin-labeled I-Ab molecules and the CrpA 63–71 
(ASFVNPIYL) biotin labeled Db tetramer were produced by the NIH tetramer facility (Emory 
University), purified and tetramerized with streptavidin allophycocyanin or phycoerythrin, 
respectively.   Spleen and lymph node cells were prepared, stained with CTA-1:I-Ab–SA-APC at 
25°C for 1 h and then spiked with CrpA:Db-SA-PE at 4°C for 30min.  Cells were then washed 
and incubated with anti-PE and anti-APC magnetic beads. Bead-bound cells were then enriched 
on magnetized columns and a sample was removed for counting. The enriched cells were 
surface stained with combinations of antibodies listed above.  
Statistical analysis 
All groups were evaluated for statistical significance through the use of unpaired two-tailed t 
tests. Where it appeared necessary to highlight significant differences between data points, the 
level of significance is depicted as: *, p < 0.05; **, p < 0.01; and ***, p < 0.005. 
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The results of this chapter are published in Mucosal Immunology  
 70 
Introduction 
The ability of a host to respond to and clear infections depends on coordinated communication 
between the innate and adaptive immune responses. Infection stimulates innate immune 
sensing mechanisms, such as Toll-like receptors that secrete specific chemokines into the 
tissues (1). Activated T cells follow these chemokine gradients by upregulating the expression of 
distinct chemokine receptors in order to exit the lymphatic system and traffic to the site of 
infection (2).  
Several previous reports have identified dominant chemokine receptors that are 
expressed by T cells in order for proper migration to mucosal tissues. For example, CCR9 is 
critical for recruitment to the intestinal tract under many conditions (3), while CXCR3 directs T 
cell migration to the lungs following influenza virus infections (4, 5).  Despite the increase in 
concern over the public health impact of sexually transmitted infections (STIs)(6), homing 
receptors for the genitourinary tract remain largely undefined. The most prevalent genital tract 
bacterial infection is caused by the obligate intracellular pathogen Chlamydia trachomatis. 
Clearance of C. trachomatis is primarily dependent on T cell secretion of IFNγ , which directly 
and indirectly targets the infected epithelial cells (7-15).  However, the immune response to C. 
trachomatis is also responsible for tissue damage and the induction of sequelae such as 
infertility and ectopic pregnancy (7, 16). Understanding the trafficking of immune cells following 
an STI is key to the development of therapeutic interventions that lead to protection and prevent 
pathology.   
In order to define how T cells respond to C. trachomatis, it is critical to elucidate what 
chemokine/chemokine receptor pairs promote proper activation and recruitment of T cells during 
infection. Reports examining the inflammatory conditions in the genital mucosa of mice following 
infection with the mouse-adapted species Chlamydia muridarum showed that the chemokines 
CCL5 and CXCL10 are upregulated and secreted at high levels from cells in the tissues (17-19). 
Another study examined samples from human patients and demonstrated an increase in CCR5 
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expression following C. trachomatis genital infections (20), while a different report showed mice 
deficient in CCR5 were unable to clear C. muridarum infections (21). Even though these data 
provide insight into expression dynamics following infection, they do not directly reveal which 
subsets of immune cells, such as T cells, are activated and recruited to the genital mucosa 
through the action of chemokine receptors. Furthermore, these studies are unable to distinguish 
the response of C. trachomatis specific lymphocytes from infiltrating bystander lymphocytes that 
respond in a non-specific manner to the general inflammatory conditions in the genital mucosa. 
In this study, we monitored CD4+ C. trachomatis-specific T cells, which harbor a fixed TCR 
specific for the C. trachomatis antigen Cta1 (12).  We were able to directly assess the impact of 
two chemokine receptors on the ability of Chlamydia-specific T cells to become activated and 
respond during infection of the genital tract.  We find that concomitant expression of CXCR3 
and CCR5 expression is required for antigen specific T cells to access, accumulate, and protect 





CXCR3 and CCR5 are upregulated on lymphocytes during C. trachomatis infection. 
Previous studies have examined chemokines and chemokine receptors that are induced in 
whole tissue homogenates of the genital tract following C. trachomatis infection. Yet these 
studies could not differentiate non-specific homing, resulting from general inflammation, from 
the truly pathogen-specific lymphocytes responding to the genital mucosa. To determine which 
receptors are required for lymphocyte homing to the genital mucosa, we surveyed chemokine 
receptor mRNA expression in isolated lymphocytes from naïve vs. C. trachomatis infected mice.  
We extracted lymphocyte RNA isolated from the draining lymph node or genital tract in naïve 
mice or from mice infected in the uterus with 106 C. trachomatis. Using RT-PCR we examined 
the differences in expression of five different chemokine receptors on tissues from uninfected 
and infected mice.  Analysis of the draining lymph node showed that only CXCR3 expression 
was increased following infection, showing a two-fold enhancement (Figure 3-1). In contrast, the 
lymphocytes isolated from the genital tract showed that expression of both CXCR3 and CCR5 
was significantly induced following C. trachomatis infection.  Expression of CXCR3 was 
increased more than ten-fold after infection, while CCR5 was upregulated by more than four-
fold.  In order for lymphocytes to exit the lymph node, they down-regulate CCR7, consistent with 
our observation that the level of this marker decreased on lymphocytes in both the draining 
lymph node and genital tract of infected mice (22). All other chemokine receptors examined 
showed no changes in expression levels following infection with C. trachomatis. Therefore, the 
expression of the chemokine receptors CXCR3 and CCR5 is upregulated in lymphocytes in 
response to a genital tract infection with C. trachomatis.  
 
Mice deficient in CXCR3 or CCR5 have increased C. trachomatis burden following genital 
tract infection.  The increase in the expression of CXCR3 and CCR5 on lymphocytes following 

















Figure 3-1. CXCR3 and CCR5 are upregulated in the genital tract during infection and 
necessary for clearance of C. trachomatis. A) RNA was isolated from tissues of uninfected 
and infected mice. RT-PCR was used to quantify the expression of five chemokine receptors 
relative to a GAPDH control. Fold-induction was calculated (relative expression 
infected)/(relative expression uninfected). The data shown are representative of three 
independent experiments. Each bar represents the average fold-induction ± SD of two pools of 
five mice for each condition B) Genomic DNA was isolated from the genital tract of wild-type, 
CXCR3-/-, or CCR5-/- mice six days following infection. Quantitative PCR was used to calculate 
the levels of C. trachomatis 16s DNA relative to levels of host GAPDH. Shown is a box and 





the resolution of infection. We therefore assessed the efficiency of C. trachomatis clearance 
from the genital tracts of mice deficient in either CXCR3 or CCR5 as compared to wild-type 
mice. Wild-type, CXCR3-/-, and CCR5-/- mice were infected in the uterus with 106 IFU of C. 
trachomatis, and levels of bacteria in the genital tract were evaluated six days later by qPCR 
(Figure 3-1)(12).  All wild-type mice had under 10 pg of bacterial 16s DNA per mg of host DNA, 
whereas both the CXCR3-/- and CCR5-/- mice had almost 8-fold higher levels of bacterial 16s 
DNA in the genital tract. Since there was no difference in bacterial load between CXCR3-/- or 
CCR5-/- mice, it suggests that both receptors may be needed for the proper resolution of genital 
tract infection with Chlamydia. 
 
Chlamydia specific CD4+ cells become activated and traffic normally to the genital tract 
in chemokine receptor-deficient hosts. The high bacterial loads observed in the CXCR3 and 
CCR5 deficient mice could be due to an inability to properly prime an immune response (23, 
24). To test this, we monitored wild-type Chlamydia specific TCR transgenic T cells during 
infection of wild-type, CXCR3-/-, and CCR5-/- host mice inoculated with C. trachomatis.  Seven 
days after infection, we found that wild-type pathogen-specific T cells showed no defect in 
trafficking to the spleen, draining lymph nodes, or the genital tract in hosts deficient for CXCR3 
or CCR5 (Figure 3-2A). Thus, the recruitment and/or retention of pathogen specific T cells in the 
genital tract is independent of chemokine receptor expression in the host.  To ensure that the 
Chlamydia specific T cells were activated normally, we stained the isolated T cells for CD62L, 
CD45Rb, and CD25 as markers of early and late activation (Figure 3-2B).  When we compared 
cells isolated from mice expressing the chemokine receptors with those lacking expression, we 
found that the cells showed identical activation.  Furthermore, these cells also secrete IFNγ to 
similar levels upon restimulation in vitro (data not shown). Most importantly, all the Chlamydia-






Figure 3-2. Wild-type Chlamydia specific CD4+ T cells are recruited to the genital tract 
and become activated in CXCR3 or CCR5 deficient mice. A) Wild-type CD90.1+ transgenic 
CD4+ T cells were transferred into CD90.2 wild-type, CXCR3-/-, or CCR5-/- host mice. The 
following day, hosts were challenged in the genital tract with C. trachomatis. Seven days after 
infection the tissues were harvested and cells prepared for flow cytometry. Antigen specific 
CD4+ T cells were identified as both CD4 and CD90.1 positive. The graph shows the percent of 
total live cells in each tissue examined and is representative of one experiment of two 
conducted. B) Surface levels of the activation markers CD45Rb and CD62L were examined by 
flow cytometry. All cells were pre-gated on CD4 and CD90.1 positive T cells. A representative 
plot from one of two independent experiments is shown.  
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even when the host bystander population is deficient in CXCR3 or CCR5 there is no deficiency 
in the priming of Chlamydia specific T cells.  
 
Both CXCR3 and CCR5 are upregulated on Chlamydia specific T cells present in the 
genital mucosa.  Because host deficiency in CXCR3 or CCR5 did not alter the priming or 
homing of wild type antigen specific T cells, we hypothesized that T cells responding to C. 
trachomatis antigens in the genital tract might be enriched for CXCR3 and/or CCR5. To test 
this, we examined the presence of CXCR3 and CCR5 on the surface of antigen specific 
transgenic T cells during infection.  Naïve Chlamydia specific T cells were isolated from TCR 
transgenic mice and stained for CXCR3 and CCR5 (Figure 3-3). All naïve cells examined 
expressed low levels of both CXCR3 and CCR5. We then transferred these antigen specific T 
cells into mice that were infected in the uterus with C. trachomatis.  Seven days after infection 
we isolated lymphocytes from the draining lymph nodes and genital mucosa and stained them 
for CXCR3 and CCR5. Chlamydia specific T cells from the lymph nodes were more than twenty 
percent positive for CXCR3 while all cells remained low for CCR5.  However, almost all of the 
antigen specific T cells isolated from the genital tract were CXCR3 high and over 80 percent 
were now CCR5 positive. We observed two distinct CCR5 positive subsets in the genital tract, 
but the significance and phenotypic difference of these distinct populations is still unclear.  
These data suggest that in response to infection Chlamydia specific T-cells upregulate CXCR3 
on their surface beginning in the draining lymph node.  Upon exiting the lymph node, CXCR3 is 
further upregulated, and CCR5 now becomes expressed on the surface at high levels, resulting 
in their recruitment to or their retention in the genital tract. Chlamydia specific CD4+ T cells 
deficient in CXCR3 or CCR5 are unable to traffic normally to the genital tract.  As 
described above we found that CXCR3 and CCR5 are upregulated on C. trachomatis specific T 
cells in response to genital tract infection and that pathogen specific T cells activate normally in 








Figure 3-3. CXCR3 and CCR5 are upregulated on the surface of antigen specific CD4+ T 
cells in a stepwise fashion following C. trachomatis infection. Wild-type CD90.1 Chlamydia 
specific CD4+ T cells were transferred intravenously into CD90.2 hosts. Mice were challenged in 
the genital tract with C. trachomatis the following day.  Seven days after infection the tissues 
were isolated and analyzed by flow cytometry. Chlamydia antigen specific cells were identified 
by CD4+CD90.1+ gating and assessed for surface expression of CXCR3 and CCR5 Shown is a 
representative plot from three independent experiments.  
  
 78 
mice deficient in CXCR3 or CCR5 is due to an inability of pathogen specific T cells to traffic to 
the genital mucosa during infection. We obtained Chlamydia specific T cells that are deficient in 
CXCR3 or CCR5 and monitored their trafficking in mice during C. trachomatis genital tract 
infection. We transferred 105 wild-type, CXCR3-/-, or 
CCR5-/- antigen specific T cells into CD90.1 wild-type hosts.  The mice were then infected with 
C. trachomatis and the number of Chlamydia specific T cells in the genital tract was assessed at 
four time points (Figure 3-4A).  Four days after infection there was no significant trafficking of 
any T cells into the genital tract.  However, by six days following infection, wild-type Chlamydia 
specific T cells amassed in the genital tract, while cells from either CXCR3-/- or CCR5-/- mice 
failed to migrate to the site of infection.  Eight days after infection the recruitment of wild-type 
cells to the genital tract continued to increase, whereas cells from CXCR3-/- and CCR5-/- mice 
showed no accumulation.  Ten days following infection, when C. trachomatis is mostly cleared 
(data not shown), the number of wild-type cells in the genital tract began to contract, whereas 
pathogen specific T cells from the chemokine receptor deficient mice showed no signs of 
trafficking to the genital tract.  These data illustrate that lack of either CXCR3 or CCR5 does not 
delay recruitment to the genital tract, rather it completely prevents homing to the site of 
infection. 
Since our time-course data suggested that the loss of either CXCR3 or CCR5 blocks 
recruitment to the genital tract, we next wanted to assess whether a loss of both CXCR3 and 
CCR5 would further impede homing to the genital tract. We bred the TCR transgenic onto the 
CXCR3/CCR5 double knockout mouse background. We then transferred these antigen specific 
CXCR3-/- CCR5-/- T cells (as well as wild-type, CXCR3-deficient, and CCR5-deficient T cells) 
into CD90.1 wild-type hosts that were then infected with C. trachomatis.  Eight days following 
infection, a time when we found the greatest difference in homing between wild-type and 










Figure 3-4. Chlamydia specific CD4+ cells lacking CXCR3 and/or CCR5 are unable to 
traffic to the genital mucosa. A) Wild-type, CXCR3-/- or CCR5-/- CD90.2+ Chlamydia specific T 
cells were transferred into CD90.1+ host mice. Mice were challenged the following day with C. 
trachomatis in the genital tract. At the timepoints indicated, the genital tract was harvested and 
cells prepared for flow cytometry. The total number of antigen specific T cells was also 
quantified. Each data point represents the total number of cells from three mice for each 
genotype. The figure represents one experiment of two conducted. B) CD90.2+ wild-type, 
CXCR3-/-, CCR5-/-, or CXCR3-/- CCR5-/- transgenic CD4+ T cells were transferred into CD90.1+ 
host mice and infected the following day with C. trachomatis. Eight days following infection the 
tissues were harvested and prepared for flow cytometry. Shown is a representative cytometry 
plot from one experiment of three conducted of the draining lymph node (top panel) and genital 
tract (bottom panel). The host CD4+ T cell population is shown in grey and the antigen specific 
CD4+ T cells are shown in black. The values presented are a percent of total live cells. C) 
Absolute total numbers of Chlamydia specific CD4+ T cells in the genital tract were quantified 
from the experiment in B. D) Cells isolated from the draining lymph node were pre-gated for 
CD90.2+ and CD4+ positive populations and examined for surface staining of the activation 




in the draining lymph nodes of infected mice (Figure 3-4B).  However, in the genital tract, wild-
type cells accumulated at levels more than twenty-fold higher than chemokine receptor-deficient 
cells (Figure 3-4B,C). All variants of the chemokine receptor-deficient Chlamydia specific T cells 
were unable to home correctly to the genital tract following infection, and the double knockout 
phenotype was identical to that of either single knockout. These data show that both CXCR3 
and CCR5 are needed to properly direct antigen specific T cells following C. trachomatis 
infection in the genital mucosa. 
While these data suggest that CD4+ cells deficient for CXCR3 or CCR5 are not recruited 
efficiently to the genital tract following infection, we wanted to confirm they were activated 
normally in order to rule out any deficiency in T cell priming.  We assessed the levels of CD62L 
and CD45Rb on all of the chemokine receptor-deficient Chlamydia specific T cells in the 
draining lymph node eight days after infection.  Surface staining showed no significant 
difference in activation pattern between the chemokine receptor-deficient T cells and wild-type T 
cells even though there is a slight decrease in activation of chemokine receptor deficient T cells 
(Figure 3-4D). Taken together, loss of CXCR3, CCR5, or both severely inhibits trafficking of 
pathogen specific T cells to the genital mucosa even though these cells accumulate equivalently 
in the draining lymph node and are activated similarly to wild-type T cells.  
 
Chlamydia-specific CD4+ cells deficient for CCR5 or CXCR3 are unable to compete with 
WT cells in trafficking to the genital tract. Since trafficking to the genital tract was completely 
ablated in transfer studies using single chemokine receptor knockouts, we were unable to 
determine if the CXCR3-/- CCR5-/- T cells exacerbated the homing deficiency to the genital 
mucosa. To test this we developed a competitive homing assay that would be more sensitive to 
subtle differences in T cell numbers homing to the genital mucosa. This approach allowed us to 
directly monitor the ability of wild-type and chemokine receptor deficient T cells to home to the 
genital tract under identical conditions in the same host (Figure 3-5A).   We first transferred an 
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equal number of CD90.1 chemokine receptor sufficient and CD90.2 chemokine receptor 
deficient antigen specific T cells into CD45.1 hosts, which we then infected in the genital tract 
with C. trachomatis.  Seven days after infection, we calculated a migration index [(% CD90.1)/ 
(%  CD90.2)] for all the T cells transferred in both the draining lymph node and the genital tract 
(Figure 5B).  T cells of all genotypes showed no statistical difference in the migration index in 
their draining lymph node. In contrast, when we calculated the migration index for T cells in the 
genital tract, only the wild-type T cell transfer yielded a migration index near 1. Pathogen 
specific T cells that were deficient in CCR5 migrated 30 percent less efficiently than wild-type 
cells, while T cells lacking CXCR3 were 20 percent less efficient. Interestingly, the antigen 
specific T cells lacking both chemokine receptors migrated ten fold less efficiently than wild-type 
cells suggesting an additive impact of both CXCR3 and CCR5. This indicates that while both 
single chemokine receptor knockouts are impaired in their ability to compete with wild-type T 
cells and be recruited to the genital tract, loss of both receptors may be more detrimental to their 
ability to access the genital mucosa.  
 
Chlamydia-specific CD4+ cells deficient for CCR5 or CXCR3 are unable to protect mice 
from genital tract infection. The experiments above show that loss of CXCR3 and/or CCR5 
impairs the recruitment of Chlamydia specific T cells to the genital mucosa following infection. 
Therefore we predicted these T cells would not be able to protect mice from infection as well as 
wild-type T cells. To assess their protective capacity, we pre-activated wild-type, CXCR3-/-, 
CCR5-/- and double deficient T cells in vitro, polarizing them to the Th1 phenotype and then 
transferred them into IFNγ -deficient hosts. Since the clearance of C. trachomatis in mice is 
dependent on IFNγ , and the only source of IFNγ was the transferred population of cells, we 
were able to directly ascertain the capacity of Chlamydia specific T cells to traffic to the site of 
infection, locally produce IFNγ, and reduce bacterial burden in the genital tract (8-10). Following 
in vitro TH1 skewing, all the chemokine receptor deficient T cells were competent at secreting 
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Figure 3-5. Chemokine receptor-deficient Chlamydia specific CD4+ T cells are unable to 
compete with wild-type cells in homing to the genital tract. A) A schematic of the 
competitive homing assay is shown. Equal numbers of antigen specific CD4+ T cells from 
CD45.2/CD90.1 wild type mice and CD45.2/CD90.2 wild-type, CXCR3-/-, CCR5-/-, or CXCR3-/- 
CCR5-/- mice were transferred into CD45.1/CD90.2 host mice. The following day mice were 
infected in the genital tract with C. trachomatis. Seven days after infection tissues were 
harvested and prepared for flow cytometry. The strategy for gating is illustrated. We first gated 
CD4 and CD45.2 positive cells. Then we compared the percent of the gated cells that were 
CD90.1 or CD90.2 positive.  Shown is a representative plot comparing the homing to the genital 
tract between the wild-type:wild-type cell mix and CXCR3-/-CCR5-/-:wild-type mix. Shown is one 
representative of four independent experiments. B) We calculated a migration index for each 
cell mix using the percent of CD90.2/CD90.1 positive cells present in the draining lymph node 
(top) and the percent of the CD90.2/CD90.1 positive cells in the genital tract (bottom). Error bars 





IFNγ equivalently to wild-type T cells (data not shown).    Activated cells were transferred into 
mice, which were subsequently challenged with C. trachomatis. After 6 days of infection, the 
peak of antigen specific T cells recruitment to the site of infection (Figure 3-4A), we isolated the 
genital tract and determined the levels of C. trachomatis by qPCR (Figure 3-6).  Mice that 
received wild-type T cells had more than two logs less C. trachomatis relative to mice receiving 
no T cells.  However, mice receiving either CXCR3 or CCR5 single knockout T cells had ten-fold 
higher bacterial levels compared to wild-type cells. This showed that single receptor knockout 
cells partially protected the host, decreasing Chlamydia burden by over one log as compared to 
mice receiving no transfer. Therefore, both CXCR3-/- and CCR5-/- antigen specific T cells are 
capable of protecting host mice from C. trachomatis infection to some degree, albeit much less 
than wild-type. Surprisingly, mice that received CXCR3-/- CCR5-/- T cells did not protect host 
mice whatsoever and had levels of C. trachomatis in the genital tract identical to mice that 
received no transfer. These data indicate that, although loss of CXCR3 or CCR5 in antigen 
specific T cells leads to a deficiency in protecting mice from infection, loss of both receptors in 
concert results in total ablation of protection against C. trachomatis. This illustrates that optimal 
trafficking and protective function of Chlamydia specific T cells in the genital tract requires a 






















Figure 3-6. Antigen specific TH1 cells deficient in both CXCR3 and CCR5, have no 
protective capacity in vivo. Wild-type, CXCR3-/-, CCR5-/-, or CXCR3-/- CCR5-/- Chlamydia 
specific CD4+ T cells were skewed in vitro to the Th1 phenotype for five days. These pre-
activated T cells were then transferred into IFNγ -/- host mice. The following day the mice were 
challenged with C. trachomatis. Six days after infection the genital tract was harvested and DNA 
was isolated. We used quantitative PCR to compare the levels of Chlamydia 16s DNA to host 
GAPDH DNA.  Levels of C. trachomatis 16s DNA were converted into pg/µl. Shown is a box and 
whisker plot from one representative experiment of two conducted. In the graph shown all 
samples are significantly different (p<0.05) except for the comparison between the CXCR3-/- and 





The ability of immune cells to traffic to sites of inflammation and infection is necessary 
for efficient clearance of invading pathogens.  While chemokine receptors that are critical for 
directing T cells to the lungs and intestinal tract have been described previously(1, 4, 5), 
characterization of receptors that are necessary for recruitment to the genital tract has remained 
elusive.  In this report, we show that a combination of CXCR3 and CCR5 is necessary for 
pathogen-specific CD4+ T cells to respond to and clear C. trachomatis infection of the genital 
mucosa. 
Previous studies showed that infection with the mouse specific pathogen C. muridarum 
led to elevated levels of the chemokines CXCL10 and CCL5 in the genital tract tissue(17). 
These chemokines, specific for the receptors CXCR3 and CCR5, promote the recruitment of 
immune cells to resolve infection.  CCR5 has been implicated in genital mucosa homing 
because CCR5 deficient mice are unable to clear C. muridarum infections efficiently(21). 
However, one recent study suggested that CXCR3 may be important for CD8+ T cells to 
respond to the vaginal tissue during herpes simplex virus infection(25). Therefore, we sought to 
determine the chemokine receptors that are necessary for pathogen specific T cells to clear a 
murine genital infection with the human bacterial pathogen C. trachomatis. Although mice clear 
C. trachomatis infection more efficiently than humans, we are able to demonstrate that T cells 
respond and migrate in the mouse following C. trachomatis infection.  Therefore we could use 
C. trachomatis-specific TCR transgenic T cells to facilitate these experiments.  It is possible that 
the rapid clearance of C. trachomatis from mice relative to humans affects the molecules 
responsible for T cell migration, but we have no evidence that this is the case. 
Following stimulation and activation, pathogen specific T cells upregulate specific 
chemokine receptors to egress from the lymph node and respond rapidly to the infected tissue.  
Indeed, we saw a trend in CXCR3 and CCR5 expression at both the transcriptional level as well 
as expression through surface staining. In the draining lymph node there was a distinct 
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upregulation of only CXCR3. Meanwhile, in the genital mucosa there was a dramatic 
upregulation of both CXCR3 and CCR5, indicating that these receptors may be regulated in a 
step-wise fashion.  Our current model proposes that the initial upregulation of CXCR3 in the 
draining lymph node allows efficient egress following T cell activation.  Upon exiting the lymph 
node, antigen specific T cells upregulate CCR5 in order to migrate to the genital mucosa. 
In this report we show that mice deficient in either CXCR3 or CCR5 are unable to clear 
genital tract infections with C. trachomatis as efficiently as wild-type mice.  One possible 
hypothesis is that the loss of chemokine receptors may alter the development of a Th1 response 
that is critical for Chlamydia clearance.  However, transfer of wild-type antigen specific T cells 
into CXCR3 or CCR5 deficient hosts resulted in no defect in T cell activation or accumulation in 
the draining lymph node. These T cells also arrive in the genital mucosa in similar numbers and 
are fully activated, showing that the chemokine receptor profile of any bystander T cells in the 
host does not affect the capacity of wild-type Chlamydia specific T cells to respond to infection 
normally. Furthermore these data suggest that the higher pathogen load seen in chemokine 
receptor-deficient mice is not due to a loss in T cell priming but rather a defect in trafficking to 
the infected tissue.   
No previous reports had assessed whether a lack of CCR5 or CXCR3 impairs 
recruitment of antigen specific T cells to the genital mucosa during C. trachomatis infections. 
Our current study demonstrates that Chlamydia-specific CD4+ T cells deficient for either CXCR3 
or CCR5 are unable to accumulate in the genital tract over the course of infection. This 
highlights the importance of CXCR3 and CCR5, as loss of either chemokine receptor does not 
delay recruitment but rather, blocks trafficking to the genital mucosa altogether.  Even though 
receptor-deficient T cells could not home to the genital mucosa, these cells trafficked normally 
to the draining lymph node, where they were properly primed with antigen. We did see a minor 
decrease in activation among all receptor deficient T cells that was not statistically significant in 
our studies.  It is possible however that this slight reduction in activation may have a small effect 
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on the severe blockage of T cell recruitment, but it does not appear to be a major contributor. 
The more sensitive competitive homing assay bolstered our time course findings by showing 
that antigen specific chemokine receptor-deficient cells are significantly less efficient at 
trafficking to the genital tract than wild-type cells when they are both present in the same 
mouse. Furthermore, when mice received pre-activated antigen specific T cells deficient for 
either CXCR3 or CCR5, the T cells could not protect recipient mice to the same extent as wild-
type cells, but each population was still able to reduce the C. trachomatis load in the genital 
tract 10-fold.  Ultimately, these approaches identified both CXCR3 and CCR5 as necessary for 
proper homing of Chlamydia specific T cells to the genital mucosa and protecting mice from 
infection.  
Previous reports have also examined a double deficiency of CXCR3 and CCR5 during 
virus infections of the lung and central nervous system (4, 26). These investigators concluded 
that CXCR3 and CCR5 might function antagonistically on T cells. However, in our study the 
data support a cooperative interaction between CXCR3 and CCR5 following a genital tract 
infection with C. trachomatis. Our single transfer and competitive homing studies showed that T 
cells lacking both CXCR3 and CCR5 were unable to be recruited to or retained in the genital 
mucosa after infection. Furthermore, transfer of pre-activated antigen specific T cells lacking 
both CXCR3 and CCR5 did not protect recipient mice at all. Together these data indicate that 
loss of both CXCR3 and CCR5 together is more detrimental than loss of either receptor 
individually. This finding does not result from a drastic T cell priming defect because all 
chemokine receptor deficient cells were able to accumulate in the draining lymph node and be 
activated similarly. Therefore we conclude that the inability of CXCR3-/- CCR5-/- antigen specific 
T cells to traffic to and be retained in the genital tract following infection with C. trachomatis 
eliminates all protective capacity of these cells.  
In contrast to the generally accepted view of CXCR3 and CCR5 as “general TH1 
inflammation chemokine receptors”, recent evidence in lung infection models have indicated 
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antigen specific cells do not utilize both receptors.  Moreover, the expression of CCR5 was 
deleterious to TH1 T cell homing to the lung (4).  This incongruity in the “general inflammation” 
model of homing suggests that monitoring antigen specific responses is required to elucidate 
lymphocyte homing to infections at disparate mucosal sites. It remains a possibility that the host 
bystander T cell population, that is present in all experiments, does play some role during the 
clearance of a genital tract infection. Our data suggests however, that these non-antigen 
specific T cells are not critical for the priming of Chlamydia specific T cells (Figure 3-2) and not 
needed for antigen specific T cells to protect host mice from infection (Figure 3-6). Our studies, 
characterizing homing to the genital tract, indicate that an antigen specific CD4 population 
requires both CXCR3 and CCR5 for homing and protection of the genital mucosa.  
The distinct chemokine receptor profiles for each mucosal site, such as CCR9 for 
homing to the intestine or CCR4/10 for homing to the skin, illustrate a coordinated specificity by 
the host to ensure that activated T cells arrive in the correct tissues efficiently.  Understanding 
the chemokine receptor repertoire required to access distinct mucosal sites may allow for the 
development of tissue specific therapeutics. With the identification of CCR5 as a major player in 
genital tract homing however, it is tempting to speculate that co-infection of patients with C. 
trachomatis would also lead to higher rates of HIV infection, where CCR5 is a major receptor for 
entry into T cells (27, 28). CCR5 has been proposed as a possible drug target to alter HIV 
infections, but it will be necessary to test these drugs for their impact on other infections of the 
genital tract to ensure that these HIV therapeutics do not promote other STIs (29). 
With additional experimentation it will be possible to determine whether T cells 
responding to other pathogens of the genital tract depend on the same chemokine receptors we 
have identified during C. trachomatis infection.  By characterizing the phenotypes of other STIs, 
as well as the immune responses that are necessary to properly clear these infections, 
therapeutics can be designed that not only control infections but also obviate disease 
pathologies. 
 89 
Materials and Methods 
Mice. C57BL/6, B6.PL-Thy1a (CD90.1 congenic), B6.129S7-IFNγtm1Agt (IFNγ-/-), C57BL/6, 
B6.SJL-Ptprca Pep3/BoyJ (CD45.1 congenic) B6.Ccr5-/-B6.129P2-Ccr5tm1kuz/J (CCR5-/-) 
B6.129P2-Cxcr3tm1Dgen/J (CXCR3-/-) were purchased from The Jackson Laboratory (Bar Harbor, 
ME).  We constructed C. trachomatis specific chemokine receptor deficient mice by breeding 
NR1 transgenic mice with either CCR5-/- or CXCR3-/- mice. All mice were maintained and 
cared for within the Harvard Medical School Center for Animal Resources and Comparative 
Medicine.  All experiments were approved by Harvard's Institutional Animal Care and Use 
Committee. 
Growth, isolation and detection of bacteria. C. trachomatis serovar L2 (434/Bu) was 
propagated within McCoy cell monolayers grown in Eagle’s MEM (Invitrogen, Grand Island NY) 
supplemented with 10% FCS, 1.5 g/L sodium bicarbonate, 0.1 M nonessential amino acids, and 
1 mM sodium pyruvate.  Infected monolayers were disassociated from plates using .05% 
trypsin/EDTA and sonicated to disrupt the inclusion.  EBs were purified by density gradient 
centrifugation as described(30).  Aliquots were stored at -80°C in medium containing 250 mM 
sucrose, 10 mM sodium phosphate, and 5 mM L-glutamic acid and thawed immediately prior to 
use. 
Flow cytometry. Tissues were mechanically disaggregated and immediately stained for 
activation markers. Cells were pre-incubated with anti-FcRγ (Bio X-Cell, West Lebanon, NH) 
before staining with anti-CD4 Pacific Blue (Biolegend, San Diego, CA), anti-CD90.1 peridinin 
chlorophyll-a protein (BD Bioscience, San Jose, CA), anti-CD90.2 (phycoerythrin or peridinin 
chlorophyll-a protein), and anti-CD45.2 (allophycocyanin).  We used anti-CD45Rb 
phycoerythrin-cychrome 7 (Biolegend) anti-CD62L allophycocyanin-Alexa 750 (Ebioscience, 
San Diego, CA) in order to examine the activation levels of antigen specific T cells following 
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infection. Data were collected on a modified FACSCalibur (Cytek Development, Fremont CA) or 
an LSRII (BD Bioscience) and analyzed using FlowJo (Tree Star Industries, Ashland OR). 
 
Transfer of Transgenic T cells, infection of mice, and preparation of tissue. Prior to 
transfer, C. trachomatis (Cta1133-152 )-specific CD4+ T cells(12)  were isolated from the peripheral 
lymphoid tissues of donor NR1 mice. Recipient mice were injected intravenously with either 105 
or 106 cells from the donors.  To infect the genital tract, mice were treated with 2.5 mg of 
medroxyprogestrone acetate subcutaneously and then infected one week later in the uterus with 
106 IFU of C. trachomatis L2(8, 12). Intrauterine infection was done using the NSET device 
(http://paratechs.com/nset.htm). In short, 5µl of SPG containing 106 C. trachomatis was 
deposited using the NSET pipet tip through the NSET speculum. Infection occurs at the base of 
the uterine horns (including the cervix).  Five days following infection, the lymph nodes, spleen, 
and uterine horns were collected. The uterus was digested with 1 mg/ml of type XI collagenase 
(Sigma) and 50 Kunitz/ml of DNase (Sigma, St Louis MO) for 45 min at 37 C. Single cell 
suspensions were prepared for staining via mechanical disaggregation. 
 
Real time PCR. Tissue from two pools of five mice infected in the uterus with 106 IFU of C. 
trachomatis L2 (and corresponding tissue from uninfected controls) were harvested and 
processed as above.  Isolated cells were resuspended in TRIzol (Invitrogen) and RNA was 
isolated using an RNeasy mini kit (Qiagen, Valencia CA).  RNA was quantified and diluted to 5 










CGGAGATGATGACCCTTTTG-3’.  Real-time PCR was conducted using the Quantitect SYBR 
Green RT-PCR kit (Qiagen) and run on an ABI prism 7000 sequence detection system (Applied 
Biosystems). Resulting Ct values were normalized against GAPDH for each sample resulting in 
a relative expression for each tissue. Fold induction was calculated by dividing relative 
expression of infected tissue by relative expression of uninfected tissue.  
 
Competitive homing. One million wild-type NR1 cells (CD45.2/CD90.1) were mixed with an 
equivalent number of wild-type, CCR5-/-, CXCR3-/-, or CCR5-/- CXCR3-/- NR1 cells 
(CD45.2/CD90.2) and transferred into CD45.1/CD90.2 hosts. Twenty-four hours following 
transfer, 106 IFU of C. trachomatis L2 were inoculated into the uterus. Tissues were harvested 
seven days post-infection and processed as described above.    
 
Skewing of NR1 cells. CD4+ T cells were purified from NR1 mice using a mouse CD4 negative 
isolation kit (Invitrogen) per the manufacturers directions.  The T cells were cultured in RPMI-
1640 (Invitrogen) supplemented with 10% FCS, L-glutamine, HEPES, 50 µM 2-
mercaptoethanol, 50 U/ml penicillin, and 50 ug/ml streptomycin.  To stimulate the T cells, 
irradiated feeder splenocytes were pulsed with 5 µM of Cta1133-152 peptide and cocultured with 
the CD4-enriched NR1 cells at a stimulator to T cell ratio of 4:1. To polarize T cells towards the 
Th1 phenotype cells were incubated with 10 ng/ml of IL-12 (Peprotech, Rocky Hill NJ) and 10 
µg/ml of anti-IL4 (Biolegend). Cells were stimulated for five days then 106 cells were transfered 
into naïve CD90.2+ host mice. Twenty-four hours following transfer, mice were challenged in the 
uterus with 106 IFU of C. trachomatis L2.  
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Quantitative PCR. To assess the levels of C. trachomatis present, we used a previously 
described qPCR method(31). Briefly we isolated nucleic acid from genital tract homogenates 
using the QIAamp DNA mini kit from Qiagen. Mouse GAPDH DNA and Chlamydia 16S DNA 
were quantified by qPCR on an ABI Prism 7000 sequence detection system using primer pairs 
and dual-labeled probes. Using standard curves from known amounts of Chlamydia and mouse 
DNA, we calculated the amount (in picograms) of Chlamydia DNA per unit weight (in 
micrograms) of mouse DNA in the samples.  
 
Statistical analysis. All groups were evaluated for statistical significance through the use of 
unpaired two-tailed t tests. Where it appeared necessary to highlight significant differences 
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Chlamydia trachomatis is the most common cause of bacterial sexually transmitted infection in 
the United States and the leading cause of preventable blindness worldwide(1). C. trachomatis 
is an obligate intracellular pathogen that infects epithelial cells of the genital tract and 
conjunctiva. In the upper genital tract, complications from C. trachomatis infection include pelvic 
inflammatory disease, ectopic pregnancy and infertility(2, 3). The high frequency of infection, 
low incidence of acquired immunity and lack of an effective vaccine make C. trachomatis a 
continuing public health concern. 
 Protection of the genital mucosa from C. trachomatis is dependent on the production of 
IFNγ(4). IFNγ protects through the upregulation of genes such as IDO, NOS and IRGs that 
interfere with various aspects of the pathogen’s developmental cycle and reduce growth(5-8). 
Transfer of Chlamydia-specific CD4+ T cells can protect naïve mice against challenge, and IFNγ 
production by the CD4+ T cells is required. Mice that are deficient in IFNγ production or depleted 
of CD4+ T cells have delayed resolution of infection in the genital mucosa(9). Overall it is well-
appreciated that antigen-specific, IFNγ-secreting CD4+ T cells must efficiently traffic to the 
genital mucosa in response to Chlamydia infection in order to drive protective immunity(10).  
Mechanisms suggesting how lymphocytes traffic to the gastrointestinal tract and central nervous 
system (CNS) have been demonstrated. Lymphocyte recruitment to the gastrointestinal tract is 
largely mediated by the chemokine receptor CCR9 and the integrin receptor α4β7(11). On the 
other hand, integrin α4β1 regulates trafficking to the CNS. In these models, interfering with α4β1 
and α4β7 profoundly impairs immune cell recruitment to the respective tissues (12, 13). In fact, 
integrin-specific antibodies are used clinically to block infiltrating immune cells and provide relief 
from autoimmune diseases such as ulcerative colitis and multiple sclerosis(14)(15). 
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Unfortunately our understanding of how CD4+ T cells traffic to the genital mucosa has been 
limited, including what combination of adhesion receptors is required.  
 In this study, we interrogated the importance of α4β1 and α4β7 integrin heterodimers in 
promoting Chlamydia-specific CD4+ T cell recruitment to the genital mucosa and protecting mice 
from C. trachomatis infection. We show that integrin α4β1 is dramatically increased on the 
surface of both polyclonal and Chlamydia-specific CD4+ T cells in the uterus following infection. 
We find that blocking or deleting integrin α4β1, but not α4β7, on pathogen-specific CD4+ T cells 
results in the impairment of trafficking to the uterus and a decrease in the protective capacity of 
CD4+ T cells. We conclude that integrin α4β1 is necessary for CD4+ T cell-mediated protection 
against C. trachomatis. Identifying the receptors required for CD4+ T cell trafficking to the genital 
tract in response to C. trachomatis is important in designing a vaccine that elicits sterilizing, long 
lasting immunity against the pathogen while limiting the extent of tissue pathology.  
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Results 
C. trachomatis infection leads to robust integrin α4β1 surface expression on bulk CD4+ T 
cells in the uterus 
 Previous studies differ regarding the levels of α4β1 and  α4β7 expression on CD4+ T 
cells in the uterus during Chlamydia infection. As a first step to resolve these discrepancies we 
examined the surface expression of α4, β1, and β7 on CD4+ T cells responding to Chlamydia 
infection in the genital mucosa. Mice were infected transcervically with C. trachomatis and 7 
days later we isolated the genital mucosa and examined the surface expression of integrins on 
endogenous polyclonal CD4+ T cells by flow cytometry. We found that the integrins α4 and β1 
were upregulated on the surface of CD4+ T cells in the uterus relative to those in the draining 
(iliac) lymph nodes of infected mice (Figure 4-1A). In contrast, the surface expression of β7 was 
only modestly increased compared to β1 on CD4+ T cells in the genital mucosa. We next 
wanted to examine the co-expression of integrins on the surface of CD4+ T cells in the genital 
tract using flow cytometry. When we gated on either α4+β1+ or α4+β7+ expressing CD4+ T cells 
in the genital mucosa we noted a higher number of CD4+ T cells expressing α4+β1+. To confirm 
this difference in the T cell population we quantified the absolute number of CD4+ T cells 
expressing either α4+β1+ or α4+β7+ in infected or naïve animals 7 days after transcervical 
Chlamydia infection. We found few CD4+ T cells in the uterus during steady state in naïve mice, 
as previously shown. Following infection with C. trachomatis, the absolute number of α4+β1+ 
CD4+ T cells in the upper genital tract significantly increased unlike the number of α4+β7+ cells 
(Figure 4-1B). We next compared activation markers between α4+β1+ or α4+β7+ CD4+ T cells 
responding to the genital mucosa. Interestingly, both the number of activated α4+β1+ and α4+β7+ 
CD4+ T cells were significantly increased in infected animals relative to naïve controls (Figure 4-
1C). Nonetheless, there was a more recruitment of activated α4+β1+ CD4+ T cells to infected 
uteri compared to α4+β7+ CD4+ T cells. Our results show that while both α4+β1+ and α4+β7+  
 









Figure 4-1. C. trachomatis infection leads to robust integrin α4β1 surface expression on 
bulk CD4+ T cells in the uterus. C57BL/6 wild type mice were transcervically infected with 106 
C. trachomatis IFUs. At day 7 after infection the uterus and draining lymph nodes were 
harvested and prepared for flow cytometry. CD3, CD4, α4, β1 and β7 positive staining as well 
as the exclusion of Live/Dead cell death stain was used as the gating strategy for the 
identification of live α4+β1+ and α4+β7+ CD4+ T cells. (A) Integrin surface expression was 
analyzed by comparing the gMFI ratio of the uterine to lymph node localized CD4+ T cells. (B) 
Total numbers of α4+β1+ and α4+β7+ CD4+ T cells were evaluated in the uteri of naïve or 
infected mice. (C) The total number of activated α4+β1+ and α4+β7+ CD4+ T cells was quantified 
in the uteri of naïve or infected mice; activation was determined by CD44+ staining. Shown are 
representative results from one of two independent experiments. * p < 0.05, ** p < 0.01, and **** 
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CD4+ T cells are found the infected genital mucosa β1 is more highly expressed. This suggests 
α4+β1+ is the primary integrin driving CD4+ T cell recruitment to genital mucosa in response to C. 
trachomatis infection.  
 
Infection leads to increased α4β1 surface expression on C. trachomatis-specific CD4+ T 
cells in the uterus 
During Chlamydia infection, antigen-specific T cells are primed and recruited specifically to the 
genital tract. However, inflammatory cytokines also activate bystander T cells at the site of 
infection independently of antigen specificity(16). Previous work characterizing integrin 
receptors required for T cell recruitment to the genital mucosa used memory CD4+ T cell 
lines(17), polyclonal CD4+ T cells(18), or bulk CD4+ T cells(19) but never examined naïve C. 
trachomatis-specific CD4+ T cells. It is only possible to model primary infection using naïve 
antigen-specific T cells. To focus on the integrin profile of only the Chlamydia-specific CD4+ T 
cell population, we took advantage of C. trachomatis specific TCR transgenic CD4+ T cells that 
are locked into specificity for the Chlamydia antigen Cta1 (referred to subsequently as NR1 
cells)(20). Based on the results from Figure 4-1, we hypothesized that NR1 cells would display 
significantly increased surface β1, rather than β7, upon trafficking to infected uteri. To test this, 
we transferred 106 NR1 cells intravenously into congenic naïve animals that were then infected 
transcervically the following day with C. trachomatis. As we observed using polyclonal CD4+ T 
cells, at 8 days following infection there was over 10-fold increased surface expression of 
integrin β1 on NR1 cells in the uterus compared to NR1 cells in the draining lymph nodes 
(Figure 4-2A). The surface expression of integrins in the genital tract and iliac lymph nodes of C. 
trachomatis infected mice was examined at three time points following infection to understand 
the dynamics of integrin expression. NR1 cells were examined at 3, 8, and 13 days following 
infection to coincide with T cell activation, peak of infiltration, and contraction, respectively 
(Figure 4-2B and C). There was a surge of both α4+β1+ and α4+β7+ NR1 cells in infected  
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Figure 4-2. Infection leads to robust α4β1 surface expression on C. trachomatis-specific 
CD4+ T cells in the uterus. 106 CD90.1+ NR1 cells were transferred to CD90.2+ recipient mice. 
The following day mice were transcervically infected with 106 C. trachomatis IFUs. The uterus 
and draining lymph nodes were harvested at different time points after infection and prepared 
for flow cytometry. Vα2 (transgenic TCR), CD4, CD90.1 and integrin positive staining as well as 
the exclusion of Live/Dead cell death stain was used as the gating strategy for the identification 
of live α4+β1+ and α4+β7+ NR1 cells. (A) Integrin surface expression was analyzed by comparing 
the gMFI ratio of the uterine to lymph node localized NR1 cells at 8 days post infection. (B) The 
total number of α4+β1+ and α4+β7+ NR1 cells was evaluated and compared at 3 and 8 days after 
infection in the uterus (left) and draining lymph nodes (right). (C) NR1 cell trafficking kinetics in 
the uterus (left) and draining lymph nodes (right) is depicted at 3, 8, and 13 days after infection. 
Shown are representative results from one of three independent experiments. * p < 0.05, ** p < 
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 uteri 8 days after infection compared to what was observed with these populations 3 days after 
infection (Figure 4-2B). Even though both NR1 populations increased during infection, the 
magnitude of infiltration of the α4+β1+ NR1 cells to the uterus was far more robust (***p<0.001) 
than the α4+β7+ population (*p<0.05) (Figure 4-2B, left). Surface integrin profiles on NR1 cells in 
the draining lymph node were found to have no statistical differences in integrin expression 
between these two time points (Figure 4-2B, right). Thirteen days after infection, the decline of 
NR1 cells (Figure 4-2C) corresponded to resolution of C. trachomatis infection in the genital 
mucosa(21). Even at this late time point, α4+β1+ NR1 cells were found significantly more 
frequently than α4+β7+ NR1 cells in the genital tract. This suggests that NR1 cells expressing 
α4+β1+ are either recruited or retained in the uterus for a longer period of time than other T cell 
populations. Together these findings demonstrate that CD4+ T cells preferentially express α4 
and β1 on their surface in the genital mucosa in response to C. trachomatis infection.   
 
Blocking integrin α4 but not α4β7 on Chlamydia-specific CD4+ T cells leads to an 
increase in C. trachomatis burden in genital mucosa  
 Since we identified a strong upregulation of α4β1 on the surface of T cells responding to 
Chlamydia infection, we next wanted to assess the functional role of β1 and β7 in promoting 
protective immunity. We have previously shown that transfer of in vitro-activated Th1-skewed 
NR1 cells into naïve mice confers significant protection from Chlamydia infection compared to 
mice that receive no T cells(10). We hypothesized that if specific integrins are required for 
recruitment to the genital mucosa, blocking these integrins on activated NR1 cells may alter 
their protective capacity. To test this and determine the relative contributions of β1 and β7 to 
CD4+ T cell-mediated protection, we selectively blocked integrin receptors following infection 
using antibodies (Figure 4-3). NR1 cells from naïve mice were harvested and polarized in vitro 
to a Th1 phenotype. IFN-γ production by the cells was assayed to confirm their Th1 phenotype 
by flow cytometry prior to transfer (data not shown). One million NR1 Th1 cells were pre-treated  













Figure 4-3. Blocking α4 but not α4β7 abolishes the protective capacity of Chlamydia-
specific CD4+ T cells following C. trachomatis infection. To confer protection, NR1 cells 
were skewed in vitro to a Th1 phenotype for 5 days using cta1 peptide and irradiated 
splenocytes. 106 CD90.1+ NR1 cells were transferred to CD90.2+ recipients and the following 
day mice were transcervically infected with 5x106 C. trachomatis IFUs. Groups were injected i.p. 
with the respective antibody at 1 and 3 days post infection. Genomic DNA was isolated from the 
uterus at 5 days after infection. Burden was determined by calculating the levels of Chlamydia 
16S DNA relative to the levels of host GADPH using qPCR. Shown are representative results 
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with antibody that blocked α4 (blocks both α4β1 and α4β7), α4β7, or an isotype control and 
transferred intravenously into host mice that were transcervically infected with C. trachomatis 
the following day. To ensure robust blockade of integrins on NR1 cells each group of mice were 
also treated with antibody 1 and 3 days following infection. Five days after infection C. 
trachomatis burden in the uterus was measured using quantitative PCR (qPCR). Mice that were 
treated with blocking antibody against α4 had significantly higher C. trachomatis burden in the 
genital tract than isotype control treated animals, burdens similar to that found in mice that 
received no NR1 cells at all. On the other hand, mice treated with α4β7 blocking antibody 
showed lower levels of C. trachomatis in the genital mucosa similar to the isotype antibody 
treated mice. Despite the lack of an antibody that specifically blocks α4β1, we can infer the 
importance of α4β1 indirectly.  Because blocking α4 with antibody prevents both α4β1 and α4β7 
signaling, the differences observed in protection between α4 and α4β7 antibody treatment 
groups point towards a function of α4β1. Since the integrin α4 chain dimerizes with either β1or 
β7(22), the results shown in Figure 3 indirectly confirm that α4β1 is required for CD4+ T cell 
mediated protection against C. trachomatis in the genital mucosa.   
 
A reduction in CD4+ T cells is responsible for the higher C. trachomatis burden in anti-α4 
antibody-treated mice 
 Even though we found that blocking α4 was sufficient to prevent CD4+ T cell mediated 
protection in the genital mucosa, we had not determined the mechanisms responsible for higher 
burden. We predicted that the loss of protection seen in mice treated with α4-blocking antibody 
was due to diminished recruitment of NR1 cells to the infected uterus. To test this possibility, we 
repeated the antibody blocking experiments and monitored the trafficking of NR1 cells to genital 
tract during infection using flow cytometry. NR1 cells were skewed to the Th1 phenotype in vitro, 
and then transferred into congenically mismatched host mice. The next day mice were infected 
transcervically with C. trachomatis. Prior to transfer, NR1 cells were pretreated with individual  
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Figure 4-4. C. trachomatis-specific CD4+ T cell trafficking to the genital tract is impaired 
in α4 but not α4β7 antibody treated mice following infection. To confer protection, NR1 
cells were skewed in vitro to a Th1 phenotype for 5 days using cta1 peptide and irradiated 
splenocytes. 106 CD90.1+ NR1 cells were transferred to CD90.2+ recipients and the following 
day mice were transcervically infected with 5x106 C. trachomatis IFUs. Groups were injected i.p. 
with the respective antibody at 1 and 3 days post infection. The uterus and draining lymph 
nodes were harvested at 5 days after infection and prepared for flow cytometry. Vα2, CD4, and 
CD90.1 positive staining as well as the exclusion of Live/Dead cell death stain was used as the 
gating strategy for the identification of live NR1 cells. (A) The percentages of NR1 cells are 
shown in the draining lymph nodes (top) and uterus (bottom). (B) Absolute numbers were 
quantified in the uterus (left) and draining lymph nodes (right). (C) The migration index was 
calculated by comparing the absolute number of NR1 cells in the uterus relative to the draining 
lymph nodes within the same animal. A higher ratio indicated more NR1 cells in the uterus. (D) 
The absolute numbers of effector NR1 cells was determined by examining the CD44+CD62Llow 
gated population. Shown are representative results from one of two independent experiments. * 
p < 0.05, ** p < 0.01, and *** p < 0.001 
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integrin blocking antibodies or an isotype control. Mice were also treated with the same blocking 
antibody or isotype control 1 and 3 days after infection. Five days after infection, we examined 
the number of NR1 cells present in the uterus and draining lymph nodes by flow cytometry. We 
noted that the number of NR1 cells in the genital mucosa was significantly diminished following 
treatment with the α4 blocking antibody relative to the isotype treated mice (Figure 4-4A and B). 
In contrast, α4β7 antibody treatment did not impact NR1 cell recruitment to the genital tract as 
absolute numbers were similar between isotype and α4β7-treated groups. The absolute 
numbers of NR1 cells present in the iliac lymph nodes were not significantly different between 
the groups suggesting no general defect in trafficking of NR1 cells following α4β7 antibody 
treatment. We also calculated a migration index (the ratio of live NR1 cells in the uteri to iliac 
lymph nodes within the same animal) to normalize for mouse-to-mouse variability. We found 
that the migration index was profoundly decreased in mice treated with α4 blocking antibody 
compared to isotype treated mice (Figure 4-4C). These results show that blocking α4 prevents 
efficient CD4+ T cell trafficking to the genital tract following C. trachomatis infection. Since the 
migration index of mice treated with α4β7 antibody was no different from isotype control treated 
mice it suggests α4β7 plays a limited role in NR1 cell trafficking to the genital mucosa.   
We then assessed what population of CD4+ T cells was being afflicted after antibody 
treatment and thus unable to protect the uteri against C. trachomatis infection. NR1 cells were 
stained for CD44 and CD62L in order to evaluate the presence of effector CD4+ T cells at the 
site of the infection. The absolute number of CD44+CD62Llow NR1 cells in the uterus was 
significantly decreased only in the α4 antibody-treated group compared to isotype-treated mice 
(Figure 4-4D). Moreover, α4β7 antibody treatment did not decrease the absolute number of 
effector NR1 cells in the uteri.  The results shown in Figure 4 allowed us to conclude that the 
lack of CD4+ T cell trafficking to the genital tract following α4 blockade is primarily due to the 
inhibition of α4β1. These observations demonstrate that disrupting the integrin α4β1 on NR1 
cells during C. trachomatis infection is sufficient to eliminate CD4+ T cell-mediated protection.  









Figure 4-5. CD4+ T cells from C. trachomatis-specific integrin deficient mice show altered 
integrin surface expression. Integrin sufficient or deficient NR1 cells were skewed in vitro to a 
Th1 phenotype for 5 days using cta1 peptide and irradiated splenocytes. (A) After stimulation, 
live NR1 cell were gated to show the percentage of β1+ β7- and β1- β7+ populations within each 
group. (B) The quantification of α4+ β1+ β7- or α4+ β1- β7+ NR1 cells is shown as percentage of 
total NR1 cells. Shown are representative results from one of two independent experiments. * p 
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Integrin β1-deficient C. trachomatis-specific CD4+ T cells are unable to protect the uterus 
 To complement the antibody-blocking experiments showing that α4β1 is required for 
Chlamydia-specific CD4+ T cells to home to and protect the genital mucosa, we generated TCR 
transgenic mice in which the T cells are deficient in either integrin β1 or β7. Because loss of β1 
results in embryonic lethality, we used a CRE-Flox system to generate NR1 cells conditionally 
deficient in β1. NR1 transgenic mice were crossed to Lck-CRE and Itgb1flox/flox animals such 
that only the lymphocytes were deficient in β1. We also crossed NR1 transgenic mice with 
Itgb7-/- mice to generate Chlamydia-specific CD4+ T cells deficient in β7. We first confirmed that 
integrin surface expression was significantly altered for each knockout T cell genotype (Figure 
4-5A and B). Interestingly, loss of β1 led to a concomitant increase of surface β7 on NR1 cells 
similar to a previous report showing that α4β7 heterodimers form more readily in the absence of 
the β1 chain(23). The loss of β7 also led to an increase of the percentage of β1+ NR1 cells after 
in vitro activation. We next confirmed that NR1 cells deficient in individual integrins were 
normally activated. Integrin-deficient NR1 cells were harvested from the knockout mice and 
polarized in vitro for 5 days to a Th1 phenotype. We found no significant difference between 
groups in the total number of recovered NR1 cells 5 days following activation, demonstrating 
that all the genotypes are viable (data not shown). We next examined the activation and 
cytokine production for each group. For all genotypes examined, NR1 cells were robustly 
activated as determined by staining for the activation markers CD25 and CD44 (Figure 4-6A). 
When we assayed the cytokine profiles of each NR1 genotype using intracellular cytokine 
staining we found similar levels of the cytokines IFN-γ and TNF-α from all groups, suggesting 
that loss of integrin β chains does not negatively impact Th1 differentiation (Figure 4-6B). 
Therefore the absence of either β1 or β7 does not interfere with activation, expansion, and Th1 
cytokine production of NR1 cells in vitro. 
Upon showing that the various genotypes of NR1 cells had normal effector phenotypes, 
we asked whether deficiency in either the β1 or β7 chain would adversely affect the protective  
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Figure 4-6. C. trachomatis-specific CD4+ T cells deficient in integrin β1 are unable to 
protect the genital tract following infection. To provide protection, integrin sufficient or 
deficient NR1 cells were skewed in vitro to a Th1 phenotype for 5 days using cta1 peptide and 
irradiated splenocytes. (A) The activation status of live NR1 cells was assessed by gating for the 
CD25+CD44+ population. (B) Th1 cytokine production was measure by intracellular cytokine 
staining for TNF-α and IFN-g. After 5 days of stimulation, 105 CD90.2 NR1 cells were 
transferred to CD90.1 recipients. The following day, mice were transcervically infected with 
5x106 C. trachomatis IFUs. Genomic DNA was isolated from the uterus at 5 days after infection. 
(C) Burden was determined by calculating the levels of Chlamydia 16S DNA relative to the 
levels of host GADPH using qPCR. Shown are representative results from one of three 
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capacity of Chlamydia-specific CD4+ T cells. Based on our previous results from antibody 
blocking experiments, we hypothesized that β1-deficient NR1 cells would be unable to protect 
the genital mucosa from C. trachomatis infection. To test this prediction, we transferred 105 
wildtype, β 1-/- or β 7-/- Th1-skewed NR1 cells into naïve mice 1 day prior to transcervical 
infection with C. trachomatis (Figure 4-6C). Five days after infection we harvested the uteri and 
quantified the levels of C. trachomatis using qPCR. As expected, mice that received wildtype 
NR1 cells showed a dramatic reduction in Chlamydia burden compared to mice that received no 
transfer. Mice that received β1-deficient NR1 cells were not protected against Chlamydia 
infection and had burdens similar to mice receiving no transferred T cells. In line with our 
previous findings using antibody blockade, we found that mice receiving β 7-/- NR1 cells were 
significantly protected against C. trachomatis infection relative to mice that received no transfer, 
and trended toward being more protective than even wild-type NR1 cells. These findings 
definitively show that integrin β7 on NR1 cells is dispensable for protecting the uterus from 
Chlamydia infection. In summary, integrin β1, but not β7, is necessary for Chlamydia-specific 
CD4+ T cells to protect against infection in the genital mucosa.  
 
Integrin β1 deficiency impairs C. trachomatis-specific CD4+ T cell homing to the uterus  
 We next sought to understand the mechanisms responsible for the loss of protective 
capacity in β1-/- Chlamydia-specific CD4+ T cells. Our previous data using antibody blocking 
showed that T cell trafficking to the genital mucosa was inhibited and therefore provided little 
protection. We used a competitive homing assay to test the trafficking potential of integrin-
deficient Chlamydia-specific CD4+ T cells. Here we directly compared the migration of integrin-
sufficient and deficient NR1 cells under identical conditions within the same infected host. We 
transferred an equal ratio of CD45.2/CD90.2 β1-/-, β7-/- or wildtype NR1 cells and 
CD45.2/CD90.1 wildtype NR1 cells into congenically mismatched CD45.1 recipients. The next 
day we infected the mice transcervically with C. trachomatis. Seven days after infection, we  






Figure 4-7. C. trachomatis-specific CD4+ T cells deficient in β1 are unable to traffic 
efficiently to the genital mucosa. An equivalent number of CD45.2/CD90.1 integrin wt and             
CD45.2/CD90.2 wt, β1 deficient, or β7 deficient NR1 cells were transferred to CD45.1/CD90.2 
recipient mice. The next day, mice were transcervically infected with C. trachomatis. The uterus, 
draining lymph nodes and spleen was harvested at 7 days post infection and analyzed by flow 
cytometry. Live NR1 cells were identified by gating for the Live/Dead negative population that 
was positive for CD45.2, va2 and CD4 staining. Trafficking competition within the host was 
determined by gating for CD90.1+ or CD90.2+ NR1 cells. (A) Shown are representative plots of 
integrin wt and deficient NR1 cells in the draining lymph nodes (top) and uterus (bottom).     
(B) The migration index within each group was calculated by comparing the percentage of 
CD90.2+ to CD90.1+ NR1 cells in the uterus to the same ratio in the lymph nodes (left) or spleen 
(right). Shown are representative results from one of three independent experiments. ** p < 0.01, 
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isolated and processed tissues to quantify the numbers of both NR1 populations using flow 
cytometry. We found that β1-/- NR1 cells were far less efficient than wildtype NR1 cells in 
trafficking to the genital mucosa, while β7-/- NR1 cells outcompeted their wildtype counterparts 
(Figure 4-7A). None of the experimental groups showed defects in their migration to the iliac 
lymph node. Interestingly, we noted a higher percentage of β1-deficient NR1 cells in the lymph 
nodes compared to the wildtype NR1 cells, inverse of what we observed in the genital mucosa. 
These results are likely due to a decreased ability of β1-/- NR1 cells to leave the circulation to 
enter the infected uterine mucosa. To normalize for mouse-to-mouse variation in absolute T cell 
numbers, we calculated a migration index for each mouse by comparing the ratio of the two 
transferred NR1 populations in the uterus (integrin deficient CD90.2% : integrin sufficient 
CD90.1%) to the ratio of the transferred populations in the draining lymph nodes or spleen 
within the same animal (Figure 4-7B). A smaller the migration index indicated less efficient 
trafficking of integrin-deficient NR1 cells specifically to the site of infection relative to the 
circulation. We found a dramatically lower migration index for β1-/- NR1 cells demonstrating that 
trafficking to the uterus during infection was significantly impaired relative to wildtype NR1 cells. 
Intriguingly, the migration index for β7-/- NR1 cells was significantly higher than wildtype, 
demonstrating enhanced homing of Chlamydia-specific CD4+ T cells to the uterus in the 
absence of integrin β7. These results suggest that integrin β7 is not only dispensable, but that 
deficiency of β7 enhances antigen-specific CD4+ T cell migration to the genital tract during C. 
trachomatis infection. Together our findings reveal that integrin β1 plays a crucial in trafficking of 
CD4+ T cells to the genital mucosa and that absence of β1 negatively affects the protective 
capacity of C. trachomatis-specific CD4+ T cells.  
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Discussion 
The orchestration of events required for a successful T cell response determines whether an 
intracellular pathogen will be eliminated from the host. In the case of C. trachomatis infection, a 
robust CD4+ Th1 cell response that homes to the genital tract provides the vigorous IFN-γ 
response necessary for bacterial clearance(10). The integrin receptors important for C. 
trachomatis-specific CD4+ T cell-mediated protection had not been previously described. Using 
C. trachomatis-specific CD4+ T cells, we demonstrated that perturbing integrin α4β1 but not 
α4β7, through antibody blockade or genetic deletion, results in a loss of protective capacity and 
increased bacterial burden in the genital tract. We attributed the impaired protection to the 
decreased trafficking of antigen-specific CD4+ T cell to the genital mucosa. Together these 
observations demonstrate that integrin α4β1 is necessary for CD4+ T cell-mediated protection 
against C. trachomatis infection in the murine genital tract. 
We previously demonstrated that the chemokine receptors CXCR3 and CCR5 are 
required for Chlamydia-specific CD4+ T cells to home to and protect the genital mucosa 
following infection with C. trachomatis (24). Here we extended these studies to identify integrin 
receptors that are important for CD4+ T cell mediated protection. Previous studies demonstrated 
that surface β1 is upregulated on lymphocytes localized in the genital tract but not in the 
intestinal mucosa following vaginal infection with the mouse-adapted species Chlamydia 
muridarum (19). In contrast, separate studies observed an enrichment of surface β7 on a 
transferred CD4+ T cell line in the genital tract following C. muridarum infection(17). However, 
these studies were unable to assess the functional consequences of perturbing integrin 
signaling on CD4+ T cells, such as loss of protective capacity. These studies also made use of 
bulk or memory CD4+ T cell lines that are unable to recapitulate the initial activation events as 
naïve antigen-specific T cells recognize C. trachomatis during primary infection. 
When we examined the surface expression of β1 and β7 on both bulk and antigen-
specific CD4+ T cells, we found that relative β1 expression was dramatically increased on the 
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majority of CD4+ T cells found in the uterus following Chlamydia infection (Figure 4-1A and 4-
2A). However, we consistently did note a smaller population of CD4+ T cells expressing 
intermediate levels of surface β7 in the genital mucosa (Figure 4-1B and 4-2B). The presence of 
two populations with distinct integrin profiles is consistent with previous reports that showed the 
surface expression of α4β1 and α4β7 on CD4+ T cells in the genital tract. When examining bulk 
lymphocytes, Perry et al observed that β1 surface expression was significantly increased in the 
genital tract 14 days after infection. Although most CD4+ T cells were expressing high levels of 
surface integrin β1, this group also noted a minor percentage of β7+ CD4+ T cells in the genital 
tract(19). Separate reports suggested that α4β7 was the dominant integrin receptor expressed 
on CD4+ T cells in the genital tract. However these studies had significant experimental 
constraints that limit their interpretation. For example, Kelly et al did not interrogate the integrin 
profile during the primary response or differentiate between antigen-specific and bystander 
CD4+ T cells in the genital tract(25). Another report examined the surface integrin receptors on a 
memory CD4+ T cell line in culture following stimulation but did not assess in vivo integrin 
dynamics. In addition, CD4+ T cells in this study were analyzed only 18 hours after adoptive 
transfer(17). Memory CD4+ T cells can exert effector activities with greater ease than primary T 
cells(26), therefore examining memory cells is not indicative of the trafficking properties T cells 
in a primary response. More importantly, these studies did not perturb integrins on C. 
trachomatis-specific CD4+ T cells to establish their necessity for protection.  
The results presented here show that α4β1-expressing CD4+ T cells mediate protective 
immunity in the genital mucosa. Even so, we did identify a second β7+ population that did not 
alter immunity in the genital mucosa. The existence of two NR1 cell populations with distinct 
integrin profiles and identical TCR specificity shows that integrin levels are not hardwired into 
cells but rather imprinted during T cell activation as has been suggested previously(27). Our 
results also suggest that only CD4+ T cells with the correct integrin profile can extravasate into 
the infected genital mucosa. We speculate that while α4β1-expressing T cells can enter the 
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infected tissue efficiently, the α4β7+ CD4+ T cells remain in the circulation, failing to provide 
protection in the genital mucosa, but perhaps contributing to immunity elsewhere in the mouse. 
Because the entire uterus, including its associated vasculature, was harvested in all 
experiments it was not possible to distinguish between those T cells present in blood vessels 
and those that had completed transendothelial migration. Interestingly, one recent report 
uncovered a mechanism that drives distinct integrin expressing T cell populations in the lungs of 
mice.  Ruane et al found that a subset of residing dendritic cells (DCs) can imprint lung T cells 
to express α4β7 instead of α4β1. The T cells expressing α4β7 do not mediate protection in the 
lungs but rather provide systemic mucosal immunity(28). Given that a subset of lung DCs can 
imprint a population of α4β7 on T cells, we speculate a similar process occurs also occurs in the 
genital tract. While the majority of CD4+ T cells are primed to express α4β1, which mediates 
immunity in the genital mucosa during C. trachomatis infection, perhaps a subset of uterine DCs 
also imprints α4β7 CD4+ T cell population that may provide systemic mucosal immunity. This 
hypothesis will need to be examined in future experiments.   
It is well established that integrin α4β1 adheres to the addressin VCAM-1 and the 
extracellular matrix protein fibronectin. Surface VCAM-1 increases on endothelial cells lining 
microvessels following inflammation(22). For example, patients with CNS autoimmune disorders 
are often treated with natalizumab, an α4 antibody that blocks α4β1 interaction with its ligands. 
Natalizumab treatment decreases undesirable inflammation in the CNS by interfering with α4β1 
mediated immune cell recruitment to this sensitized area in the body(29). Previous studies have 
also shown that surface VCAM-1 becomes abundant on murine and human genital mucosa 
following Chlamydia infection. In contrast, the expression of the mucosal addressin cell 
adhesion molecule-1 (MAdCAM-1), the binding partner for α4β7, has been reported to be 
expressed robustly in the gut but only modestly in the genital tract(19, 30). The noticeable 
increase of surface VCAM-1 in the genital mucosa following C. trachomatis infection 
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corresponds to the upregulation of surface α4β1 on Chlamydia-specific CD4+ T cells in the 
uterus observed in this study. 
Several other signals stimulate the rapid increase of VCAM-1 on vaginal epithelial cells 
including IFNγ treatment and herpes simplex virus infection(31). Given that VCAM-1 expression 
can be selectively upregulated on both endothelial and non-endothelial cells, CD4+ T cells may 
require α4β1 signaling for multiple steps in protection. Previous studies have characterized the 
importance of α4β1 to slow/arrest lymphocytes in the blood vessel, but additionally α4β1 may 
mediate the interactions between effector CD4+ T cells and infected epithelial cells as has been 
suggested to occur during Chlamydia infection (32). It remains unknown whether C. 
trachomatis-specific CD4+ T cells directly interact with infected epithelial cells in the genital 
mucosa or if their antimicrobial effects occur by altering the cytokine milieu at the site of 
infection. Here we observed that integrin β1 and β7 were dispensable for proliferation and 
differentiation to a Th1 phenotype, as IFNγ production and recovery of live NR1 cells was 
similar between wildtype and knockout cells (Figure 4-6A and B). Consequently, we conclude 
that the function of β1 in mediating protection is to allow successful Chlamydia-specific CD4+ T 
cell trafficking to the uterus rather than playing a role in activation or production of IFNγ. Future 
studies must further explore the interaction between IFNγ-producing CD4+ T cells and the 
infected epithelium to determine whether β1 is required for cellular interactions in vivo at the 
genital mucosa.   
Our group previously identified the chemokine receptors important for antigen-specific 
CD4+ T cells to home to and protect the uterus following C. trachomatis infection(24). The 
results obtained through this study further elucidate the essential trafficking receptors required 
for an effective CD4+ T cell defense in the genital mucosa. It remains to be determined whether 
CD4+ T cells responding to other pathogens in the genital tract also require the same adhesion 
receptors we have identified (CXCR3, CCR5 and α4β1) for successful trafficking. Generating a 
robust and long-lived protective T cell response is crucial to clear infection and avoid recurrent 
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cycles of inflammation and associated pathology. Vaccine efforts against intracellular pathogens 
should examine whether the appropriate T cell population, with the necessary homing 
molecules, is being generated to ensure protection and minimize pathology. In addition to the 
current treatments for autoimmune diseases in the gut and the CNS, integrin and chemokine 
receptor targeted therapies could be used to selectively shape the recruitment of desired T cells 
to other mucosal tissues. 
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Materials and Methods 
Mice   
C57BL/6, B6.PL-Thy1a (CD90.1 congenic), C57BL/6, B6.SJL-Ptprca Pep3/BoyJ (CD45.1 
congenic), B6.Cg-Tg548Jxm/J (Lck-CRE), C57BL/6-Itgb7tm1Cgn/J (Itgb7-/-), and B6;129-
Itgb1tm1Efu/J (Itgb1flox/flox) mice were purchased from the Jackson Laboratory (Bar Harbor, 
ME) and NR1 mice were previously described(33). C. trachomatis-specific integrin-deficient 
mice were generated by breeding NR1 mice to either Lck-CRE and Itgb1flox/flox  or Itgb7-/- 
mice. All mice were maintained in facilities managed by the Harvard Medical School Center for 
Animal Resources and Comparative Medicine. To normalize for the murine estrous cycle, mice 
were treated subcutaneously with 2.5 mg of medroxyprogesterone 7 days prior to infection. 
Harvard’s Institutional Animal Care and Use Committee approved all the experiments described. 
A minimum of 4 mice per group was used in each experiment.  
Growth, isolation and detection of C. trachomatis 
C. trachomatis serovar L2 (434/Bu) was propagated using McCoy cell monolayers grown in 
Eagle’s MEM (Invitrogen, Grand Island, NY) plus 10% FCS, 1.5 g/l sodium bicarbonate, 0.1 M 
nonessential amino acids, and 1 mM sodium pyruvate. Infected McCoy cells were detached 
from plates using sterile glass beads and then sonicated to disrupt C. trachomatis inclusions. 
Density gradient centrifugation was used to purify elementary bodies(24). Aliquots were stored 
at -80˚C in a medium containing 250 mM sucrose, 10 mM sodium phosphate, and 5 mM L-
glutamic acid.   
Transfer of NR1 cells, infection of mice, and tissue preparation  
 C. trachomatis-specific CD4+ T cells were isolated from the lymph nodes and spleens of naïve 
donor NR1 mice. Recipient mice received 106 NR1 cells and were infected the following day 
with 106 C. trachomatis inclusion forming units (IFU) in 10 ml of sucrose-phosphate-glutamate 
media. We used the NSET device (ParaTechs) to bypass the cervix and directly infect the 
uterine horns(34). The uterus was harvested and disaggregated by digestion with 1 mg/ml of 
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type XI collagenase (Sigma, St. Louis, MO) and 50 Kunitz/ml of DNase (Sigma) for 30 min at 
37˚C. Single cell suspensions from tissues were obtained by mechanical disaggregation prior to 
staining. Suspensions of splenocytes were treated with a hypotonic buffer to lyse red blood cells 
prior to use. 
Flow cytometry 
Single cell suspensions were stained immediately for activation markers or stimulated for            
5 hours with 100 ng/ml PMA (Alexis Biochemical) and 1 mg/ml ionomycin (Calbiochem) in 
brefeldin A (BD Biosciences) for intracellular cytokine staining. Cells were treated with anti-
FcgR (BioXCell) before staining with combinations of the following antibodies: anti-b1 Pacific 
Blue, anti-b7 FITC, anti-TCRva2 allophycocyanin, anti-CD90.1 Peridinin Chlorophyll Protein, 
anti-CD45.2 phycoerythrin (PE), anti-CD90.2 FITC, anti-IFN-g PE, anti-TNF-a PE-cy7, anti-
CD25 PE, anti-CD44 PE or Pacific Blue, anti-CD62L FITC (Biolegend), anti-CD3e 
allophycocyanin, anti-a4 PE (BD Biosciences), anti-CD4 Qdot605 and a LIVE/DEAD dead cell 
stain kit (Invitrogen). For cytokine staining, cells were permeabilized using a Cytofix/Cytoperm 
Plus Kit following manufacturer’s instructions (BD Biosciences). Cell number was determined 
with AccuCheck Counting Beads (Invitrogen). Flow cytometry data were collected on a modified 
FACSCalibur (Cytek Development) or an LSRII (BD Biosciences) and analyzed using FlowJo 
(Tree Star). 
Th1 polarization and protection against C. trachomatis 
CD4+ T cells were harvested from the lymph nodes and spleens of naïve NR1 mice and 
enriched with a mouse CD4 negative isolation kit (Invitrogen) following the manufacturer’s 
protocol. CD4+ T cells were cultured in media consisting of RPMI 1640 (Invitrogen), 10% FCS, 
L-glutamine, HEPES, 50 mM 2-ME, 50 U/ml penicillin, and 50 mg/ml streptomycin. NR1 cells 
were activated by co-culture with irradiated or mitomycin-treated splenocytes pulsed with 5 mM 
of Cta1133-152 peptide at a stimulator:T cell ratio of 4:1. Th1 polarization was achieved by 
supplying cultures with 10 ng/ml of IL-12 (Peprotech, Rocky Hill, NJ) and 10 mg/ml of anti-IL-4 
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antibody (Biolegend). After 5 days of stimulation, NR1 Th1 cells were transferred i.v. into naïve 
recipient mice. In integrin antibody blocking experiments, NR1 cells were treated with 100 ug of 
anti-α4, anti-α4β7 or isotype antibody (BioXCell) for 1 hour at room temperature prior to transfer 
into recipients. The next day, mice were challenged with 5x106 C. trachomatis IFUs and the 
upper genital tract was analyzed for burden 5 days after infection. Mice were treated i.p. with 
200 ug of the respective antibody at 1 and 3 days post-infection for integrin blocking 
experiments. 
Competitive homing 
For this assay(35) an equivalent number of integrin wildtype NR1 cells (CD45.2/CD90.1) and 
congenic wildtype, Lck-CRE/Itgb1flox/flox, or Itgb7-/- NR1 cells (CD45.2/CD90.2) were 
combined and transferred into congenically mismatched CD45.1 hosts. The following day, mice 
were transcervically infected with 5x106 C. trachomatis IFUs. Tissues were harvested and 
analyzed 7 days after infection.   
Quantitative PCR 
Bacterial burden was evaluated by quantifying C. trachomatis 16S DNA relative to mouse 
GADPH DNA(33). The uterus was homogenized and DNA was extracted using the DNeasy 
blood and tissue kit (Qiagen). DNA was analyzed using C. trachomatis- and mouse-specific 
primer pairs and dual-labeled probes. Threshold values were detected by an ABI Prism 7000 
sequence system. The ratio of C. trachomatis to host DNA was obtained using a standard curve. 
Statistical analysis 
Statistical significance between groups was determined using an unpaired two-tailed t test and 
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Chapter 5: Quantitative proteomics reveals pathogen-
induced changes to the host proteome, independent of 
changes in host transcription, that are required for 
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Introduction 
Intracellular bacterial pathogens infect host cells and manipulate cellular processes in order to 
gain nutrients, evade the immune response, and promote bacterial growth and survival. 
Chlamydia trachomatis, is a gram-negative obligate intracellular pathogen that must survive 
within cells to productively infect mammallian hosts.  Although most investigators studying the 
effects of bacteria on host cells appreciate that gene regulation and protein turnover are both 
key to understanding how bacteria alter host cell functions, there has been a bias towards the 
study of gene regulation rather than protein stability.  This bias is the result of the availability of 
microarrays and other tools that allow the simultaneous measurement of thousands of individual 
host cell gene transcripts during a particular stage of cell infection in a high throughput fashion.  
 Previous work examined how infection with Chlamydia trachomatis alters the host 
transcriptional landscape in human epithelial cells. The results from these studies showed that 
during infection there is a strong upregulation of transcriptional networks that drive the initial 
immune response and inflammation. While these studies informed our understanding of the 
intial stages of the immune detection of Chlamydia and the early host response to infection, they 
cannot discern between changes in host transcription that are driven actively by Chlamydia or 
are a result of TLR/NLR signaling. Furthermore, it remains possible that the changes in 
transcription identified in these studies do not entirely reflect changes to protein levels. To 
address how the host proteome is altered during infection requires quantitative proteomic 
approaches that examine the levels of host proteins directly. 
Although proteomics is an active area of investigation, the ability to monitor changes in 
protein abundance on a global level is limited.  Approaches to study protein levels globally 
usually involve pulse-chase experiments, the administration of protease inhibitors followed by 
biochemical analysis, or biochemically trapping individual protein-protein interactors.  These 
approaches are inherently limited in the number of proteins that can be monitored at one time, 
and are not scalable to make them “more global”.  In the case of C. trachomatis, modern 
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proteomic approaches have never been used to characterize changes in host cell proteins (only 
studies using 2-D gels have been performed (1)), despite a general appreciation that the 
pathogen manipulates host cell proteins during infection (2-7).  We have been interested in 
understanding how C. trachomatis manipulates host cell protein function and turnover to 
successfully replicate what occurs in the cell, but we were frustrated by the inavailability of 
methodology to study changes in host cell protein stability at the scale available for the study of 
transcriptional changes.   
The quantitative mass spectrometry approach known as stable isotope labeling with 
amino acids in culture (SILAC) is a highly innovative method to globally monitor levels of 
endogenous proteins in mammalian cells.  Here we adapted SILAC in combination with global 
transcriptional profiling as a new approach to understand host-pathogen interactions in 
mammalian cells (8). We found that Chlamydia infection dramatically alters the makeup of the 
host cellular proteome. Surprisingly, we found that the majority of proteins that were altered 
during infection remained unchanged in parallel transcriptional analysis. When we examined the 
mechanisms driving the discordant levels of mRNA and protein, we found that during infection 
with Chlamydia, host cell translation is significantly decreased. Finally, using a gain-of-function 
screen, we identified individual host proteins alterations that are required for efficient Chlamydia 
replication. Taken together, these results highlight the important role that proteomic studies play 
in developing a better understanding of the host pathways that are targeted by pathogens and 
are critical for intracellular growth. Better characaterization of host-pathogen interactions that 
occur during infection will significantly increase our ability to target and cure infectious disease.  
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Results  
Identification of host proteins altered following infection with C. trachomatis 
Chlamydia trachomatis has been shown to directly alter host-cell proteins, yet the scale 
of these changes and the identity of many host targets remains unknown (9). In order to identify 
host proteins that are altered during infection on a large scale, we used the quantitative 
proteomic approach known as stable isotope labeling of amino acids in cell culture (SILAC) to 
compare levels of all identified host proteins in infected and uninfected cells (10). For these 
studies we used HEK293T cells, which lack almost all TLRs and NLRs, and therefore will not 
mount a robust initial immune response. We reasoned that using these cells would allow us to 
examine the direct effects of Chlamydia infection on human cells in the absence of host 
responses that are not driven specifically by C. trachomatis.  We infected 13C-lysine (“heavy”) 
labeled human HEK293T cells with C. trachomatis and cultured 12C-lysine (“light”) labeled 
uninfected cells in parallel.  At 4, 14 and 24 hours after infection, we mixed lysates from the 
heavy labeled infected cells with lysates from the uninfected light labeled cells at a 1:1 ratio. 
(Figure 5-1A). These mixed lysates were then digested with trypsin and analyzed via tandem 
mass spectrometry to identify individual peptides and to compare their relative abundances in 
the presence and absence of C. trachomatis infection.  Peptides were identified by comparing 
MS/MS fragmentation patterns with human protein sequences and were quantified by 
comparing the intensities of the heavy and light forms (11). Peptides were then grouped by their 
protein of origin and used to infer relative levels of protein abundance under each condition. We 
found that at four hours after infection, over 100 proteins were altered more than two-fold 
(Figure 5-1B). This increased to almost 200 proteins at 14 hours post-infection. By 24 hours 
post-infection we saw an additional significant increase in the number of host proteins that were 
altered more than two-fold, suggesting that C. trachomatis dramatically alters the host-proteome 
during infection (Figure 5-1B). In order to increase our confidence in the protein alterations that 
we identified, we performed an independent biological replicate at 24 hours post-infection  











Figure 5-1. SILAC identifies host proteins altered during infection with C. trachomatis.  
A) Schematic representation of the SILAC proteomic screen.  
B) The differential levels (log2  ratio on the x-axis) of all proteins quantified by LC-MS/MS at 4, 
14, and 24 hours post-infection. Red bars indicate changes of two-fold (left: destabilized; right: 
stabilized).  
C) Top: The overlap of total proteins between two independent replicates 24 hours after 
infection with C. trachomatis. Bottom: The overlap of proteins between the two replicates at 24 
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(Figure 5-1C). Between the two 24 hour replicates, we identified 1834 common proteins (of 
4405 total proteins identified in both replicates), from which we identified 389 common altered 
proteins (of 805 total altered proteins identified in both replicates). We binned potential hits into 
low and high confidence groups depending on whether they were found in one or both 
replicates, respectively (Table S5-1).  These data reveal that C. trachomatis alters the host 
proteome to a scale not previously appreciated. Interestingly, the number of host proteins 
altered increases as infection progresses, suggesting that C. trachomatis actively manipulates 
host cells throughout its developmental cycle. In order to validate the dataset directly, we 
examined changes in protein levels throughout infection by immunoblot analysis. In all cases 
where antibodies were available to detect the protein of interest, the immunoblot confirmed the 
changes measured by SILAC in the screen (Figure 5-2).  
Through the use of quantitative mass spectrometry we identified a large number of host 
proteins whose levels were altered following infection with C. trachomatis. We next used 
bioinformatic analysis to gain a better understanding of how individual hits fit into the larger 
context of host cell biology. We conducted DAVID functional annotation clustering to identify 
gene ontology groups and host pathways that were significantly enriched during Chlamydia 
infection.  We used host proteins that were identified as high confidence hits at 24 hours 
following infection with Chlamydia for our analysis. Among the top enriched cluster groups, we 
identified proteins involved in cytoskeleton/microtubule networks, RNA processing and 
translation, as well as organelles such as the Golgi apparatus and nuclear lumen (Summarized 
in Table S5-2). Previous work has suggested that Chlamydia directly alters the Golgi during 
infection via fragmentation, highlighting the utility of our data for identifying larger host cell 
interactions beyond the individual proteins that were found in the SILAC screen. We were 
surprised to find the strong impact of Chlamydia infection on RNA splicing and host protein 
translation because these processes have not been widely implicated as targeted during 
Chlamydia infection. Our data suggested that changes in host protein levels may not mirror  









Figure 5-2. Validation data for the SILAC proteomic screen. 
293T cells were mock-infected or infected with C. trachomatis for the indicated amount 
of time. Immunoblots were performed using antibodies for selected proteins (Cep170, 
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changes in mRNA levels.  
Identification of genes altered transcriptionally following infection with C. trachomatis   
If specific host cellular processes, such as RNA stability and translation, are directly altered 
during infection with Chlamydia, it suggests that the changes that we identified at the protein 
level using SILAC may differ from the changes that have been identified at the transcriptional 
level. Our initial quantitative proteomic experiments showed that C. trachomatis alters hundreds 
of host proteins following infection, and we wanted to determine which genes were also 
changed at the transcriptional level. In order to address this question, we performed 
transcriptional analysis of the host cells at the same time points after infection at which we 
conducted SILAC analysis (Table S5-1). Our microarray analysis overlapped with previously 
published studies of host cells infected with C. trachomatis, with the exception of some 
differences in the upregulation of a number of pro-inflammatory genes (12, 13). These 
differences were expected because our studies were performed in HEK293T cells, which lack 
the majority of innate sensing genes (14).  This also suggests that most of our observations are 
not the result of innate immune responses. Similar to what we observed in the SILAC time 
course described above, we saw an increase in the total number of genes whose transcription 
was altered more than two-fold as the infection progressed (Figure 5-3A).  
 Our initial transcriptional analysis identified only a handful of host genes that were 
altered significantly during Chlamydia infection in HEK293T cells, and few of these genes 
appeared to overlap with the protein changes that were identified using SILAC. We next wanted 
to independently validate our microarray findings using a more sensitive quantitative RT-PCR 
approach. We took advantage of the Bio-Rad PrimePCR resource to investigate changes in 
mRNA expression for a wide-range of host genes in a single 384 well plate assay format. We 
isolated mRNA from HEK 293T cells mock-infected or infected with C. trachomatis for 30 hours 
and reverse-transcribed total mRNA into cDNA. Using pre-mixed primer pairs for 90 host genes, 
we amplified individual genes by RT-PCR in technical duplicates to analyze changes in  





Figure 5-3. Transcriptional analysis and validation of host cells infected with C. 
trachomatis 
A)The differential levels (log2  ratio on the y-axis) of all genes quantified by microarray for mRNA 
levels at 4, 14, and 24 hours post-infection compared to uninfected controls. Red bars indicate 
changes of two-fold (Below: Down-regulated; Above: Up-regulated). 
B) 293T cells were mock-infected or infected with C. trachomatis for 30 hours. Isolated RNA 
was transcribed into cDNA and analyzed by quantitative RT-PCR using PrimePCR high 
throughput analysis and normalized to Actin.  Bars indicate changes of two-fold. Positive control 
genes not related to SILAC are indicated with +. 
C) Shown is the fold-change in gene expression following C. trachomatis infection for a 
representative group of genes. Light gray bars represent positive controls as determined by 
initial microarray analysis. Dark gray bars represent genes that were altered in the SILAC 
analysis.    
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transcription. Eighty of the genes we chose to examine were high confidence hits identified in 
the initial SILAC screen (31 stabilized and 49 destabilized). We also included 5 positive controls 
and 5 negative controls consisting of genes that were found to be differentially altered at the 
transcriptional level during infection, but were not found to be altered at the protein level in the 
SILAC screen.  
 We found that the mRNA levels for only four genes of the eighty tested from proteins 
altered in SILAC were altered more than two-fold following infection with C. trachomatis (Figure 
5-3B, Table S5-1). In contrast, all 5 positive control genes were altered significantly following 
Chlamydia infection and no negative controls. Together these data suggest that the 
transcriptional changes to the host that occur during infection with C. trachomatis may not be 
predictive of changes that occur directly in protein levels.  
  
Many changes in host protein levels are not predicted by transcriptional profiling  
Since we found very few proteins that were altered transcriptionally in our RT-PCR 
validation, we next wanted to globally assess how each individual protein was altered at both 
the transcriptional level and the protein level. This analysis aimed to identify changes to host 
proteins that are occurring independently of transcription, and therefore may be directly targeted 
during infection with C. trachomatis. We plotted the changes in each gene at the transcriptional 
level versus changes in that same gene at the protein level (Figure 5-4). Surprisingly, we 
noticed that over 90% of the protein changes identified were occurring independently of 
changes in host transcription.  One explanation for this is that changes in transcription may 
occur prior to changes in the protein level. However, when we compared differing time points 
(SILAC at 24 hr vs. transcription at 14 hr) we saw no evidence of such a delay being 
responsible for the lack of correlation between the array data and SILAC data (data not shown). 
We conclude that infection with C. trachomatis extensively alters the host proteome 
independently of its effects on the host transcriptome.  















Figure 5-4. Changes in host protein levels do not correlate with changes in host mRNA 
levels during C. trachomatis infection. 
Scatter plots show the correlation between changes in mRNA levels as determined by 
microarray analysis and protein levels as determined by SILAC at three timepoints after 
infection of HEK293T cells with C. trachomatis. 
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C. trachomatis infection alters host translation efficiency late during infection  
Our data presented up to this point demonstrate that changes to the host proteome are 
discordant with changes to host transcription. This suggests that Chlamydia infection is able to 
alter levels of host proteins in a manner independent of changes in transcription. Our 
bioinformatics analysis of host proteins that were identified as altered in our SILAC screen 
showed a strong enrichment for genes involved in ribosome function and in host protein 
translation efficiency. This hinted that infection with C. trachomatis might alter the host cell’s 
ability to translate proteins. Several bacterial pathogens have been shown to directly inhibit host 
protein translation through the action of toxins or effector proteins in order to promote pathogen 
survival. Furthermore, previous studies have shown that Chlamydia replicates more efficiently in 
the presence of low levels of the antibiotic cyclohexamide, which inhibits eukaryotic protein 
translation. We hypothesized that one mechanism by which Chlamydia infection may 
differentially alter mRNA and protein levels is by preventing robust host translation throughout 
the developmental cycle, phenocopying cyclohexamide treatment. 
 To examine the impact of infection on host translation, we employed a protein translation 
assay that measures the incorporation of radioactive amino acids in cells that are either mock-
infected or infected with C. trachomatis. HeLa cells were mock-infected or infected with C. 
trachomatis for 30 hours, were then washed, and the media was replaced with [3H]-leucine and 
media containing defined antibiotics that inhibit either host or bacterial translation. Cells were 
incubated in the radioactive media for one hour to allow for the incorporation of amino acids into 
proteins. Cells were then washed extensively, placed in scintillation fluid, and the level of 
radioactivity in each well was determined. We found that in the absence of antibiotics, the total 
incorporation of radioactive leucine was significantly decreased in cells infected with C. 
trachomatis, with levels that were almost two-fold lower than in the mock-infected cells (Figure 
5-5). In the untreated condition, the total radioactivity is representative of the sum of the 
translation of both host and bacterial proteins. In order to assess how either host or bacterial  







Figure 5-5. Infection with C. trachomatis decreases host protein translation efficiency. 
HeLa cells were mock-infected or infected with C. trachomatis (MOI=10) for 29 hours. Cells 
were then treated with 100µg of the indicated antibiotic. 30 hours following infection cells were 
were washed and fresh media with [3H]-leucine was added to all cells for 1 hour. Cells were 
then lysed and the level of radioactivity in each well was determined. Shown is a representative 
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translation is altered, we treated cells with the antibiotic cyclohexamide, chloramphenicol, which 
inhibits bacterial protein translation, or both. In cells that were treated with cyclohexamide, we 
found that incorporation of radioactive amino acids is entirely inhibited in uninfected cells, but 
that there is a small level of incorporation in infected cells. This level of incorporation represents 
the translation that occurs in Chlamydia in host cells. In cells treated with chloramphenicol, 
which inhibits C. trachomatis translation, any radioactivity detected should represent only host 
amino acid incorporation. We found significantly lower levels of radioactive incorporation 
between infected and uninfected cells. Furthermore we found that cells treated with 
chloramphenicol, and therefore only examine host protein translation, had even less amino acid 
incorporation than cells with no drug treatment. As a control to ensure that our drug 
concentrations effectively inhibited translation, we examined the incorporation of radioactive 
leucine in cells treated with both antibiotics. We found almost no radioactive incorporation in the 
dual-treated controls compared to untreated cells, demonstrating that our drug treatments are at 
sufficient to inhibit translation in this assay. Taken together, these data suggest that host 
translation efficiency is lowered in cells infected with C. trachomatis. This underscores one 
mechanism driving discordant levels in host proteins and mRNA in Chlamydia-infected cells.   
 
Overexpression of destabilized host proteins inhibits the growth of C. trachomatis 
Our proteomic analysis identified pathways that were significantly altered during infection 
with C. trachomatis, and found that many host proteins that were altered would not have been 
predicted by examining changes in mRNA alone. However, it remained unclear whether these 
changes in host proteins directly impacted the ability of Chlamydia to aquire nutrients and to 
grow efficiently inside host cells. We next wanted to examine the individual role of the proteins 
that were identified as altered in our protemic screen. We hypothesized that a subset of C. 
trachomatis-induced changes may be essential for C. trachomatis infection to progress  




Figure 5-6. Optimization of gain-of-function screen protocol and cell lines. 
A) Schematic representation of the constitutive expression screen. 
B) A random subset of 293T constitutive expression cell lines were analyzed by immunoblot for 
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normally. To test this hypothesis, we piloted a gain-of-function screen which functionally 
reversed the specific protein changes that were driven by C. trachomatis (Figure 5-6A). Initially, 
we focused on proteins that were shown to be destabilized following infection. We reasoned that 
if destabilizing a particular host protein is essential for Chlamydia replication that over-
expression of this protein may overwhelm the capacity of C. trachomatis to destabilize the 
protein and thus restrict bacterial growth. The general scheme for the overexpression screen is 
depicted in Figure 5-6A. We picked three hundred destabilized proteins from our hit list and 
cloned each protein into a retroviral flag-tagged over-expression vector. As a “neutral” control, 
we also cloned 50 randomly chosen proteins that were identified in our screens as unchanged 
following infection and 12 negative controls that contained the empty vector. We then created 
stable lines in HEK 293T cells that over-expressed each protein to levels well above the 
endogenous levels. We randomly selected 20 experimental cell lines and confirmed that the 
majority of cell lines were overexpressing a flag-tagged protein (Figure 5-6B). An important 
caveat to this methodology is that similar to large-scale siRNA experiments, over-expression 
efficiency was variable between cells lines, which could lead to false negatives due to low 
expression of individual proteins. We infected each cell line in duplicate with C. trachomatis for 
48 hours. Cells were then lysed, diluted in media, and titered using normal HeLa cells as 
targets. After 24 hours, the cells were fixed and stained for the C. trachomatis major outer 
membrane protein (MOMP) and for host cell nuclei. We then used high content imaging to 
quantify the number of inclusions for each sample. Each well was normalized and the fold 
change in growth was calculated for each cell line containing an overexpressed host protein 
(Figure 5-7). The position within the distribution of experimental samples where the neutral and 
negative controls fall is noted in the figure. Importantly, all negative controls (0%) and all but one 
neutral control (2%) had changes in bacterial growth of less than 1.5 fold. In contrast, we 
identified 35 experimental proteins (12%) that inhibited C. trachomatis growth by over 1.5 fold. 
Because changes in protein stability as determined by GPS or SILAC may be caused by several  
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Figure 5-7. Gain-of-function screen identifies destabilized host proteins that are 
necessary for C. trachomatis growth and propagation. 
A) Distribution of the mean fold change in C. trachomatis IFU production. All data points are 
shown in black triangles. The distributions of vector controls (yellow hash through the triangle) 
or neutral controls (orange hash through the triangle) were overlayed on the primary screen. 
Blue lines indicate 1.5 fold changes in C. trachomatis IFU. 
B) A subset of overexpression cell lines was infected with C. trachomatis for the indicated 
timepoints. Levels of C. trachomatis were determined by qPCR of the 16s gene and compared 
to vector control cells. The graphs show the mean levels of C. trachomatis from triplicate 
samples +/- the standard deviation (*p<.05, **p<.01 by paired student t-test) (n=3). 
C) A subset of overexpression cell lines was infected with C. trachomatis for the indicated 
timepoints. Levels of C. trachomatis were determined by IFU production and compared to vector 
control cells. The graphs show the mean IFU of C. trachomatis produced from triplicate samples 
+/- the standard deviation (*p<.05, **p<.01 by paired student t-test) (n=3). 
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factors such as phosphorylation, ubiquitination or protein complex formation, we would not 
expect to see growth defects for the majority of cell lines containing overexpressed host 
proteins. 
 We then further validated the capacity of these 35 transduced cell lines to inhibit C. 
trachomatis growth (Table S5-3). These validation studies verified 16 cell lines that reproducibly 
inhibited the ability of C. trachomatis to grow by at least 1.5 fold following infection (Table S5-3). 
We then selected 3 of these cell lines and examined their ability to inhibit C. trachomatis through 
an infection time course. We examined the levels of C. trachomatis by quantitative PCR, as well 
as the capacity of the cells to produce progeny by counting inclusion forming units (IFU). In all of 
these cases, overexpression of a single host protein decreased the levels of C. trachomatis 
present during primary infection (Figure 5-7B), as well as the ability of the pathogen to produce 
infectious elementary bodies (Figure 5-7C). These data suggest that a subset of proteins that 
appeared destabilized in our screens actually must be destabilized in order for efficient 
replication of C. trachomatis to occur in host cells.  
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Discussion 
Infections with intracellular pathogens lead to a reorganization of host cells directed both by the 
host response to infection and by active mechanims employed by the invading bacteria. In order 
for investigators to develop novel antibiotics that target pathogenic mechanims occuring during 
infection, we must broadly characterize how host cells are directly altered during infection and 
understand which of those changes are directed by the pathogen. Recently, investigators have 
focused on transcriptome analysis to identify global changes in host mRNA expression during 
infection. In this study, we combined quantitative proteomic and global transcriptional analysis to 
characterize changes that occur to host cells during infection with C. trachomatis. Our results 
show that Chlamydia broadly rearranges the host proteome independently of changes in host 
transcription beyond levels previously appreciated. It also demonstrates that several of these 
host protein changes are essential for bacterial growth.  
For the intracellular pathogen Chlamydia trachomatis, global transcription studies have 
led to the identification of transcriptional networks that are broadly altered throughout infection. 
Unfortunately, these analyses have limited ability to identify host processes that are targeted 
directly by C. trachomatis throughout the developmental cycle. First, all transcriptional studies 
examining C. trachomatis infection to date have used cultured cell lines that are competent in 
the majority of innate immune signaling pathways. When analyzing these data, it is clear that 
many genes that are transcriptionally altered during infection are in fact related to the host 
response to infection that occurs following most intracellular infections. In the data presented 
here, we circumvented innate sensing pathways in all our global analysis by using HEK293T 
cells, which lack almost all TLRs and NLRs. The lack of these signaling molecules prevents 
robust innate activation following infection, and should allows for the identification of changes in 
host processes that are the direct result of C. trachomatis infection. Our transcriptional 
analysisof HEK293T cells throughout infection with Chlamydia supports this hypothesis, as we 
identified far fewer genes that were altered at the mRNA level than previous studies and 
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importantly, several of the genes that were unaltered transcriptionally in our study were pro-
inflammatory genes such as IL-8, which are predicted to be driven by the host response. 
Therefore using HEK293T cells as a screening tool enhances our ability to identify changes to 
human cells directed by C. trachomatis and to bypass the effects of the innate immune 
response.  
While transcriptional analysis is a robust starting point to charactize host-pathogen 
interactions, ultimately the levels of host proteins, which are the molcules of action in cells, may 
be a better indicator of host cell alterations. In this study, for the first time quantitative 
proteomics were used to characterize ways in which the host cell proteome is altered during 
infection with Chlamydia trachomatis. Previous work examining changes to host proteins have 
relied on 2D-Gel electrophoresis and targeted immunoblot analysis, providing limited 
information about proteomic changes that occur during Chlamydia infection. Our results show 
that there are a dramatic number of host proteins that are altered even as early as four hours 
following infection, compared to uninfected cells. As infection progresses, the changes in the 
host proteome become exacerbated. After 24 hours of Chlamydia infection, we identified over 
380 host proteins that were reproducibly altered by more than two-fold. These changes were far 
more robust than we anticipated based on our transcriptional analysis, and suggest that 
Chlamydia broadly alters the host proteome during infection. One caveat to these experiments 
is they were done withiout inhibiting CPAF, which may have lead to unintended changes in host 
proteins that are not representative of physiological interactions. However, because only the 24 
hour timepoint when CPAF would be expressed in these experiments, and with the combination 
of two biological replicates and immunoblot validation done under CPAF inhibiting conditions, 
we are confident that the majority of the protein changes identified are not artificial CPAF 
substrates. Therefore, broad changes to the host proteome occur during infection with 
Chlamydia to levels not previously appreciated.  
When we examined the changes in host transcription and host proteins levels from the 
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same infected cells, we noted that there was a very low correlation between the two. In fact, 
over 90% of the host protein changes found in SILAC were altered independently of changes in 
host transcription. We further validated a subset of high confidence SILAC hits by quantitative 
RT-PCR and found none of thes proteins were altered transcriptionally during C. trachomatis 
infection. It is an intriguing finding that C. trachomatis broadly elicits changes in host proteins 
idependent of changes to host transcription. We hypothesized that one way C. trachomatis may 
accomplish this is by altering the efficiency of host translation. Bioinformatic analysis of the host 
proteins altered following infection with C. trachomatis identified a number of ribosomal proteins 
and other translation regulating proteins. Supporting this hypothesis, we identified that 
constitutive expression of elongation factor EEF1D reduced replication of C. trachomatis in host 
cells. EEF1D is a guanine nucleotide exchange factor that is needed to deliver aminoacyl tRNAs 
to the ribosome. Loss of EEF1d represses the translation efficiency of host proteins, as seen 
during HIV infection (15).  Likewise, it is known that treatment of cells with cyclohexamide 
promotes increased C. trachomatis replication (16). When we examined amino acid 
incorporation into proteins in cells that were mock-infected or infected with C. trachomatis, we 
found that a significant inhibition of host translation occurs during infection. This is one potential 
mechanism that drives the discordant levels of mRNA and protein observed during the 
Chlamydia infectious cycle. It will be important to begin studies to understand whether C. 
trachomatis encodes effectors that directly target the ribosome, similar to another intracellular 
pathogen, Legionella pneumophila (17).  This could provide evidence that repression of host cell 
translation may be a common strategy employed by bacterial pathogens to promote growth 
within host cells.  
Another mechanism by which C. trachomatis may directly alter host proteins 
independent of transcription is by altering the host cell ubiquitin landscape. One hit identified 
in the SILAC screen was the E3 ubiquitin ligase component Cul4A (18). We confirmed Cul4A 
is destabilized following infection by immunoblot. While our ongoing studies are examining 
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individual Cul4 substrates that may be altered, we hypothesize that by targeting the removal 
of a single E3 ubiquitin ligase or host deubiquitinating enzyme, C. trachomatis may be able to 
indirectly change the rate of turnover of specific host proteins or classes of host proteins. 
Further studies must begin to take advantage of resources that have helped characterized the 
mammalian ubiquitin system and apply them to identify specific host ubiquitin ligases or 
deubiquitinating enzymes that are critical for C. trachomatis replication. Our current study 
shows that C. trachomatis broadly alters host proteins post-transcriptionally and this may be a 
broad mechanism used by bacterial pathogens to promote survival. 
While our study identified hundreds of host proteins that are altered during infection, 
the majority of these proteins were not essential for normal bacterial replication to occur. 
There are a number of possibilities for why we did not see a higher number of host proteins 
that are critical for normal growth to occur. One potential pitfall using a single gene gain-of-
function approach is the inability to account for redundant host pathways that may circumvent 
the perturbations on a single protein tested. Another possibility for false-negative results is the 
inherent limitations to precisely control the expression of genes in our gain-of-function screen. 
Furthermore, we predict that a number of host protein alterations that we identified are not 
targeted directly by C. trachomatis, but rather are indirect consequences of other events such 
as the induction of host stress responses and therefore are not essential for growth. Finally 
some alterations may be important for other survival mechanisms that are not tested by the 
assays presented here, such as immune evasion. It is critical that we expand on our findings 
presented here to identify which essential protein changes are directed by C. trachomatis. By 
identifying specific host proteins that are essential for infection to occur normally, we can 
develop host-based antibiotics that disrupt pathogen interactions with the host cell, rather than 
poisoning the organism directly. A proof-of-principle of this concept was recently described for 
Mycobacterium tuberculosis (19). In this study investigators targeted host tyrosine kinases 
using the drug imatinib (Gleevec) and showed a reduction in both bacterial load and in the 
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development of granulomas. The potential of host-based therapeutics is an exciting possibility 
that has also been pursued for viral infection, because it may be very difficult for the pathogen 
to evolve resistance to these compounds (20). Overall applying these new global approaches 
will help us better understand pathogenesis and prevent disease. 
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Materials and Methods 
Tissue Culture, Reagents, and General Procedures 
HeLa, and 293T cells were maintained in Dulbecco’s Minimum Essential Media supplemented 
with Penicillin/Streptomycin and 10% fetal bovine serum (Invitrogen). HeLa cells stably 
expressing CrpA-EGFP or EGFP alone were passaged in the medium described plus 200 
µg/ml G418. For hypoxia-like induction experiments cells were cultured in DMEM containing 
200 uM CoCl2 for the indicated amount of time. 293T and HeLa cells were transfected using 
the TransIT transfection reagent (Mirus). Retroviruses were packaged in 293T cells 
transfected with the plasmid of interest as well as plasmids expressing VSVg and Gag-pol 
(Luo et al., 2009). Viral infections were supplemented with hexadimethrine bromide at a 
concentration of 8 µg/ml. Transfection of siRNA oligonucleotides was performed with 
Dharmafect (Dharmacon) lipid transfection reagent according to the manufacturer's protocols. 
siRNA were purchased from Dharmacon as smart pools. A complete list of immunological 
reagents used in this study is below. Flow cytometry was performed on a BD-LSRII Flow 
Cytometer (Becton Dickinson). Data were collected using BD FACS Diva software (Becton 
Dickinson) and analysis was performed using FloJo software.  
Validation was performed by individually picking ORFeome clones and cloning them 
using gateway recombination into the GPS vector. All inserts were sequenced using the 
primer: 5’-AGCTGTACAAGTCCGAACTCGT-3’. The vectors were used to package virus and 
used to generate cell lines expressing individual GPS-ORFs. For immunoblot validation of 
endogenous proteins after Chlamydia infection, cells were lysed at the indicated time points.  
EBs of C. trachomatis serovar L2 434/Bu were propagated within McCoy cell 
monolayers.  A combination of glass bead disruption and sonication was used to release 
EBs from infected McCoy cells.  EBs were further purified by ultracentrifugation over 
Renograffin gradients, as previously described (15). Aliquots of C. trachomatis EBs were 
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stored at -80° C in SPG buffer (250 mM sucrose, 10 mM sodium phosphate, and 5 mM L-
glutamic acid, pH 7.2). Prior to infection with C. trachomatis, cells were cultured for 12-24 h 
in their respective media minus antibiotics.  Cells were infected with C. trachomatis by 
adding media containing dilute EBs to host cells. Centrifugation was not used unless 
specified in the text. The multiplicity of infection (MOI) used for C. trachomatis was 3:1 
unless indicated.  DMEM alone was used for mock-infected cells. 
 
Immunoblot analysis. For immunoblot analysis, cells were lysed at indicated timepoints 
following infection in glycerol lysis buffer (10 mM HEPES, 150 mM NaCl, 0.1% NP-40, 10% 
glycerol) in the presence of a complete protease inhibitor cocktail (Roche Applied Science, 
Indianapolis, IN) and phosphatase inhibitor.  Lysates were normalized for total protein content 
by measuring absorption at 280 nm or using a BCA test (Pierce).  Normalized samples were 
subjected to SDS-PAGE analysis (TGX gels, BD), transferred to nitrocellulose, and 
immunoblotted with the following antibodies:  
Actin (Licor), Cep170 (AbCam), Cul4A (Cell Signaling), EEF1D (Santa Cruz) Flag
 (Invitrogen), Golga3 (AbCam), Trip12  (AbCam), Tubulin (Licor), SMC4 (AbCam)  
 
Automated image analysis.  Stained cells were imaged with a Cellomics ArrayScan VTI 
automated microscope.  Six fields per well of a 96-well plate were imaged at 20x magnification.  
First, cells were identified by their nuclei staining in channel 1 of Cellomics.  Cells that scored 
positive in channel 1 were analyzed for Alexa-488 (inclusions) in channel 2.  A minimum 
average intensity in the Alexa-488 channel was calculated by manual inspection and applied to 
each selected object.  The selected objects that were above this threshold are shown in blue 
while those that were below are shown in orange.  Once the threshold was determined, all of 
the plates were subjected to data analysis using vHCS Scan Target Activation software v5.1.2.  
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Data were obtained by using vHCS View software and the number of inclusions in the well was 
identified as “valid object count” (VOC). 
 
Quantitative PCR. To assess the levels of C. trachomatis present, we used a previously 
described qPCR method (21). Briefly, we isolated nucleic acid from infected cells using the 
DNeasy kit (Qiagen). Chlamydia 16S DNA was quantified by qPCR on an ABI Prism 7000 
sequence detection system using primer pairs and dual-labeled probes. Using standard curves 
from known amounts of Chlamydia the levels of 16s DNA per well was calculated. 
 
Microarray analysis. To compare relative levels of RNA expression, HEK293T cells were 
grown in DMEM (10% FBS). Cells were then infected with C. trachomatis or left uninfected. 
Cells were harvested at three time points after infection (4, 14, and 24 hours). Cells were then 
lysed using a Trizol (Invitrogen) and RNA was isolated using RNeasy kit (Qiagen) according to 
manufacturer’s instructions. RNA levels and quality was analyzed using an Agilent Bioanalyzer. 
RNA was then fragmented, labeled, and hybridized onto an Affymetrix GeneChip Human Gene 
1.0 ST Array. Chips were read using an Affymetrix chip reader and were normalized and 
analyzed using GeneSpring software. Normalized expression levels were compared between 
conditions and two-fold changes were identified across all genes.  
 
Overexpression Screen. Candidate proteins expression constructs were made by individually 
picking ORFeome clones and cloning them using gateway recombination into the iTAP vector. 
Each clone was sequenced using the primer: 5’-CGTGTACGGTGGGAGGTCTA-3’. For each 
ORF, retrovirus we made as described above. 293T cells were transduced individually in one 
well of a six-well plate. 48 hours later cells were selected with puromycin. Following selection 
cells were plated into duplicate 96 well plates with 104 cells per well. Cells were then infected 
with C. trachomatis at an MOI of 1:1. Forty-eight hours after infection cells were lysed and the 
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lysate was diluted 1:1000 and re-seeded into 96-well plates containing 104 normal HeLa cells. 
Twenty-four hours after inoculation with the lysate, cells were fixed with ice-cold MeOH for 30 
minutes. Cells were washed two times with PBS containing 0.1% tween. Cells were then 
stained for with DAPI and C. trachomatis was stained using the antibody to the outer membrane 
protein MOMP contained in the C. trachomatis pathfinder diagnosis kit (Roche). Cells were 
quantified by automated microscopy as described above. The mean number of IFU produced by 
vector control samples was calculated, along with the mean IFU produced for each 
experimental ORF. A fold-change in C. trachomatis growth was calculated against the vector 
controls for each sample. Cells that inhibited growth more than 1.5-fold were maintained and 
used for subsequent infection studies. 
 
RT-PCR analysis 
Predesigned primers were selected from the BioRad human PrimePCR collection. Primers were 
pre-aliquoted in quadruplicates across a 384 well plate. HeLa cells were mock-infected or 
infected with C. trachomatis for 30 hours. Cells were then lysed in Trizol (Invitrogen) and RNA 
was isolated using RNeasy purification (Qiagen). cDNA was then synthesized using an iScript 
Advanced cDNA Synthesis Kit for RT-qPCR.  SsoAdvanced SYBR Green Supermix was then 
used to amplify cDNA by RT-PCR using an ABI Prism 7000 sequence detection system in 
technical duplicates. All wells were normalized to host beta-actin and analyzed using CFX 
Manager Software (BioRad).  
 
Protein translation assay  
HeLa cells were plated in DMEM at 104 cells per well in a 96-well plate and incubated overnight 
at 37 C. The following day, cells were mock-infected or infected with 105 C. trachomatis for 29 
hours. Cells were then washed and fresh media was added that contained no antibiotics, or 
contained 100ug Cyclohexamide and/or 10ug Chloramphenicol.  After a one hour incubation, 
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the medium was removed and replaced with leucine-deficient medium supplemented with 1 mCi 
of [3H]-leucine/ml (PerkinElmer, Billerica, Massachusetts) and the same antibiotics as before. 
Cells were then incubated for an additional hour. Plates were washed twice with cold PBS (200 
ul) prior to the addition of 200 ul of scintillation fluid. The amount of [3H]-leucine incorporated 
was determined by scintillation counting using a Wallac MicroBeta TriLux 1450 LSC 
(PerkinElmer, Waltham, MA).  
 
Mass Spectrometric Comparison of Protein Abundances via SILAC. To compare relative 
levels of protein expression, HEK293T cells were grown in DMEM (10% FBS) prepared with 
either 13C-labeled or normal 12C lysine. After 14 days of growth in these media, we achieved 
complete labeling of cellular proteins in the 13C medium as verified by mass spectrometry 
analysis.  Cells grown in 13C-lysine were then infected with C. trachomatis while 12C-lysine-
labeled cells were left uninfected. Both infected and non-infected cells were harvested at three 
time points after infection (4, 14, and 24 hours). Cells were then lysed using a glycerol lysis 
buffer containing protease and phosphatase inhibitor cocktails, and mixed at a 1:1 ratio based 
on total protein concentration as measured by the BCA assay.  The combined lysates from each 
timepoint were then separated via SDS-PAGE, followed by excision and division of the gel into 
12 bands with roughly equal protein content as judged by visual inspection of Coomassie 
staining patterns. Bands subsequently underwent digestion in-gel with endoproteinase Lys-C 
(Wako).  Finally, peptides extracted from each gel band were resuspended in 5% 
acetonitrile/5% formic acid for mass spectrometric analysis. 
 Peptides extracted from each gel band were identified and quantified via LC-MS/MS 
analysis using an LTQ-Orbitrap mass spectrometer (Thermo Fisher Scientific) equipped with a 
Famos autosampler (LC Packings) and an Agilent 1100 binary HPLC pump (Agilent 
Technologies) essentially as described previously (22). Briefly, a gradient from 6-30% 
acetonitrile in 0.125% formic acid was used to separate peptides via reversed phase 
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chromatography at approximately 300 nl/min over 70 minutes (total run time was 90 minutes). 
After acquisition of each high-resolution survey scan in the Orbitrap, low resolution MS/MS 
spectra were collected in data-dependent mode to match the top twenty most intense 
precursors following collision-induced dissociation within the linear ion trap.  A minimum signal 
of 500 counts and a well-defined isotopic envelope were required for MS/MS selection, while 
singly charged peptides and peptides with unknown charge states were excluded. Ions were 
excluded from further sequencing for 30 seconds following MS/MS selection. 
 After LC-MS analysis, RAW files were converted to mzXML format and data were loaded 
into our in-house system for storage and processing of proteomics data.  Features selected for 
MS/MS sequences were examined to ensure accurate monoisotopic mass determination and to 
optimize mass measurements. The Sequest search algorithm (11) was then used to match 
MS/MS spectra with peptides drawn from the human proteome (IPI; version 3.6) (23). 
Sequences of common protein contaminants including endoproteinase Lys-C were included as 
well. Sequences of all proteins were considered in both forward and reversed orientations to 
enable subsequent estimation of peptide and protein false discovery rates via the target-decoy 
method (24). The following parameters were used for database searching: 100 ppm precursor 
ion tolerance; 1.0 Da fragment ion tolerance; Lys-C digestion with up to 2 missed cleavages; 
fixed carbamidomethylation of cysteine (+57.0214); and variable methionine oxidation 
(+15.9949) and 13C6-labeling of Lysine (+6.0201). Peptide identifications were filtered to a 
preliminary false discovery rate of 1% using the target-decoy method and linear discriminant 
analysis to distinguish correct and incorrect peptide identifications based on multiple metrics 
including Sequest's Xcorr and DCn scores, mass error, charge state, and peptide length (25). 
Probabilistic scores were then determined for each protein based on its matching peptides and 
the entire dataset was further filtered to achieve a final protein-level false discovery rate of 2%. 
After this additional protein-level filtering, the resulting peptide-level false discovery rate was 
reduced to well below 1%.   
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 Relative quantitation of each identified peptide was accomplished using the Vista 
algorithm (26), as described previously (22). To be eligible for quantification, each quantified 
peptide was required to earn a Vista score of at least 79, and isotopic envelopes for both heavy 
and light forms were required to achieve a minimum signal-to-noise ratio of 3. Alternatively, if 
one form was found to have a S/N ratio less than 3, its partner was required to have a S/N ratio 
exceeding 5. In cases where only a single isotopic form (heavy or light) was observed, it was 
required to attain a minimum S/N ratio of 5; such peptides were quantified based on their signal-
to-noise ratio since its corresponding isotopic pair could not be found. Furthermore, to limit 
quantitation of false identifications, peptides matching such 'exclusive' peptide identifications 
were required attain Q-values of 0.001 or better, meaning that they had to be identified at a 
minimum false discovery rate of no greater than 0.1%.  Relative protein abundance levels were 
inferred from the median ratio of all matching peptides. To correct for minor errors in sample 
mixing, raw abundance ratios were normalized to ensure that the median Log(2)-transformed 
protein ratio was 0, corresponding to 1:1 mixing of heavy and light samples.  
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Chapter 6: Pathogen-induced alterations to the host cell 
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Introduction 
Intracellular bacterial pathogens have evolved to exploit host cells in order to survive, 
replicate, and spread from mammalian hosts (1-3). Many of these bacterial pathogens reside in 
host-cell vacuoles and translocate virulence factors directly into the host cytosol through 
specialized secretion systems (4-6).  This allows bacterial pathogens to avoid destruction by the 
endocytic pathway and enables them to replicate within the host cell (7, 8). The activities of 
secreted effectors and their impact on host cell functions are areas of intense investigation, 
however significant progress has been hindered because there is redundancy among bacterial 
effector proteins as well as the host pathways they target (9-11). To completely understand how 
secreted effectors exploit host cell functions during infection, investigators must study multiple 
aspects of host cell protein regulation (12).  Over the last decade there has been a major focus 
on understanding changes in host transcription following infection (13). The availability of 
microarrays has allowed analysis of global changes to thousands of gene transcripts 
simultaneously. These approaches have probed host transcriptional responses to infection and 
identified host responses that bacterial pathogens manipulate in order to promote survival (14).  
Most bacterial manipulations of host cell proteins however cannot be identified through 
transcriptional arrays alone. Many of the effectors that have been identified modify or alter the 
stability of host proteins directly (15-17). Unfortunately, studies examining global changes to 
proteins following bacterial infection have been limited. Investigators have used pulse-chase 
experiments as well as 2D-Gel electrophoresis coupled with mass spectrometry to identify 
proteins that are altered during infection (18). Even with the advances in quantitative 
proteomics, few studies have assessed changes to entire proteomes following infection (19-21).  
Here, we take advantage of global proteomic and genomic techniques to identify host 
proteins that are altered in stability following infection with Chlamydia trachomatis. Chlamydia is 
the leading cause of bacterial sexually transmitted disease in the United States, and the leading 
cause of preventable blindness worldwide (22). C. trachomatis has two developmental forms; 
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the elementary body (EB) that is infectious, but metabolically inactive, and the reticulate body 
(RB) that is the replicating, metabolically active form. EBs are taken up into host cell vacuoles, 
and once inside EBs rapidly convert to RBs (23).  Replication occurs within the vacuole (known 
as the “inclusion”) over approximately 36-48 hours. Just before the cell becomes compromised, 
the RBs convert back to EBs so that infection of neighboring cells can occur. Our lab and others 
have shown that some C. trachomatis proteins can be translocated into cells by the type III 
secretion systems (TTSS) of other pathogens (24-26). This provides some of the evidence 
leading to the conclusion that inclusion-bound C. trachomatis traffic bacterial proteins across the 
vacuolar membrane into the host cell cytosol. Among the proteins secreted into the cytosol by 
C. trachomatis are two deubiquitinating enzymes and several secreted proteases, suggesting 
that C. trachomatis directly manipulates host protein levels during infection (16, 27, 28).  
Because C. trachomatis is dependent on the host cell for survival, it is an ideal bacterial 
pathogen to begin using global approaches to study how it alters the host cell proteome.  Here, 
we used both quantitative proteomics and transcriptional analysis during infection to identify 
changes in host proteins that occur independently of changes in transcription.  In parallel, we 
adapted a recently developed global protein stability (GPS) platform to screen the human 
ORFeome for changes in host protein stability following infection with C. trachomatis (29, 30). 
Using these approaches we identified hundreds of host proteins that are altered in stability 
following infection. We next used a multi-pronged approach, consisting of bioinformatics, gain-
of-function and loss-of-function screens, as well as directed bacterial effector-host substrate 
identification in order to understand Chlamydia-induced changes to host proteins. Our results 
indicate that C. trachomatis dramatically alters the host proteome in order to successfully 
replicate, and that a subset of these changes are driven by secreted effectors and are essential 
for bacterial replication. By understanding how intracellular bacterial infections directly alter the 
proteome of host cells, we will become equipped to discover new interventions that block 
changes to host proteins required by pathogens and ultimately prevent infection and disease.   
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Results 
The global protein stability platform identifies hundreds of host proteins that are altered 
following infection with C. trachomatis 
To begin a search for host proteins whose stability might be altered following infection with C. 
trachomatis, we adapted the Global Protein Stability (GPS) screening platform. GPS is a system 
originally designed as a fluorescent protein-based method to identify the substrates of 
mammalian ubiquitin ligases (30, 31). The GPS platform is a pooled library of HEK293T cells 
each expressing a single copy of a reporter cassette that contains DsRed, an internal ribosome 
entry site (IRES), and a human ORF fused to EGFP (Figure 6-1A). This allows the expression of 
both reporters as a single mRNA from a CMV promoter, making transcription constant and 
differences in EGFP/DsRed reflective of differences in protein levels.  Over 10,000 unique 
human ORFs are represented in the library with each cell expressing a single EGFP-ORF fusion 
protein. Cells in the library were sorted by FACS into seven bins corresponding to lowest to 
highest EGFP:DsRed ratio a reflection of the stability of each human ORF in the library (29, 31).  
In order to identify what ORFs are present in each bin we amplified the ORFs from a genomic 
DNA sample from each bin and then applied them to a custom microarray composed of probes 
to each of the 10,000 ORFs.  This allowed us to determine the relative number of cells 
expressing each ORF contained in each bin.  A protein stability index (PSI) was assigned to 
each ORF based on the weighted average of the bin numbers containing cells expressing that 
ORF (29). After confirming that infection of cells with C. trachomatis does not alter the inherent 
stability of either DsRed or EGFP, we performed the identical experiment described above after 
infecting the GPS library with C. trachomatis for 24 hours (Figure 6-1B). Using the PSI value for 
each protein in the library under uninfected and infected conditions, we calculated the ΔPSI 
resulting from infection (Figure 6-1C). We then used a priority rank system to order the proteins 
from most stabilized to most destabilized identifying over 600 proteins (out of 8000 that passed 
initial filtering from the microarrays) that are altered in stability (ΔPSI < -.25 or ΔPSI > .25)  










Figure 6-1. GPS profiling identifies host proteins altered during C. trachomatis infection.  
A) Schematic representation of the GPS screen.  
B) Histograms show the EGFP/DsRed ratio for cells expressing GFP for varying half-life and the 
entire GPS library. The cell lines were mock-infected (red line) or infected with C. trachomatis at 
an MOI of 5 (blue line) or 50 (green line) for 24 hours and analyzed by flow cytometry.  
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following infection with C. trachomatis (Table S6-1 and described in detail in the methods). This 
was far more proteins than we anticipated based on previously reported transcription data and 
suggested that C. trachomatis was profoundly remodeling the host proteome upon infection 
(32).  In order to determine the overall validation rate of the GPS screen we randomly chose a 
subset of 175 ORFs from the 600 initial hits and created unique GPS reporter cell lines each 
expressing a single EGFP-ORF fusion. This validation approach was designed to ensure an 
unbiased estimate of the reproducibility of the entire GPS screen. Reporter cell lines were either 
mock-infected or infected with C. trachomatis for 24 hours, and then analyzed by flow cytometry 
for changes in the EGFP:DsRed ratios. We found that 109 cell lines (62%) had altered ratios 
reproducibly following infection (Figure 6-2A, Figure 6-2B and Table S6-1). To confirm that 
some of these ORFs were altered by infection we used immunoblots specific for an epitope tag 
on the host protein (14 of 20 confirmed) or using endogenous antibodies (7 of 9 confirmed) 
(Figure 6-3A, Figure 6-3B and Table S6-1). Interestingly, we found that while the GFP fusions 
accurately informed us when a specific protein was altered, they did not always predict whether 
a protein was stabilized or destabilized. For example, we identified the host protein SNCG as 
stabilized following infection with C. trachomatis using the GPS reporter, yet immunoblot 
analysis showed that this protein is actually cleaved following infection (Figure 6-3A and 6-3B). 
These data suggest that cleavage of host proteins in the GPS platform can remove specific 
degrons, leading to the stabilization of the EGFP reporter even though cleavage has occurred. 
To help integrate our GPS hit data into the overall biology of the host cell we conducted 
bioinformatics analysis using DAVID clustering analysis (details are described in the 
methods)(33).  Within the most enriched clusters in our analysis we identified host proteins that 
have been previously described to be important for Chlamydia infection (Table S6-2). These 
included chromatin remodeling proteins, the Golgi apparatus, cell cycle control proteins, and 
host cytoskeleton networks, supporting the concept that our GPS data can identify pathways 
important for Chlamydia growth  (Table S6-2) (34-38). When we examined top clusters that  




































Figure 6-2. Infection of clonal GPS cell lines recapitulates screen phenotypes. 
A) A subset of candidates that were tested by expressing the host gene in HEK293T cells. Cells 
were mock-infected (red line) or infected with C. trachomatis (blue line) for 24 hours and 
evaluated using flow cytometry.  
B) Infected 293T cells expressing the indicated ORFs in the GPS vector were analyzed by flow 
cytometry after 24 hours. The microarray probe distributions are shown at the right for probes of 
the indicated ORFs. A complete list of the validation status of tested proteins can be found in 
Table 6-2. 
  





















Figure 6-3. Immunoblot validation of proteins identified in GPS. 
A) HEK293T cells were mock-infected or infected with C. trachomatis for the indicated amount 
of time. Cells were analyzed by immunoblot for the expression of the experimental proteins 
(Dusp16, SNCG, and NCAP-G) as well as beta-tubulin (loading control). 
B) A subset of HEK293T cells expressing tagged versions of potential GPS targets were mock-
infected or infected with C. trachomatis for 24 hours. Cell lysates were analyzed by immunoblot 
for the indicated experimental proteins and beta tubulin (loading control). 
C) 293T cells were mock-infected or infected with C. trachomatis for the 30 hours when cells 
were lysed in 8M Urea. Shown are representative immunoblots for selected proteins (Ciao1, 
USH1C, DUSP16, Men1, NCAP-G and BNIP3L) and beta-actin (loading control). Replicate 
samples were quantified using the Odyssey infrared imaging system or imageJ and the relative 
intensities were plotted in the graphs. 
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contained protein families not previously associated with Chlamydia infection, we found an 
enrichment of protein families containing transcription factors, host-signaling cascades such as 
JNK, and vesicular trafficking components (Table S6-2). We also found a number of proteins 
that were enriched in the nuclear membrane or mitochondria suggesting that Chlamydia 
infection directly alters the makeup of these intracellular organelles (Table S6-2).  
We next used the data from the GPS screen and our bioinformatics analysis to execute 
a small-scale proof-of-principle study to test the whether the interactions between Chlamydia 
and host cells we identified could reveal broader alterations to these pathways that occur during 
infection. To do this we mined the GPS dataset for proteins that had robust shifts in 
EGFP:DsRed, were members of a larger family of proteins, and where only a small percentage 
of the larger “family” were identified as hits in the initial screen. Two protein families we explored 
were the dual specificity phosphatases (Dusps) and nuclear pore proteins (Nups) that both had 
family members shift (Dusp15/16 and Nup50/160) in the GPS screen (Table S6-1), but did not 
have broad coverage of the entire protein family in our screen. To test whether Chlamydia 
infection more broadly alters this protein family we cloned a larger panel of Dusps (12 members) 
and Nups (8 members) into the GPS vector and created stable reporter cell lines for each 
member. We then infected these cells with Chlamydia and examined the shift of EGFP:DsRed 
24 hours later by flow cytometry. We found that infection with Chlamydia broadly influenced the 
stability of 11 out of 12 Dusps and 6 out of 8 Nups suggesting this family of proteins may be 
broadly altered during infection (Figure 6-4B). These data show further utility of the GPS 
platform to drive additional studies that should reveal mechanisms in play during Chlamydia 










Figure 6-4. Identification of protein families altered broadly during infection using GPS. 
A) The entire Dusp family was selected from the ORFeome library and cloned into the GPS 
vector. 293T cells expressing the indicated ORFs from the Dusp family were made by lentiviral 
transduction and were analyzed by flow cytometry after 24 hours following infection. Shown are 
representative plots from one of three independent experiments. 
B) The entire Nup family was selected from the ORFeome library and cloned into the GPS 
vector. 293T cells expressing the indicated ORFs from the Nup family were made using the 
GPS vector and were analyzed by flow cytometry 24 hours following infection. Shown are 
representative plots from one of three independent experiments.  
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Knockdown of a subset of altered host proteins inhibits the growth of C. trachomatis 
While infection-mediated alterations in the proteome were extensive in the GPS screen, it was 
unclear which, if any, of these changes were critical for infection to occur normally. We 
predicted that a subset of host proteins were altered following infection in order for C. 
trachomatis to evade immunity and/or acquire nutrients and therefore might be required for 
normal growth. To explore the consequences of the host protein changes we uncovered, we 
sought to functionally “undo” the changes in individual proteins by preventing those changes 
from occurring following infection. We reasoned that a loss-of-function screen, reducing 
expression of proteins stabilized following infection, might uncover host factors important for C. 
trachomatis growth and lead us to identify host pathways that could be targeted 
pharmacologically. We optimized an imaging based siRNA protocol using siRNA targeting 
PTEN as a positive control and a non-targeting siRNA as a negative control (Figure 6-5A) (39). 
Cells were transfected with pools of 4 siRNAs for 72 hours, infected with C. trachomatis, and 
subsequently evaluated for growth by measuring the production of infectious progeny (Inclusion 
forming units, IFU).  In triplicate, we conducted a siRNA screen of 200 human genes.  Of those, 
147 were genes encoding proteins we had identified as stabilized following infection with C. 
trachomatis (and were available to us in a local siRNA library) while the remaining 50 genes 
were randomly chosen among those we scored as unchanged in the original GPS screen. We 
hypothesized that siRNA-mediated knockdown of stabilized host proteins might functionally 
undo Chlamydia-driven alterations and identify host proteins that are essential for intracellular 
replication. We initially found 26 host genes that inhibited C. trachomatis growth two-fold or 
more compared to non-targeting siRNA controls (Figure 6-5B and Table S6-3). Importantly, of 
the 50 control host proteins we included that were unchanged in their stability following 
infection, only two reduced Chlamydia growth more than two-fold.  This suggested that these 
proteins were host factors needed for bacterial growth (Table S6-3).  To validate these findings, 
we conducted a screen that contained four individual duplexes per gene and identified 13 host  












































Figure 6-5. Loss-of-function screen of stabilized proteins to identify host factors that 
alter C. trachomatis growth. A) Optimization of a loss-of-function screen to identify host 
factors important for Chlamydia infection. HeLa cells were treated with non-targeting siRNA or 
siPTEN. Graphs show the mean infectivity relative to the non-targeting siRNA +/- the standard  
















Figure 6-5 (Continued) deviation (**p<.01)(n=3).  Immunoblot analysis of PTEN and tubulin 
(loading control) after 72 hour treatment with non-targeting siRNA or siPTEN.  
B) Distribution of the mean fold-change in C. trachomatis IFU production in experimental siRNA 
knockdown cell lines relative to negative controls.  
C) A subset of stable shRNA knockdown cell lines was infected with C. trachomatis for 48 
hours. Levels of C. trachomatis were determined by qPCR of the 16s gene and compared to 
non-targeting controls (left) and IFU production (right). The graphs show the mean levels of C. 
trachomatis from two independent hairpins from triplicate samples +/- the standard. All 
experimental hairpins are p<.05 compared to control knockdown by one way ANOVA (n=3). 
D) Representative immunofluorescence micrographs from IFU analysis in (D) (Mag 10x) (n=3).     
E) Immunoblot analysis to confirm the knockdown of indicated proteins compared to control 
hairpins. Actin is used as a loading control. 
genes that inhibited C. trachomatis growth with at least two independent duplexes (Table S6-3).  
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These data illustrate that a subset of host proteins that were identified as stabilized following 
infection are required for normal Chlamydia growth, and suggests that these are host proteins or 
pathways that could be targets for host-based therapeutics.  
 We next wanted to independently confirm that the suppression of a subset of genes 
identified in our screen would alter C. trachomatis growth using an alternative knockdown 
method. We selected three genes, Pin1, Men1 and MAGEA11 that were stabilized in the GPS 
screen and created stable knockdown cell lines using two independent lentivirus-delivered 
shRNAs for each gene of interest or for control genes.  Positive transductants were selected 
with puromycin, and knockdown was confirmed using immunoblot (Figure 6-5E). We then 
examined the ability of C. trachomatis to grow and produce infectious progeny in each 
knockdown cell line. To differentiate between bacterial replication and infectivity we employed 
two distinct assays. We used qPCR to examine bacterial replication by quantifying the number 
of Chlamydia genomes present and we also determined the number of infectious progeny 
produced by titering lysates from infected cells.  This allowed us to query the entire Chlamydia 
life cycle, including re-differentiation into EBs from the same samples. When we examined the 
levels of C. trachomatis by qPCR, we found modest but reproducible 1.5-2-fold defects in 
replication in each knockdown (Figure 6-5C). However, these deficiencies were amplified when 
we examined the production of infectious progeny, with some knockdowns causing almost a 
ten-fold reduction in IFU (Figures 6-5C). We also examined the development of inclusions in 
knockdown cells by fluorescence microscopy. Thirty hours after infection there was no 
significant difference in the morphology of inclusions between control and experimental 
knockdown cells. When we quantified inclusion size, there was trend toward smaller inclusions 
yet no differences reached statistical significance. This suggests that the pathways interacting 
with these host proteins may be required for late bacterial replication and/or the re-differentiation 
of RBs to EBs. Together these data confirm that a subset of proteins that are stabilized during 
infection with C. trachomatis are also required for intracellular growth of the pathogen.  
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AP-1 dependent transcription is activated following infection with C. trachomatis 
The bioinformatics analysis of the GPS screen showed a strong enrichment in kinase 
signaling cascades and transcription factors. When we individually examined the role of the 13 
genes identified in the loss-of-function screen using natural language processing we also found 
several genes, including Pin1 and Men1 that directly influence the activation and amplitude of 
the host transcription factor AP-1 (40-43)(Figure 6-6A).  AP-1 is a heterodimeric transcription 
factor that regulates the expression of a large range of host genes related to inflammation, 
stress, and cell survival (44). The AP-1 complex is activated following infection with a wide 
range of bacterial pathogens but its role in C. trachomatis intracellular growth has not been 
described. We first wanted to examine whether AP-1 dependent transcription occurred following 
infection by C. trachomatis. By understanding the timing of AP-1 dependent transcription, we 
can begin to understand the requirements for upstream host signaling cascades that activate 
AP-1 and may be needed during C. trachomatis growth and development. To determine if AP-1 
driven transcription occurs during infection, we used a reporter cell line that expresses EGFP in 
an AP-1 dependent manner. We mock-treated these reporter cells, treated cells with PMA (a 
known activator of AP-1 driven transcription), or infected them with C. trachomatis. Thirty-six 
hours after PMA treatment or infection we analyzed cells by flow cytometry in order to determine 
the levels of EGFP. Relative to controls there was distinct upregulation of EGFP in cells treated 
with PMA that was even more pronounced in cells infected with C. trachomatis (Figure 6-6B). 
We quantified the mean fluorescence intensity (MFI) of each population, and found a greater 
than three-fold increase in the MFI of EGFP in cells infected with C. trachomatis compared to 
control cells (Figure 6-6C).  These data show that following infection with C. trachomatis, AP-1-
directed transcription is activated.  
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Figure 6-6. The transcription complex AP-1 is activated during C. trachomatis infection.  
A) Natural language processing of top hits from the loss-of-function screen point towards a role 
for AP-1 signaling. Chilibot analysis was used in a candidate gene approach to examine 
interactions of loss-of-function hits and host signaling pathways. Shown are interactions of 4 hits 
that all interact with c-Jun based on literature analysis. Green arrows mean all sources show 
positive regulation while yellow means there are differing reports. 
B) pAP-1 EGFP reporter cells were mock-infected, infected with C. trachomatis, or treated with 
PMA. Thirty hours later EGFP expression was determined by flow cytometry; A representative 
plot overlaying the three conditions is shown (n=3). 
C) Quantification of the mean-fluorescence intensity for each condition from (A) +/- the standard 
deviation (n=3). p<.05 compared to Mock by two-tailed students t-test (n=3). 
D) Immunoblot analysis of and phosphorylated (top) c-Fos and (Bottom) c-Jun in mock-infected 
HeLa cells or HeLa cells infected with C. trachomatis every five hours for 40 hours. Loading was 
normalized to Actin. Shown is representative blot from one of three independent experiments. 
E) Total c-Jun and c-Fos remain unchanged during infection with Chlamydia. HeLa cells were 
infected with Chlamydia or mock-infected. At the indicated timepoints cells were lysed and 
analyzed for total levels of c-Fos and c-Jun. All lysates were normalized using tubulin. Shown is 
a representative blot from three independent experiments. 
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One step required for AP-1 dependent transcription is the phosphorylation of AP-1 
components including the proteins c-Jun and c-Fos, which leads to direct transcriptional 
activation of target genes. We next wanted to examine the phosphorylation of both c-Jun and c-
Fos over time in cells infected with C. trachomatis. We mock-infected or infected HeLa cells with 
C. trachomatis and examined the levels of total and phosphorylated c-Jun and c-Fos by 
immunoblot every five hours throughout infection (Figure 6-6D). Cells infected with C. 
trachomatis showed minimal phosphorylation of c-Fos or c-Jun for the first 20 hours of infection. 
However, 20-25 hours after infection, there was a significant increase the phosphorylation of 
both c-Fos and c-Jun that increased in magnitude through the remainder of the timecourse 
(Figure 6-6D). When we examined the levels of total c-Jun and c-Fos we found minimal 
changes in the overall levels of both proteins (Figure 6-6E). These experiments validated our 
findings using the AP-1 reporter and showed that AP-1 is activated late in host cells infected 
with C. trachomatis.  
As mentioned above, our loss-of-function screen identified genes that altered C. 
trachomatis growth and also influence AP-1 signaling (Fig 6-6A). We were curious whether one 
potential mechanism for Chlamydia restriction in these knockdown cells might be alterations in 
the activation of AP-1. To test this, we mock infected or infected stable control knockdown cells 
or cells containing shRNA against Men1 or Pin1 with C. trachomatis for 40 hours. Cells were 
then lysed and probed for the activation of AP-1 components by immunoblot. Both shPin1 and 
shMen1 knockdown cells showed a significant decrease in the phosphorylation of c-Fos and c-
Jun (Fig 6-7A) compared to shGFP controls. These data show a direct link between the loss-of-
function data and the activation of the AP-1 signaling cascade and suggests one potential 
mechanism preventing efficient Chlamydia growth in these cells.   
If AP-1 dependent transcription is required for C. trachomatis growth, we hypothesized 
that upstream signaling components would also be activated during infection. We next wanted 
to examine what signaling pathways may be modulated by infection in order to activate the AP-1  






Figure 6-7. Loss of AP-1 activation alters C. trachomatis replication. 
A) Indicated shRNA knockdown cells were infected or mock-infected with Chlamydia for 40 
hours.  Cells were lysed and the levels of phosphorylated c-Fos and c-Jun were determined by 
immunoblot. Loading was normalized to host Actin. Shown is a representative blot from three. 
B) Immunoblot analysis of cells mock-infected or infected with C. trachomatis for 30 hours to 
determine the levels of total SAPK/JNK (bottom) and phosphorylated SAPK/JNK (top) (n=4).  
C) ELISA analysis to determine the levels of total SAPK/JNK (top) and phosphorylated 
SAPK/JNK (bottom) in cells left untreated, treated with PMA, or infected with C. trachomatis for 
the indicated times. Bars represent standard deviation from triplicate samples from one of two 
independent experiments. 
D) shJUN knockdowns were infected with C. trachomatis for 48 hours. Levels of C. trachomatis 
were determined by IFU production and compared to non-targeting control hairpins. The graphs 
show the mean IFU of C. trachomatis produced from triplicate samples +/- the standard 
deviation for each individual hairpin. All experimental hairpins have p<.05 compared to control 
knockdown by one way ANOVA (n=3). 
E) Immunoblot analysis to confirm the knockdown of JUN compared to control hairpins. Actin is 
used as a loading control. 
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complex. The MAPK pathways p38, ERK, and JNK, have previously been shown to mediate c- 
Jun phosphorylation and both p38 and ERK are activated throughout infection with C. 
trachomatis (45, 46). However, one previous study showed that inhibition of ERK and p38 leads 
to continued c-Jun phosphorylation (46). We hypothesized that the JNK pathway may also play 
a role in this process. Two previous studies examined JNK activation early following infection 
with C. trachomatis but did not observe activation. However these reports may have overlooked 
subtle activation of this cascade that occurs later during infection (45, 46). Therefore, we 
examined JNK activation throughout infection with C. trachomatis. We infected HeLa cells with 
C. trachomatis and then lysed the cells at various timepoints. These lysates were then used to 
perform a sandwich ELISA to detect total levels of SAPK/JNK as well as phosphorylated levels 
of SAPK/JNK. We found that following infection with Chlamydia there was a negligible change in 
the levels of total SAPK/JNK (Figure 6-7C). However, there was a general accumulation in the 
levels of phosphorylated SAPK/JNK that increased as infection progressed similar to what was 
observed with c-Fos and c-Jun (Figure 6-7C). We confirmed these findings by immunoblot and 
determined that infection with C. trachomatis leads to the phosphorylation of SAPK/JNK 
compared to mock-treated cells (Figure 6-7B). Taken together these data show that infection 
with C. trachomatis induces AP-1 dependent transcription late in the developmental cycle and 
may be influenced by the JNK signaling cascade. 
 Since AP-1 complex regulators and robust AP-1 activation were found to be required for 
normal Chlamydia growth, we next directly tested the necessity of AP-1 components for 
Chlamydia replication. We created shRNA knockdowns of c-Jun using two independent hairpins 
(Figure 6-6E) and compared the production of infective C. trachomatis progeny in these cells 
compared to control shRNA knockdowns (Figure 6-6D). Consistent with the knockdowns of AP-
1 regulating components depletion of c-Jun significantly reduced the production of IFU. These 
data confirm that AP-1 is activated late during infection and required for C. trachomatis to 
efficiently complete its developmental cycle. 
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AP-1 activation is required for C. trachomatis growth in vitro and in vivo 
One goal of the GPS screen was to identify host proteins or pathways that may be 
targetable by small molecules to inhibit bacterial growth. As shown above, the AP-1 complex is 
activated during infection with C. trachomatis and through loss-of-functions screens we 
identified that AP-1 activation is required for growth. We hypothesized that pharmacological 
inhibitors of this pathway might directly inhibit the growth and replication of C. trachomatis. To 
test this we used two distinct inhibitors to prevent AP-1 dependent transcription and determine 
their effects on C. trachomatis growth and development. We used a JNK inhibitor (SP600125) 
that blocks upstream activation of the AP-1 complex as well as Juglone a specific inhibitor of 
Pin1, which prevents prolonged amplification of AP-1 dependent transcription (47). Because we 
found that Pin1 is required for C. trachomatis replication by shRNA it suggested Pin1 as a target 
for inhibition (Figure 6-5). We infected HeLa cells with C. trachomatis for one hour then added 
media containing various concentrations of SP600125, Juglone or the vehicle in which they 
were prepared (DMSO or EtOH alone) and examined bacterial replication by determining the 
quantity of C. trachomatis genomes present in the samples using qPCR 24 and 48 hours 
following infection. The presence of either SP600125 or Juglone at concentrations of 1 uM or 
higher significantly decreased the levels of C. trachomatis by qPCR at 48 hours post-infection 
(Figure 6-9A) yet low concentrations of either inhibitor (100 nM) did not alter C. trachomatis 
growth compared to control treatments. When we examined inclusions in the presences of 
inhibitors using immunofluorescence microscopy, we noted a significant decrease in the size of 
inclusions (Figure 6-9B). These data suggest that inhibiting AP-1 activation can directly alter C. 
trachomatis growth.  
We next wanted to confirm that both SP600125 and Juglone inhibited the activation of 
AP-1 components during Chlamydia infection. We infected cells with C. trachomatis then treated 
them with vehicle alone, 1uM of SP600125, or 1uM of Juglone. We also included a washout 
condition for the reversible inhibitor SP600125 to determine if removal allowed recovery of AP-1  














































Figure 6-8. Characterization of chemical inhibitors on signaling pathways during C. 
trachomatis infection.  
A) HeLa cells were infected with C. trachomatis and treated with vehicle alone, SP600125, or 
Juglone 20 hours post-infection. Thirty hours after infection cells were lysed and applied to 
PathScan Intracellular signaling arrays in duplicate per condition. Arrays were read and  














Figure 6-8 (Continued) analyzed using the Odyssey infrared imaging system. The relative 
intensity of each spot was calculated using Odyssey software. Shown are the mean fluorescent 
intensities for each phosphorylated MAPK pathway for all inhibitor conditions +/- the standard 
deviation. 
B) SP600125 or Juglone inhibits the phosphorylation of c-Jun during infection with C. 
trachomatis. HeLa cells were infected with Chlamydia, and 10 hours post-infection cells were 
treated with the indicated inhibitor or vehicle control. For the washout cells were washed 20 
hours post-infection to remove the inhibitor. Cells were then lysed 35 hours post-infection and 
analyzed for total p-c-Jun in cells. Loading was normalized to tubulin. Shown is a representative 
immunoblot from one of three independent experiments.  
C) Combining both inhibitors at low concentrations increases growth inhibition. Cells were 
infected with Chlamydia and treated with the indicated vehicle alone or inhibitor 10 hours post-
infection. 40 hours post-infection cells were lysed and titered onto fresh HeLa cells. Shown is 
the mean IFU produced from each condition from one independent experiment of three (n=4). 
p<.05 for treatment with both inhibitors by one-way ANOVA.  
D) AP-1 transcription is needed for C. trachomatis growth. Cells were infected Cells were 
infected with Chlamydia and treated with the indicated vehicle alone or inhibitor 10 hours post-
infection. Only for Tanshione IIa were multiple concentrations used. 40 hours post-infection cells 
were lysed and titered onto fresh HeLa cells. 24 hours following re-infection cells were fixed and 
stained for C. trachomatis and the number of inclusions following each treatment was 
enumerated. (Left) Shown is the mean pg C. trachomatis 16s DNA per condition (n=4). No 
comparison is significant. (Right)Shown is the mean IFU produced from one independent 
experiment of three. All conditions p<.05 compared to DMSO control by one-way ANOVA.  
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activation. We examined the phosphorylation of c-Jun by immunoblot 40 hours post-infection for 
all conditions. In the presence of either SP600125 or Juglone, there was a significant decrease 
in the phosphorylation of c-Jun compared to the vehicle control, indicating the inhibitors directly 
alter AP-1 signaling. Importantly, removal of SP600125 20 hours post-infection led to the 
recovery of c-Jun phosphorylation (Figure 6-8B). In order to examine potential off target effects 
of these inhibitors we conducted phospho-array analysis of infected lysates in the presence and 
absence of vehicle alone or inhibitors. We determined that the presence of either 1uM 
SP600125 or juglone did not alter the phosphorylation state of other major signaling cascades 
including the MAPK pathways p38 or ERK (Figure 6-8A). While this does not eliminate the 
possibility of potential off target effects not included in the phosphoarray, it suggests the 
inhibition of c-Jun phosphorylation is partially dependent on JNK signaling. 
We next examined IFU production following treatment with these compounds and found 
that either inhibitor significantly decreased the production of infectious progeny at all 
concentrations tested (Figure 6-9C). This was surprising based on our data showing no growth 
defect as measured by qPCR when using 100 nM concentrations of either inhibitor, yet these 
data were consistent with those obtained using shRNA knockdowns where the defects in 
replication were also more pronounced when measured as IFU (Figure 6-5). We further 
inhibited infectious progeny production by combining both inhibitors even at low concentrations 
(Figure 6-8C). We next speculated that AP-1 should only be required late in C. trachomatis 
infection in line with our timecourse analysis of activation. In order to test this we first conducted 
a washout experiment where an inhibitor was removed at certain timepoints after infection. 
Because Juglone is a non-reversible inhibitor we chose to run these experiments only with the 
reversible JNK inhibitor. Cells were infected with C. trachomatis in the presence of 1 uM 
SP600125 or DMSO. Ten, 15 or 20 hours after infection the media was removed, cells were 
washed, and fresh media lacking the inhibitor was added. After allowing the infection to continue 
to 48 hours, the cells were lysed and the levels of C. trachomatis were determined by both  




































Figure 6-9. Inhibition of AP-1 signaling prevents C. trachomatis growth and the 
production of elementary bodies. 
A) HeLa cells were infected with C. trachomatis and then treated with the indicated 
concentration of JNK inhibitor (SP600125), Pin1 inhibitor (Juglone), or vehicle alone (DMSO or 
EtOH). The number of Chlamydia genomes was quantified using qPCR at 48 hours post-
infection (n=4).  














Figure 6-9 (Continued) B) Infected HeLa cells were treated with vehicle alone or indicated 
inhibitors and fixed 30 hours post-infection. Cells were stained for C. trachomatis major outer 
membrane protein (MOMP). (Top) Representative images of C. trachomatis inclusions treated 
with DMSO, EtOH, SP600125 or Juglone (1 uM each at Magnification 20x). (Bottom) 
Quantification of average inclusion diameter following inhibitor treatment. p<.001 by students t-
test (n=2). 
C) Production of IFU from cells infected with C. trachomatis then treated with the indicated 
inhibitors for 48 hours (n=4).  
D) HeLa cells were infected with C. trachomatis and then treated with SP600125. At the 
indicated times post-infection, the inhibitor was removed and replaced with fresh media. C. 
trachomatis levels were determined by qPCR (Left) and IFU analysis (Right) 48 hours post-
infection (n=3).  
E) HeLa cells were infected with C. trachomatis and at the indicated timepoints were treated 
with SP600125. 48 hours post infection cells were lysed and the levels of C. trachomatis were 
determined by qPCR (Left) and IFU analysis (Right) (n=3).  
F) HeLa cells were infected with C. trachomatis, and then at the indicated timepoints the cells 
were treated with Juglone. 48 hours post infection cells were lysed and the levels of C. 
trachomatis were determined by qPCR (Left) and IFU production (Right).  
In all experiments the graphs represent the mean level of C. trachomatis +/- the standard 
deviation (n=3). 
G) Mice were infected transcervically with 106 IFU of C. trachomatis. Twenty-four, 48 and 72 
hours post-infection mice were treated with indicated inhibitors or vehicle alone. Six days after 
infection the levels of C. trachomatis were determined using qPCR. Graphs show bacterial 
levels in individual mice and mean distribution for each treatment group p< 0.01 (n=2). 
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qPCR and determination of IFU (Figure 6-9D). When we removed the inhibitor as late as 15 
hours post-infection we found no effect on C. trachomatis growth or IFU production. However, if 
we removed the inhibitor 20 hours following infection, we saw a profound defect in Chlamydia 
levels and IFU production. These data suggest that AP-1 dependent transcription is not required 
early in C. trachomatis infection, yet it is required by 20 hours post-infection.  
As a complement to these experiments we next wanted to determine the effect of adding 
inhibitors at certain time points after infection. Cells were infected with C. trachomatis and 
SP600125, Juglone, or vehicle alone were added 10, 15 or 20 hours post-infection. Forty-eight 
hours after infection, the cells were lysed and we determined the levels of C. trachomatis by 
qPCR and by measuring IFU (Figure 6-9E and 6-9F). Similar to the washout experiment, 
addition of either SP600125 or Juglone to infected cells at 10 or 15 hours post-infection reduced 
C. trachomatis levels and IFU production. Interestingly, addition of either inhibitor 20 hours post-
infection had a negligible effect on the growth of C. trachomatis by qPCR yet caused a 
significant decrease in the production of IFU, similar to the defect seen following inhibitor 
addition at earlier timepoints. These data show that AP-1 signaling is required for efficient C. 
trachomatis growth in vitro. 
It remained possible that the activation of AP-1 components, but not AP-1 mediated 
transcription, was all that was required for Chlamydia growth. To examine whether AP-1 
mediated transcription was also required for intracellular survival we employed a third inhibitor, 
Tanshinone IIa, which allows AP-1 phosphorylation but prevents DNA binding and subsequent 
transcriptional activity (48). Cells were infected with C. trachomatis for 20 hours then treated 
with various concentrations of Tanshione IIa to limit the time of inhibitor treatment. Cells were 
then lysed at 48 hours post-infection and bacterial levels and the production of infectious 
progeny were determined by qPCR and IFU analysis respectively. We saw minimal defects in 
bacterial growth by qPCR but observed a significant inhibition in the production of infectious 
progeny in a dose-dependent manner (Figure 6-8D). These data show that preventing AP-1 
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mediated transcription directly inhibits the ability of Chlamydia to complete the developmental 
cycle.  
We next wanted to determine whether activation of this pathway would also be required 
for C. trachomatis growth in vivo. We have recently described a murine model of C. trachomatis 
infection that allows the use of human Chlamydia strains in mice, and recapitulates many 
aspects of human disease in the upper genital tract (49). Using this model we infected mice 
transcervically with C. trachomatis and 24, 48 and 72 hours post-infection mice were treated 
with vehicle alone, SP600125, or Juglone by both IP injection and transcervical application. Six 
days post-infection, mice were sacrificed, the upper genital tract was isolated, and the burden of 
C. trachomatis in the tissue was determined using qPCR. Treatment of mice with either 
SP600125 or Juglone led to a 10-100 fold decrease in the levels of C. trachomatis in the upper 
genital mucosa compared to vehicle alone (Figure 6-9G). This suggests that C. trachomatis 
requires AP-1 dependent signaling in order to survive in the murine upper genital mucosa. 
Together these results show that C. trachomatis manipulates host signaling cascades that are 
required for bacterial growth both in vitro and in vivo.  
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Discussion 
During infection with intracellular pathogens, the host proteome is broadly remodeled 
(12). However, changes in host protein stability during bacterial infection have not previously 
been evaluated globally. Most studies focusing on host alterations following C. trachomatis 
infection have examined only transcriptional changes (50). Here we employed systematic 
methodology to globally identify host proteins that were altered in stability following infection 
with C. trachomatis, characterized which of these host proteins were necessary for growth, and 
identified host pathways that are necessary for normal infection to occur.  
In this report we applied GPS, a system designed to identify substrates of human 
ubiquitin ligases, to evaluate how infection with a bacterial pathogen directly alters host protein 
stability. Investigators studying various aspects of mammalian cell biology commonly use 
ORFeome-based screens to understand how global dynamics change following specific 
perturbations (30). Our study takes advantage of the human ORFeome as a resource to 
understand bacterial pathogenesis by evaluating over 12,000 proteins simulatenously. Using the 
GPS platform we uncovered a dramatic shift in the host proteome that occurs during C. 
trachomatis infection. The GPS platform is also lysis independent and is not subject to potential 
post-lysis effects of the Chlamydia protease CPAF that have recently been described (51). By 
coupling the global coverage of ORFeome screens with a systematic validation scheme we 
identified a large number of host proteins that are altered in stability following C. trachomatis 
independently of changes in host transcription and may be required for bacterial growth.  
The proteins we identified are involved in a wide-range of host cell functions, revealing 
new insights into how C. trachomatis alters the host in order to successfully replicate. The 
GPS platform identified host proteins such as Mcl1 that were previously shown to be stabilized 
during C. trachomatis infection and uncovered host cell processes, such as histone 
modifications and the Golgi functions that are known to be altered during infection with 
Chlamydia (34, 36-38, 52). This shows that GPS is well suited to identify C. trachomatis-
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mediated alterations to host proteins that occur independently of host transcription. We further 
used bioinformatics analysis along with focused GPS experiments to uncover entire protein 
families such as Dusps and Nups that were altered in concert during infection. Among 
proteins that are stabilized during infection we identified a strong enrichment in host 
transcription pathways, nuclear components, and vesicular trafficking (Table S6-2). We also 
found that mitochondrial and ubiquitin related proteins were enriched among destabilized 
proteins. While it remains unclear whether these host cell processes are directly or indirectly 
altered during infection, it suggests Chlamydia infection broadly disrupts host cell functions. 
Future studies will be required to uncover the mechanisms underlying individual protein 
changes as well as identify specific Chlamydia virulence determinants that target particular 
host cell functions. For example, while Golgi fragmentation occurs following infection and is 
necessary for normal C. trachomatis growth, we still do not understand bacterial proteins 
driving this cellular change (36, 51). Several strong hits in the GPS screen were golgi proteins 
including Golga2 and Golga4.  This highlights the functionality of the GPS system as a 
possible screening platform to identify (through gain-of-function approaches) C. trachomatis 
effector/s that are responsible for golgi fragmentation.  Future work will be focused on 
applying these technologies to better understand the host targets of individual virulence 
determinants that Chlamydia secretes into host cells in order to infect cells and promote 
intracellular growth. 
In order to elucidate potential host pathways that may regulate C. trachomatis infection 
we combined bioinformatics analysis and a loss-of-function screen to suppress individual host 
proteins identified through GPS. We identified a subset of host proteins that are required for C. 
trachomatis growth (Figure 6-5). In exploring intracellular survival of Chlamydia, our 
bioinformatics analysis of the GPS screen and natural language processing analysis of the loss-
of-function screen pointed towards a critical role of MAPK signaling and specific host 
transcription factors including AP-1. Therefore we focused our attention on AP-1 activation and 
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function throughout Chlamydia infection. When we inhibited AP-1 activation using a JNK 
inhibitor (SP600125) or a Pin1 inhibitor (Juglone) throughout infection, we saw a dramatic 
decrease in C. trachomatis growth. Using add-in and washout experiments we further showed 
that AP-1 activity is required later than 20 hours after infection in order for normal IFU 
production to occur. One of the most intriguing findings was that addition of either inhibitor later 
during infection had dramatic effects on IFU production. This suggests that AP-1 activity may be 
required for RB replication and/or re-differentiation into the EB form. One might imagine that the 
intracellular growth of C. trachomatis might trigger host stress responses, and that C. 
trachomatis may have mechanisms that sense these host stress pathways to initiate 
differentiation and exit from the failing host cell. 
The AP-1 complex is a critical transcription factor that regulates the expression of a large 
range of host genes in response to diverse stimuli (44). The AP-1 complex is targeted by 
several bacterial pathogens to alter cellular survival or prevent inflammation and cytokine 
production, with some pathogens preventing activation and some inducing activation of host 
signaling cascades (53). However, it has not previously been shown to play a role during C. 
trachomatis infection (54). Previous studies have shown both ERK and p38 MAPK activation is 
required for a normal pro-inflammatory cytokine response during Chlamydia infection (54, 55). 
We confirmed that AP-1 activation occurs during infection with C. trachomatis and found a role 
for the JNK signaling cascade in this process. Even though previous reports have not observed 
JNK activation during C. trachomatis infection, these studies only examined early timepoints 
and were focused on IL-8 signaling, not bacterial growth (54). Our results show that JNK is 
activated late in infection, albeit less robustly than ERK (data not shown). This may explain why 
the JNK signaling cascade has been overlooked as playing a role in C. trachomatis 
pathogenesis. Interestingly, a recent report using C. pneumoniae suggested that AP-1 activation 
is responsible for inflammation seen in vivo (56). While the effect of AP-1 on inflammation 
during infection in vivo remains to be confirmed for C. trachomatis, these data together suggest 
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that finely tuned AP-1 signaling is required for robust intracellular growth. Our current model 
speculates that too much AP-1 activation and the inflammation may overwhelm bacterial growth 
while too little signaling prevents the production of infectious progeny. We hypothesize that AP-
1 activity influences Chlamydia growth through either the induction of specific gene product/s 
that are required by Chlamydia, or by altering the overall cellular state which in turn triggers final 
Chlamydia replication and re-differentiation. Future studies are required to elucidate the 
mechanisms underlying Chlamydia dependence on AP-1 as well as to better understand the 
balance between AP-1 dependent bacterial survival and inflammation in vivo.  
  Overall, the methods described here are widely applicable to a variety of pathogens 
and can also be adapted to examine less dramatic perturbations to host cells. For example, 
comparing changes in host proteins altered only in the presence of specific secretion systems, 
such as a type III secretion system, should enrich for host protein changes altered directly by 
the secreted effectors of the system. GPS screens can also be used to examine changes to the 
host proteome resulting from the expression of a single virulence determinant. This may allow 
the identification of substrates notoriously difficult to identify such as E3 ubiquitin ligases or 
deubiquitinating enzymes (12, 16, 57, 58). Examining how pathogens (or commensals) directly 
alter the host proteome is essential to understanding basic mechanisms of bacterial-host cell 
interactions. It also may drive the development of novel therapeutics that target host functions 
required for growth of pathogens, resulting in antimicrobials that will have less impact on natural 
flora and where drug resistance would not develop. 
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Materials and Methods 
Tissue Culture, Reagents, and General Procedures HeLa, and 293T cells were maintained in 
Dulbecco’s Minimum Essential Media supplemented with Penicillin/Streptomycin and 10% fetal 
bovine serum (Invitrogen). 293T and HeLa cells were transfected using the TransIT transfection 
reagent (Mirus). Lentiviruses were packaged in 293T cells transfected with the plasmid of 
interest as well as plasmids expressing VSVg and Gag-Pol-Rev (Luo et al., 2009). Viral 
infections were supplemented with hexadimethrine bromide at a concentration of 8 µg/ml. 
Transfection of siRNA oligonucleotides was performed with Dharmafect (Dharmacon) lipid 
transfection reagent according to the manufacturer's protocols. siRNA were purchased from 
Dharmacon as smart pools. A complete list of immunological reagents used in this study is 
below. Flow cytometry was performed on a BD-LSRII Flow Cytometer (Becton Dickinson). Data 
were collected using BD FACS Diva software (Becton Dickinson) and analysis was performed 
using FloJo software.  
Validation was performed by individually picking ORFeome clones and cloning them 
using gateway recombination into the GPS vector. All inserts were sequenced using the 
primer: 5’-AGCTGTACAAGTCCGAACTCGT-3’. The vectors were used to package virus and 
used to generate cell lines expressing individual GPS-ORFs. For immunoblot validation of 
endogenous proteins after Chlamydia infection, cells were lysed at the indicated time points.  
EBs of C. trachomatis serovar L2 434/Bu were propagated within McCoy cell 
monolayers.  A combination of glass bead disruption and sonication was used to release 
EBs from infected McCoy cells.  EBs were further purified by ultracentrifugation over 
Renograffin gradients, as previously described (15). Aliquots of C. trachomatis EBs were 
stored at -80° C in SPG buffer (250 mM sucrose, 10 mM sodium phosphate, and 5 mM L-
glutamic acid, pH 7.2). Prior to infection with C. trachomatis, cells were cultured for 12-24 h 
in their respective media minus antibiotics.  Cells were infected with C. trachomatis by 
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adding media containing dilute EBs to host cells. Centrifugation was not used unless 
specified in the text. The multiplicity of infection (MOI) used for C. trachomatis was 3:1 
unless indicated.  DMEM alone was used for mock-infected cells. 
Immunoblot analysis. For immunoblot analysis, cells were lysed at indicated timepoints 
following infection in Urea lysis buffer unless otherwise indicated (8M Urea, 150 mM NaCl, 0.1% 
NP-40) in the presence of a complete protease inhibitor cocktail (Roche Applied Science, 
Indianapolis, IN) and phosphatase inhibitor (Cell Signaling).  Lysates were normalized for total 
protein content by measuring absorption at 280 nm or using a BCA test (Pierce).  Normalized 
samples were subjected to SDS-PAGE analysis (BD and Lonza), transferred to nitrocellulose or 
PVDF (Licor), and immunoblotted with the following antibodies:  
Actin (Licor), BNIP3L (AbCam), Ciao1 (AbCam), Dusp16 (AbCam), JNK (Cell signaling), p-
JNK (Cell signaling), Jun (Cell signaling), p-JUN (Cell Signaling) Men1 (AbCam),  Ncap-G 
(Santa Cruz), Pin1 (Cell Signaling), PTEN (AbCam), SNCG (AbCam), Stk24 (AbCam), Tubulin 
(Licor), USH1C (AbCam) 
Automated image analysis.  Infected cells were fixed and permeabilized with MeOH and 
stained for Chlamydia MOMP (FITC-MOMP, BioRad) for 1 hour.  Stained cells were imaged 
with a Cellomics ArrayScan VTI automated microscope.  Six fields per well of a 96-well plate 
were imaged at 20x magnification.  First, cells were identified by their nuclei staining in channel 
1 of Cellomics.  Cells that scored positive in channel 1 were analyzed for Alexa-488 (inclusions) 
in channel 2.  A minimum average intensity in the Alexa-488 channel was calculated by manual 
inspection and applied to each selected object.  The selected objects that were above this 
threshold were shown in blue while those that were below are shown in orange.  Once the 
threshold was determined, all of the plates were subjected to data analysis using vHCS Scan 
Target Activation software v5.1.2.  Data were obtained by using vHCS View software and the 
number of inclusions in the well was identified as “valid object count” (VOC). 
	   191 
Immunofluorescence analysis. Cells were seeded on coverslips in 24 well dishes. The next 
day cells were infected with C. trachomatis at an MOI of 3. 24 hours following infection cells 
were fixed using paraformaldehyde and permeablized using .1% tween in PBS. We then stained 
cells with anti-Chlamydia antibody linked to FITC and DAPI. Cells were analyzed at 20x using a 
NIKON Eclipse 200. At least 10-20 images were captured per coverslip. We then analyzed the 
average diameter of inclusions using imageJ analysis.  
Quantitative PCR. To assess the levels of C. trachomatis present, we used a previously 
described qPCR method (59). Briefly, we isolated nucleic acid from infected cells using the 
DNeasy kit (Qiagen). Chlamydia 16S DNA was quantified by qPCR on an ABI Prism 7000 
sequence detection system using primer pairs and dual-labeled probes. Using standard curves 
from known amounts of Chlamydia the levels of 16s DNA per well was calculated. For in vivo 
experiments the upper genital tract was isolated and DNA was isolated and the levels of C. 
trachomatis were determined relative to levels of host DNA as described previously (49). 
AP-1 complex activation. For examination of AP-1 dependent transcription an AP-1 driven 
EGFP reporter cell line was created using pre-made Lentivirus (SAbioscience). After puromycin 
selection cells were infected or treated PMA and examined by flow cytometry using a FACs 
Calibur (BD). Plots were analyzed using FlowJo software.  
JNK and p-JNK Activation. Cell lysates from cells infected for the indicated times were used 
as samples in a sandwich ELISA to detect levels of total JNK and p-JNK following infection (Cell 
Signaling). The manufacturer instructions were followed. Samples were tested for their 
absorbance 450 nm.  
Chemical Inhibitors. The JNK inhibitor (SP600125) and Pin1 inhibitor (Juglone) were 
purchased from EMD Millipore for pathway analysis and used at the indicated concentrations. 
Tanshione IIa was purchased from (Santa Cruz). For in vitro experiments Juglone was 
resuspended in EtOH, for in vivo experiments Juglone was resuspended in DMSO. SP600125 
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and tanshione IIa were dissolved in DMSO for all experiments. Vehicle controls contain the 
appropriate solvent for each experiment.  
Phospho-Array. Cells infected with C. trachomatis for 20 hours were treated with vehicle alone, 
SP600125, or Juglone for 10 hours. Cells were processed and the arrays were conducted by 
following manufacturers directions for the Pathscan Intracellular Signaling Array Kit (Cell 
Signaling). Arrays were scanned and quantified using an Odyssey Infrared Imaging system and 
software (LiCor). 
siRNA Screen. siRNA smart pools were cherry picked into 96 well plates from the complete 
Dharmacon siRNA genome set at the Harvard Institute of Chemistry and Cell Biology (ICCB).  
The outer wells of each plates were excluded. Each plate contained 6 non-targeting controls 
and 6 positive controls used to optimize the assay. HeLa cells were seeded at a density of 
2.5x103 into 96-well plates. Each siRNA was transfected in triplicate for 72 hours. Cell viability 
was examined at 72 hours and scored on 0-5 scale (0=all cells dead 5=no obvious cell death). 
Cells that scored 2 or less were not analyzed further. Cells were then infected with 104 IFU of C. 
trachomatis for 48 hours. Cells were then lysed and dilute 1:1000 and re-seeded into 96 well 
plates containing 104 normal HeLa cells. Twenty-four hours following infection, cells were fixed 
with ice-cold MeOH for 30 minutes. Cells were washed two times with PBS containing 0.1% 
tween. Cells were then stained using DAPI and an antibody to C. trachomatis MOMP. Cells 
were quantified by automated microscopy as described above. The mean number of IFU 
produced by non-targeting controls for each plate was calculated. A fold-change in C. 
trachomatis growth was calculated against non-targeting mean for each plate. A mean fold-
change was then calculated for all triplicate samples. Cells that inhibited growth more than 2-
fold were picked for a deconvolution screen. Individual shRNA(2 per gene) were then purchased 
from the TRC library.  Lentiviral particles were packaged transduced and selected as above. 
The identical infection protocol was used as described above.  
GPS Screen. The GPS screen was conducted essentially as described (Yen et al., 2008). Cells 
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were mock-infected or infected with C. trachomatis for 24 hours. Infection was confirmed 
visually by the presence of inclusions in almost all cells. The general workflow of the GPS 
screen is as follows. 293T cell libraries were sorted into either 7 bins, based on their 
EGFP/DsRed ratio. Approximately equal numbers of cells were sorted into each bin, with the 
outermost bins receiving slightly fewer cells than those in the middle. We sorted a minimum of 
1.2 million cells per bin. Sorting was carried out at the Immune Diseases Institute at Harvard 
Medical School with the assistance of Natasha Barteneva. Following sorting, cells were pelleted 
and frozen at −80°C. Pellets were subsequently thawed and lysed in 10 mM Tris pH 8.0, 10 mM 
EDTA, 0.5% SDS, and 0.2 mg/ml Proteinase K at 55°C overnight with agitation. Genomic DNA 
(gDNA) was extracted using Phaselock tubes with phenol:chloroform and then chloroform. 
RNase A was added to a final concentration of 25 µg/ml and following incubation overnight at 
37°C, gDNA was extracted using Phaselock tubes, as above. DNA was ethanol precipitated 
(with glycogen), recovered by centrifugation, and washed three times with 75% ethanol. The 
dried, resuspended pellet was PCR amplified with Takara hot start polymerase (Takara 
RR006B) using common PCR primers as described (Yen and Elledge, 2008). PCR amplified 
DNA was transcribed with T7 using Ambion MEGAscript and purified with Qiagen RNeasy kits. 
RNA was labeled with a ULS labeling kit (Kreatech: unsorted samples-Cy5, sorted samples-
Cy3). Hybridization was performed on custom Agilent DNA microarrays printed as 4 x 44k 
arrays according to manufacturer's protocols. The probe sequences used are listed in the 
supplemental table. Microarrays were read using an Agilent scanner. The GPS screen was 
performed using version 3.1 of the ORFeome collection. PSI was calculated as described (Yen 
et al., 2008). Percent shift was calculated by summing absolute values of the subtracted relative 
abundance from probes across all bins.  
GPS Data Analysis. Probes were first filtered by removing probes with signals below five-time 
the average background signal. Probes with signals less than zero were reset to zero. 
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Microarrays from each bin were normalized within each screen based on their spike-in control 
signals. After filtering low signal probes and normalizing, we examined the EGFP signals for all 
probes within a single bin between treated and untreated conditions for every bin to confirm 
probe and hybridization reliability. We next calculated the PSI for each probe and compared 
those between treated and untreated conditions. These numbers are reported in the 
supplementary table. The average PSI of all probes, for each condition, was determined and 
normalization was performed as necessary. A ΔPSI was calculated by subtracting the PSI 
numbers of the uninfected from those of the infected. We rank ordered probes based on ΔPSI 
and used a custom macro in Microsoft Excel to graph the distribution for every probe across 
bins, comparing infected and uninfected conditions on each graph, for every probe that passed 
our low signal cut-off (Table S6-1). We have included a blank excel file with the coding for this 
macro as supplementary table S6-4. Visual inspection of the graphs was essential for high 
validation rates and to easily discriminate against hits that are influenced by noise seen in 
microarray studies. Graphs were ranked based on the ΔPSI and were visually inspected one at 
a time to determine if there was a significant probe shift. We have listed those ORFs that had a 
sufficient ΔPSI and passed visual inspection. We often found that a high ΔPSI could be 
attributed to erroneous noise in outside bins, making visual inspection essential. Genes that 
showed a significant shift from multiple probes (when available) were designated for further 
study and are listed in Table S6-1 worksheet 2.  
Bioinformatic Analysis. We used DAVID bioinformatics resources to identify enriched 
annotation clusters within the GPS dataset as done previously (33). We uploaded our stabilized 
and destabilized protein lists independently into DAVID and used the human proteome as the 
background list. We used cluster analysis to identify redundant enriched terms for each group 
through several categories including KEGG pathway and Gene Ontology terms. We listed the 
top enriched clusters including enrichment scores and genes identified in Table S6-2.   
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 We also used natural language processing analysis in a candidate gene approach to 
identify connections in the published literature among genes found in the loss-of-function screen 
as done by others previously (43). We used Chilibot freeware and searched for interactions 
between c-Jun and loss-of-function hits and create a graphic representation of these 
interactions (60).  
Mice and in vivo inhibitor treatment  
C57BL/6 were purchased from The Jackson Laboratory and were maintained and cared for 
within the Harvard Medical School Center for Animal Resources and Comparative Medicine 
(Boston, MA). All mice were treated with 2.5mg of medroxyprogesterone subcutaneously seven 
days prior to infection in order to normalize the murine estrous cycle. Mice were infected 
transcervically with 106 IFU of C. trachomatis. For inhibitor treatments mice were injected IP and 
transcervically with vehicle alone, 10 mg/kg of SP600125 per injection route (61), and 1 mg/kg 
of Juglone per injection route (62) similar to previous studies. All experiments were approved by 
Institutional Animal Care and Use Committee. In all experiments ten mice per group were used.  
  
	   196 
References  
1. Ashida H, Ogawa M, Kim M, Mimuro H, Sasakawa C. Bacteria and host interactions in 
the gut epithelial barrier. Nature chemical biology. 2012;8(1):36-45. Epub 2011/12/17. doi: 
10.1038/nchembio.741. PubMed PMID: 22173358. 
 
2. Ham H, Sreelatha A, Orth K. Manipulation of host membranes by bacterial effectors. 
Nature reviews Microbiology. 2011;9(9):635-46. Epub 2011/07/19. doi: 10.1038/nrmicro2602. 
PubMed PMID: 21765451. 
 
3. Rohmer L, Hocquet D, Miller SI. Are pathogenic bacteria just looking for food? 
Metabolism and microbial pathogenesis. Trends in microbiology. 2011;19(7):341-8. Epub 
2011/05/24. doi: 10.1016/j.tim.2011.04.003. PubMed PMID: 21600774; PubMed Central 
PMCID: PMC3130110. 
 
4. Ge J, Shao F. Manipulation of host vesicular trafficking and innate immune defence by 
Legionella Dot/Icm effectors. Cellular microbiology. 2011;13(12):1870-80. Epub 2011/10/11. doi: 
10.1111/j.1462-5822.2011.01710.x. PubMed PMID: 21981078. 
 
5. Cornelis GR. The type III secretion injectisome, a complex nanomachine for intracellular 
'toxin' delivery. Biological chemistry. 2010;391(7):745-51. Epub 2010/05/21. doi: 
10.1515/BC.2010.079. PubMed PMID: 20482311. 
 
6. Bingle LE, Bailey CM, Pallen MJ. Type VI secretion: a beginner's guide. Current opinion 
in microbiology. 2008;11(1):3-8. Epub 2008/02/22. doi: 10.1016/j.mib.2008.01.006. PubMed 
PMID: 18289922. 
 
7. Barry AO, Mege JL, Ghigo E. Hijacked phagosomes and leukocyte activation: an 
intimate relationship. Journal of leukocyte biology. 2011;89(3):373-82. Epub 2010/08/20. doi: 
10.1189/jlb.0510270. PubMed PMID: 20720162. 
 
8. Cossart P, Roy CR. Manipulation of host membrane machinery by bacterial pathogens. 
Current opinion in cell biology. 2010;22(4):547-54. Epub 2010/06/15. doi: 
10.1016/j.ceb.2010.05.006. PubMed PMID: 20542678; PubMed Central PMCID: PMC2975266. 
 
9. McDermott JE, Corrigan A, Peterson E, Oehmen C, Niemann G, Cambronne ED, et al. 
Computational prediction of type III and IV secreted effectors in gram-negative bacteria. 
Infection and immunity. 2011;79(1):23-32. Epub 2010/10/27. doi: 10.1128/IAI.00537-10. 
PubMed PMID: 20974833; PubMed Central PMCID: PMC3019878. 
 
10. Galan JE. Common themes in the design and function of bacterial effectors. Cell host & 
microbe. 2009;5(6):571-9. Epub 2009/06/17. doi: 10.1016/j.chom.2009.04.008. PubMed PMID: 
19527884; PubMed Central PMCID: PMC2729653. 
 
11. O'Connor TJ, Adepoju Y, Boyd D, Isberg RR. Minimization of the Legionella 
pneumophila genome reveals chromosomal regions involved in host range expansion. 
Proceedings of the National Academy of Sciences of the United States of America. 
2011;108(36):14733-40. Epub 2011/08/30. doi: 10.1073/pnas.1111678108. PubMed PMID: 
21873199; PubMed Central PMCID: PMC3169125. 
	   197 
12. Ribet D, Cossart P. Pathogen-mediated posttranslational modifications: A re-emerging 
field. Cell. 2010;143(5):694-702. Epub 2010/11/30. doi: 10.1016/j.cell.2010.11.019. PubMed 
PMID: 21111231. 
 
13. Burrack LS, Higgins DE. Genomic approaches to understanding bacterial virulence. 
Current opinion in microbiology. 2007;10(1):4-9. Epub 2006/12/13. doi: 
10.1016/j.mib.2006.11.004. PubMed PMID: 17161645. 
 
14. Arbibe L, Kim DW, Batsche E, Pedron T, Mateescu B, Muchardt C, et al. An injected 
bacterial effector targets chromatin access for transcription factor NF-kappaB to alter 
transcription of host genes involved in immune responses. Nature immunology. 2007;8(1):47-
56. Epub 2006/12/13. doi: 10.1038/ni1423. PubMed PMID: 17159983. 
 
15. Mukherjee S, Keitany G, Li Y, Wang Y, Ball HL, Goldsmith EJ, et al. Yersinia YopJ 
acetylates and inhibits kinase activation by blocking phosphorylation. Science. 
2006;312(5777):1211-4. Epub 2006/05/27. doi: 10.1126/science.1126867. PubMed PMID: 
16728640. 
 
16. Misaghi S, Balsara ZR, Catic A, Spooner E, Ploegh HL, Starnbach MN. Chlamydia 
trachomatis-derived deubiquitinating enzymes in mammalian cells during infection. Molecular 
microbiology. 2006;61(1):142-50. Epub 2006/07/11. doi: 10.1111/j.1365-2958.2006.05199.x. 
PubMed PMID: 16824101. 
 
17. Ensminger AW, Isberg RR. E3 ubiquitin ligase activity and targeting of BAT3 by multiple 
Legionella pneumophila translocated substrates. Infection and immunity. 2010;78(9):3905-19. 
Epub 2010/06/16. doi: 10.1128/IAI.00344-10. PubMed PMID: 20547746; PubMed Central 
PMCID: PMC2937443. 
 
18. Savijoki K, Alvesalo J, Vuorela P, Leinonen M, Kalkkinen N. Proteomic analysis of 
Chlamydia pneumoniae-infected HL cells reveals extensive degradation of cytoskeletal proteins. 
FEMS immunology and medical microbiology. 2008;54(3):375-84. Epub 2008/12/04. doi: 
10.1111/j.1574-695X.2008.00488.x. PubMed PMID: 19049650. 
 
19. Vogels MW, van Balkom BW, Heck AJ, de Haan CA, Rottier PJ, Batenburg JJ, et al. 
Quantitative proteomic identification of host factors involved in the Salmonella typhimurium 
infection cycle. Proteomics. 2011;11(23):4477-91. Epub 2011/09/16. doi: 
10.1002/pmic.201100224. PubMed PMID: 21919203. 
 
20. Shi L, Adkins JN, Coleman JR, Schepmoes AA, Dohnkova A, Mottaz HM, et al. 
Proteomic analysis of Salmonella enterica serovar typhimurium isolated from RAW 264.7 
macrophages: identification of a novel protein that contributes to the replication of serovar 
typhimurium inside macrophages. The Journal of biological chemistry. 2006;281(39):29131-40. 
Epub 2006/08/09. doi: 10.1074/jbc.M604640200. PubMed PMID: 16893888. 
 
21. Shi L, Chowdhury SM, Smallwood HS, Yoon H, Mottaz-Brewer HM, Norbeck AD, et al. 
Proteomic investigation of the time course responses of RAW 264.7 macrophages to infection 
with Salmonella enterica. Infection and immunity. 2009;77(8):3227-33. Epub 2009/06/17. doi: 
10.1128/IAI.00063-09. PubMed PMID: 19528222; PubMed Central PMCID: PMC2715674. 
 
22. Holmes KK. Sexually transmitted diseases. 4th ed. New York: McGraw-Hill Medical; 
2008. xxv, 2166 p. p. 
	   198 
23. Moulder JW. Interaction of chlamydiae and host cells in vitro. Microbiological reviews. 
1991;55(1):143-90. Epub 1991/03/01. PubMed PMID: 2030670; PubMed Central PMCID: 
PMC372804. 
 
24. Subtil A, Delevoye C, Balana ME, Tastevin L, Perrinet S, Dautry-Varsat A. A directed 
screen for chlamydial proteins secreted by a type III mechanism identifies a translocated protein 
and numerous other new candidates. Molecular microbiology. 2005;56(6):1636-47. Epub 
2005/05/27. doi: 10.1111/j.1365-2958.2005.04647.x. PubMed PMID: 15916612. 
 
25. Ho TD, Starnbach MN. The Salmonella enterica serovar typhimurium-encoded type III 
secretion systems can translocate Chlamydia trachomatis proteins into the cytosol of host cells. 
Infection and immunity. 2005;73(2):905-11. Epub 2005/01/25. doi: 10.1128/IAI.73.2.905-
911.2005. PubMed PMID: 15664932; PubMed Central PMCID: PMC547017. 
 
26. Fields KA, Hackstadt T. Evidence for the secretion of Chlamydia trachomatis CopN by a 
type III secretion mechanism. Molecular microbiology. 2000;38(5):1048-60. Epub 2000/12/21. 
PubMed PMID: 11123678. 
 
27. Chellas-Gery B, Linton CN, Fields KA. Human GCIP interacts with CT847, a novel 
Chlamydia trachomatis type III secretion substrate, and is degraded in a tissue-culture infection 
model. Cellular microbiology. 2007;9(10):2417-30. Epub 2007/05/30. doi: 10.1111/j.1462-
5822.2007.00970.x. PubMed PMID: 17532760. 
 
28. Zhong G. Chlamydia trachomatis secretion of proteases for manipulating host signaling 
pathways. Frontiers in microbiology. 2011;2:14. Epub 2011/06/21. doi: 
10.3389/fmicb.2011.00014. PubMed PMID: 21687409; PubMed Central PMCID: PMC3109274. 
 
29. Yen HC, Xu Q, Chou DM, Zhao Z, Elledge SJ. Global protein stability profiling in 
mammalian cells. Science. 2008;322(5903):918-23. Epub 2008/11/08. doi: 
10.1126/science.1160489. PubMed PMID: 18988847. 
 
30. Emanuele MJ, Elia AE, Xu Q, Thoma CR, Izhar L, Leng Y, et al. Global identification of 
modular cullin-RING ligase substrates. Cell. 2011;147(2):459-74. Epub 2011/10/04. doi: 
10.1016/j.cell.2011.09.019. PubMed PMID: 21963094; PubMed Central PMCID: PMC3226719. 
 
31. Yen HC, Elledge SJ. Identification of SCF ubiquitin ligase substrates by global protein 
stability profiling. Science. 2008;322(5903):923-9. Epub 2008/11/08. doi: 
10.1126/science.1160462. PubMed PMID: 18988848. 
 
32. Xia M, Bumgarner RE, Lampe MF, Stamm WE. Chlamydia trachomatis infection alters 
host cell transcription in diverse cellular pathways. The Journal of infectious diseases. 
2003;187(3):424-34. Epub 2003/01/29. doi: 10.1086/367962. PubMed PMID: 12552426. 
 
33. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large 
gene lists using DAVID bioinformatics resources. Nature protocols. 2009;4(1):44-57. Epub 
2009/01/10. doi: 10.1038/nprot.2008.211. PubMed PMID: 19131956. 
 
34. Balsara ZR, Misaghi S, Lafave JN, Starnbach MN. Chlamydia trachomatis infection 
induces cleavage of the mitotic cyclin B1. Infection and immunity. 2006;74(10):5602-8. Epub 
2006/09/22. doi: 10.1128/IAI.00266-06. PubMed PMID: 16988235; PubMed Central PMCID: 
PMC1594933. 
	   199 
35. Rejman Lipinski A, Heymann J, Meissner C, Karlas A, Brinkmann V, Meyer TF, et al. 
Rab6 and Rab11 regulate Chlamydia trachomatis development and golgin-84-dependent Golgi 
fragmentation. PLoS pathogens. 2009;5(10):e1000615. Epub 2009/10/10. doi: 
10.1371/journal.ppat.1000615. PubMed PMID: 19816566; PubMed Central PMCID: 
PMC2752117. 
 
36. Heuer D, Rejman Lipinski A, Machuy N, Karlas A, Wehrens A, Siedler F, et al. 
Chlamydia causes fragmentation of the Golgi compartment to ensure reproduction. Nature. 
2009;457(7230):731-5. Epub 2008/12/09. doi: 10.1038/nature07578. PubMed PMID: 19060882. 
 
37. Chumduri C, Gurumurthy RK, Zadora PK, Mi Y, Meyer TF. Chlamydia infection 
promotes host DNA damage and proliferation but impairs the DNA damage response. Cell host 
& microbe. 2013;13(6):746-58. Epub 2013/06/19. doi: 10.1016/j.chom.2013.05.010. PubMed 
PMID: 23768498. 
 
38. Hybiske K, Stephens RS. Mechanisms of Chlamydia trachomatis entry into 
nonphagocytic cells. Infection and immunity. 2007;75(8):3925-34. Epub 2007/05/16. doi: 
10.1128/IAI.00106-07. PubMed PMID: 17502389; PubMed Central PMCID: PMC1952008. 
 
39. Gurumurthy RK, Maurer AP, Machuy N, Hess S, Pleissner KP, Schuchhardt J, et al. A 
loss-of-function screen reveals Ras- and Raf-independent MEK-ERK signaling during 
Chlamydia trachomatis infection. Science signaling. 2010;3(113):ra21. Epub 2010/03/18. doi: 
10.1126/scisignal.2000651. PubMed PMID: 20234004. 
 
40. Park JE, Lee JA, Park SG, Lee DH, Kim SJ, Kim HJ, et al. A critical step for JNK 
activation: isomerization by the prolyl isomerase Pin1. Cell death and differentiation. 
2012;19(1):153-61. Epub 2011/06/11. doi: 10.1038/cdd.2011.82. PubMed PMID: 21660049; 
PubMed Central PMCID: PMC3252824. 
 
41. Chen CB, Ng JK, Choo PH, Wu W, Porter AG. Mammalian sterile 20-like kinase 3 
(MST3) mediates oxidative-stress-induced cell death by modulating JNK activation. Bioscience 
reports. 2009;29(6):405-15. Epub 2009/07/17. doi: 10.1042/BSR20090096. PubMed PMID: 
19604147. 
 
42. Ikeo Y, Yumita W, Sakurai A, Hashizume K. JunD-menin interaction regulates c-Jun-
mediated AP-1 transactivation. Endocrine journal. 2004;51(3):333-42. Epub 2004/07/17. 
PubMed PMID: 15256779. 
 
43. Chittenden TW, Howe EA, Culhane AC, Sultana R, Taylor JM, Holmes C, et al. 
Functional classification analysis of somatically mutated genes in human breast and colorectal 
cancers. Genomics. 2008;91(6):508-11. Epub 2008/04/25. doi: 10.1016/j.ygeno.2008.03.002. 
PubMed PMID: 18434084; PubMed Central PMCID: PMC2492759. 
 
44. Schonthaler HB, Guinea-Viniegra J, Wagner EF. Targeting inflammation by modulating 
the Jun/AP-1 pathway. Annals of the rheumatic diseases. 2011;70 Suppl 1:i109-12. Epub 
2011/02/26. doi: 10.1136/ard.2010.140533. PubMed PMID: 21339212. 
 
45. Buchholz KR, Stephens RS. The extracellular signal-regulated kinase/mitogen-activated 
protein kinase pathway induces the inflammatory factor interleukin-8 following Chlamydia 
trachomatis infection. Infection and immunity. 2007;75(12):5924-9. Epub 2007/09/26. doi: 
10.1128/IAI.01029-07. PubMed PMID: 17893134; PubMed Central PMCID: PMC2168325. 
	   200 
46. Chen F, Cheng W, Zhang S, Zhong G, Yu P. [Induction of IL-8 by Chlamydia 
trachomatis through MAPK pathway rather than NF-kappaB pathway]. Zhong nan da xue xue 
bao Yi xue ban = Journal of Central South University Medical sciences. 2010;35(4):307-13. 
Epub 2010/05/08. doi: 10.3969/j.issn.1672-7347.2010.04.005. PubMed PMID: 20448351. 
 
47. Lee NY, Choi HK, Shim JH, Kang KW, Dong Z, Choi HS. The prolyl isomerase Pin1 
interacts with a ribosomal protein S6 kinase to enhance insulin-induced AP-1 activity and 
cellular transformation. Carcinogenesis. 2009;30(4):671-81. Epub 2009/01/27. doi: 
10.1093/carcin/bgp027. PubMed PMID: 19168580. 
 
48. Lee CY, Sher HF, Chen HW, Liu CC, Chen CH, Lin CS, et al. Anticancer effects of 
tanshinone I in human non-small cell lung cancer. Molecular cancer therapeutics. 
2008;7(11):3527-38. Epub 2008/11/13. doi: 10.1158/1535-7163.MCT-07-2288. PubMed PMID: 
19001436. 
 
49. Gondek DC, Olive AJ, Stary G, Starnbach MN. CD4+ T cells are necessary and 
sufficient to confer protection against Chlamydia trachomatis infection in the murine upper 
genital tract. J Immunol. 2012;189(5):2441-9. Epub 2012/08/03. doi: 
10.4049/jimmunol.1103032. PubMed PMID: 22855710. 
 
50. Lad SP, Fukuda EY, Li J, de la Maza LM, Li E. Up-regulation of the JAK/STAT1 signal 
pathway during Chlamydia trachomatis infection. J Immunol. 2005;174(11):7186-93. Epub 
2005/05/21. PubMed PMID: 15905563. 
 
51. Chen AL, Johnson KA, Lee JK, Sutterlin C, Tan M. CPAF: a Chlamydial protease in 
search of an authentic substrate. PLoS pathogens. 2012;8(8):e1002842. Epub 2012/08/10. doi: 
10.1371/journal.ppat.1002842. PubMed PMID: 22876181; PubMed Central PMCID: 
PMC3410858. 
 
52. Rajalingam K, Sharma M, Lohmann C, Oswald M, Thieck O, Froelich CJ, et al. Mcl-1 is 
a key regulator of apoptosis resistance in Chlamydia trachomatis-infected cells. PloS one. 
2008;3(9):e3102. Epub 2008/09/05. doi: 10.1371/journal.pone.0003102. PubMed PMID: 
18769617; PubMed Central PMCID: PMC2518856. 
 
53. Alto NM, Orth K. Subversion of cell signaling by pathogens. Cold Spring Harbor 
perspectives in biology. 2012;4(9):a006114. Epub 2012/09/07. doi: 
10.1101/cshperspect.a006114. PubMed PMID: 22952390. 
 
54. Buchholz KR, Stephens RS. Activation of the host cell proinflammatory interleukin-8 
response by Chlamydia trachomatis. Cellular microbiology. 2006;8(11):1768-79. Epub 
2006/06/29. doi: 10.1111/j.1462-5822.2006.00747.x. PubMed PMID: 16803583. 
 
55. Vignola MJ, Kashatus DF, Taylor GA, Counter CM, Valdivia RH. cPLA2 regulates the 
expression of type I interferons and intracellular immunity to Chlamydia trachomatis. The 
Journal of biological chemistry. 2010;285(28):21625-35. Epub 2010/05/11. doi: 
10.1074/jbc.M110.103010. PubMed PMID: 20452986; PubMed Central PMCID: PMC2898388. 
 
56. Wang A, Al-Kuhlani M, Johnston SC, Ojcius DM, Chou J, Dean D. Transcription factor 
complex AP-1 mediates inflammation initiated by Chlamydia pneumoniae infection. Cellular 
microbiology. 2012. Epub 2012/11/21. doi: 10.1111/cmi.12071. PubMed PMID: 23163821. 
	   201 
57. Mesquita FS, Thomas M, Sachse M, Santos AJ, Figueira R, Holden DW. The 
Salmonella deubiquitinase SseL inhibits selective autophagy of cytosolic aggregates. PLoS 
pathogens. 2012;8(6):e1002743. Epub 2012/06/22. doi: 10.1371/journal.ppat.1002743. PubMed 
PMID: 22719249; PubMed Central PMCID: PMC3375275. 
 
58. Rytkonen A, Poh J, Garmendia J, Boyle C, Thompson A, Liu M, et al. SseL, a 
Salmonella deubiquitinase required for macrophage killing and virulence. Proceedings of the 
National Academy of Sciences of the United States of America. 2007;104(9):3502-7. Epub 
2007/03/16. doi: 10.1073/pnas.0610095104. PubMed PMID: 17360673; PubMed Central 
PMCID: PMC1802004. 
 
59. Coers J, Gondek DC, Olive AJ, Rohlfing A, Taylor GA, Starnbach MN. Compensatory T 
cell responses in IRG-deficient mice prevent sustained Chlamydia trachomatis infections. PLoS 
pathogens. 2011;7(6):e1001346. Epub 2011/07/07. doi: 10.1371/journal.ppat.1001346. PubMed 
PMID: 21731484; PubMed Central PMCID: PMC3121881. 
 
60. Chen H, Sharp BM. Content-rich biological network constructed by mining PubMed 
abstracts. BMC bioinformatics. 2004;5:147. Epub 2004/10/12. doi: 10.1186/1471-2105-5-147. 
PubMed PMID: 15473905; PubMed Central PMCID: PMC528731. 
 
61. Wang W, Shi L, Xie Y, Ma C, Li W, Su X, et al. SP600125, a new JNK inhibitor, protects 
dopaminergic neurons in the MPTP model of Parkinson's disease. Neuroscience research. 
2004;48(2):195-202. Epub 2004/01/27. PubMed PMID: 14741394. 
 
62. Kim SE, Lee MY, Lim SC, Hien TT, Kim JW, Ahn SG, et al. Role of Pin1 in neointima 
formation: down-regulation of Nrf2-dependent heme oxygenase-1 expression by Pin1. Free 
radical biology & medicine. 2010;48(12):1644-53. Epub 2010/03/24. doi: 























	   203 
      Chlamydia trachomatis is a persistent bacterial pathogen that has infected humans for 
thousands of years (1). Over time, Chlamydia has adapted to survive and evade immune 
mechanisms initiated by the human host to avoid clearance and blunt protective immunity (2). In 
turn, the host becomes susceptible to the development of severe disease sequelae that are 
major public health threats, such as ectopic pregnancy and infertility (3). The majority of 
Chlamydia infections remain asymptomatic, complicating diagnosis and treatment. Because of 
this, there is a great need to develop a long-lived protective vaccine that will not only protect 
against C. trachomatis, but will also prevent immunopathologies. This dissertation examined 
both host mechanisms that drive protective immunity in the genital mucosa, as well as bacterial 
strategies that are used to manipulate host cells in order to promote intracellular growth and 
survival. Together these findings uncover important aspects of C. trachomatis host-pathogen 
interactions that now open new avenues of study that will lead to the development of a 
protective vaccine. 
 
Mouse models of Chlamydia trachomatis genital infection 
     As a first step towards developing a Chlamydia vaccine, there is a need to develop small 
animals models that can be used to test vaccine candidates in vivo. In order to be useful the 
small animal models must recapitulate many aspects of human disease, including the 
development of chronic infections and immune sequelae. Unfortunately, current murine models 
of Chlamydia infection remain limited (4).  
 Many investigators studying immunity to C. trachomatis use the murine-adapted 
Chlamydia muridarum as a surrogate pathogen in mice (5-7). As described in Chapter 2, while 
C. muridarum infections robustly colonize mice via the intravaginal route of infection and lead to 
the development of immune pathologies, there are several aspects of this model that cannot 
recapitulate human disease and therefore limit its utility (8). It is clear that a protective vaccine 
against C. trachomatis must drive cell-mediated immunity, as antibodies are not broadly 
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protective (7, 9). Antibody-based vaccines against C. trachomatis did not induce protection in 
early clinical trials, leading investigators to pursue strategies that robustly activate T cell 
responses (10). Unfortunately C. muridarum-derived peptides differ from human strains of C. 
trachomatis to a large enough degree that protective peptides from one species many times do 
not exist in the other (8). Therefore, the development of infection models in mice using human 
strains of C. trachomatis is an area of study that is required to more rapidly progress with 
vaccine development. 
 Previous studies in which mice were infected intravaginally with C. trachomatis 
described weak colonization, ascension to the upper genital tract, and minimal development of 
immune sequelae (11, 12). In Chapter 2 of this dissertation, I described data showing that these 
previous findings were mostly because human stains of Chlamydia are unable to withstand the 
lower genital tract environment in mice. However, using a novel transcervical infection method 
that deposits Chlamydia directly into the upper genital mucosa, I found robust colonization of the 
upper genital tract, induction of immune pathologies, and development of protective immunity. 
The disease course seen following transcervical infection with C. trachomatis closely mirrors 
that seen following infection with C. muridarum, only with shorter duration due to restriction by 
murine IFNγ responses. Unfortunately, mice that were infected transcervically with C. 
trachomatis did not develop the chronic infections that are associated with human disease. 
Therefore, while transcervical infection with C. trachomatis can now be used to model several 
aspects of acute disease seen in humans, it does not currently recapitulate persistent phases of 
infection. Future studies will need to investigate methods to further improve the transcervical 
model in order to make it more representative of human infections.   
 One important topic that remains to be examined in depth in the transcervical model is 
the disease course of various clinical strains of human C. trachomatis. For my initial 
characterization of the transcervical infection model I exclusively used the lymphogranuloma 
venereum (LGV) strain L2. In humans, L2 is among the most virulent strains of C. trachomatis 
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that infects the human genital mucosa. However, after colonizing the genital tract, L2 infection 
spreads systemically to the lymphatic system, causing severe inflammation in these tissues 
(13). L2 infections of the genital tract may not be the most accurate model of persistent genital 
infections. In the context of public health, infections with LGV make up a small percentage of 
documented C. trachomatis infections, limiting the direct clinical relevance of studies using this 
strain (13). The majority of human C. trachomatis genital infections are caused by serovars D-K. 
Intravaginal infection with serovar D has previously been shown to cause hydrosalpinx in mice, 
unlike intravaginal infection with L2 (3). This suggests that serovar D may be better adapted to 
persist in the genital mucosa than L2. We are now pursuing experiments to determine whether 
transcervical infections of mice with C. trachomatis serovar D lead to more robust and extended 
colonization of the upper genital tract, ascend more efficiently to the ovaries, and promote the 
development of more consistent immunopathologies than transcervical infection with L2. These 
studies will help to improve our small animal infection model so that it better recapitulates the 
most common type of C. trachomatis infection seen in the clinic. 
 The next step in refining murine models of human C. trachomatis infection will be to 
develop methods that also induce long-term chronic infections in vivo. Since C. muridarum does 
not cause persistent infections, new chronic infection models will need to use human C. 
trachomatis strains in order to recapitulate the persistent disease state. One reason that human 
strains of C. trachomatis are rapidly cleared from mice is that they are sensitive to the murine 
IFNγ response , which induces the IRG system (14). Work performed by our lab and others 
showed that mouse cells that are stimulated with IFNγ direct IRGs to restrict C. trachomatis (15-
17).  In contrast, IFNγ stimulation of human epithelial cells, which do not possess IFNγ inducible 
IRGs, induce IDO expression (18). This in turn leads to intracellular tryptophan depletion. The 
differential response to IFNγ between mice and humans leads to dramatically different 
outcomes of infection. We hypothesized that performing transcervical infection in mice deficient 
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in IRGs may lead to persistent Chlamydia infection. However, in IRG-deficient mice, we found 
enhanced bacterial replication early during infection, which ultimately led to an exacerbated 
CD4+ T cell response and infection clearance within two weeks (19). This suggests that 
unimpeded replication may ultimately be detrimental to the induction of quiescent Chlamydia 
infections.  
Human strains of C. trachomatis have adapted to withstand to the human IFNγ 
response, allowing for their survival even under high levels of IDO and subsequent tryptophan 
depletion (18). Therefore, we speculate that a more physiological murine infection model that 
recapitulates all aspects of human disease will not only require the removal of murine specific 
IFNγ responses, but also require the addition of human IFNγ responses. The laboratory of Dr. 
Jorn Coers, in collaboration with our laboratory, has recently developed a “humanized” knock-in 
mouse model, which removes the murine IRG system while knocking in a cassette that 
enhances the expression of IDO to levels seen in human epithelial cells (data not shown) (20). 
We will now begin to examine the transcervical infection model using these humanized mice to 
determine if we are able to more closely recapitulate all aspects of the human disease. 
Ultimately, the development of these models is necessary to safely evaluate the potential of 
candidate vaccine formulations that drive protective immunity against C. trachomatis and 
prevent the induction of immune sequelae.  
 
Immunity in the genital mucosa: implications for vaccine development 
    Since the transcervical infection model is a robust and reproducible model of C. trachomatis 
infection, it has opened new avenues of research that will increase our understanding of the 
mechanisms responsible for protection in the genital mucosa. By characterizing the factors that 
mediate long-term protective immunity, I hypothesized that I could uncover hallmarks of the 
immune response that are associated with protective immunity in the genital mucosa. These 
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findings could then be leveraged during vaccine development to promote a broadly protective 
immunization strategy. As a first step in this process, I characterized the cellular populations 
that afford protection in the genital mucosa following transcervical infection with C. trachomatis. 
Through these studies I found that CD4+ T cells drove the majority of protection that is observed 
following C. trachomatis infection in the upper genital tract. When I depleted CD4+ T cells from 
mice that had been previously infected with C. trachomatis, the mice were not protected against 
subsequent C. trachomatis challenge and harbored similar bacterial levels to naïve mice 
following primary infection. In addition, transferring Chlamydia-specific CD4+ T cells into naïve 
mice afforded significant protection to C. trachomatis infection in the genital tract. Other recent 
work in our lab investigated the role of CD8+ T cells and B cells during infection and found them 
to both be dispensable for protection from C. trachomatis in the genital tract (data not shown). 
These studies showed that transfer of serum or purified CD8+ T cells from immune mice into 
naïve mice affords no protection, in contrast to CD4+ T cells. Taken together, these data 
demonstrate that during use of the transcervical model there is a critical role for CD4+ T cells in 
protecting the murine genital tract from infection with C. trachomatis. Therefore, in order for a 
Chlamydia vaccine candidate to be efficient, it must stimulate a robust Chlamydia-specific CD4+ 
T cell response in the genital mucosa. 
 Despite the fact that these experiments showed a critical role for CD4+ cells in the long-
term protection of the genital mucosa, the steps that lead to the activation, recruitment and 
retention of T cells in the genital tract remained ambiguous. In order for CD4+ T cells to mediate 
protection in the genital tract they must be activated in the iliac lymph node by antigen 
presenting cells, traffic into the genital tissue where infection occurs, and release effector 
cytokines such as IFNγ that promote clearance (21). In Chapters 3 and 4 of this dissertation, I 
characterized homing molecules that are required for Chlamydia-specific CD4+ T cells to traffic 
efficiently to the genital tract and to afford protection from C. trachomatis infection. Loss of the 
chemokine receptors CXCR3 and CCR5, or the integrin α4β1 on Chlamydia-specific CD4+ T 
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cells, negatively impacted both T cell recruitment to the genital tract and the T cells’ protective 
capacity. While previous studies suggested potential chemokine receptors and integrins that 
promote T cell recruitment to the genital mucosa, these studies examined bulk T cells and were 
unable to track Chlamydia-specific T cells. Previous studies also failed to examine the role of 
individual receptors on the protective capacity of T cells. In this dissertation, the use of antigen 
specific techniques and the transcervical infection model allowed for the identification and 
characterization of CXCR3, CCR5 and α4β1 in promoting a robust and protective CD4+ T cell 
response following C. trachomatis infection in the genital mucosa.  
As the mechanisms that promote protective CD4+ T cell responses in the genital mucosa 
are elucidated, we can begin to optimize vaccine strategies that promote the development of 
these protective cellular populations following immunization. Based on the findings in Chapters 
2, 3, and 4, I hypothesize that a vaccine that induces CD4+ T cells with the proper chemokine 
receptor and integrin profiles would be the most protective immunization strategy. One way to 
leverage these findings as a vaccine approach may be to use a “prime and pull” method that 
attracts T cells of the correct homing molecule profile to the mucosal site of interest. This 
strategy has recently been used successfully in a herpes infection model in the genital tract of 
mice (22). In this vaccine approach, an initial immunization is given systemically in mice to 
prime pathogen-specific T cells. Then the chemokines CXCL9 and CXCL10, which bind to the 
receptor CXCR3, are topically applied to the genital tract. This chemokine then pulls activated 
antigen specific T cells that express CXCR3 from the periphery to the genital mucosa, where 
they can develop into long-term memory cells. It is possible that the same vaccine strategy 
could be used to protect from infections with C. trachomatis, and may even be further enhanced 
by including chemokines that bind CXCR3 and CCR5.  
The prime and pull strategy is successful because it enhances the recruitment of 
activated pathogen-specific T cells that express specific homing molecules to the genital 
mucosa following vaccination (22). However, studies have yet to examine how different 
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immunization strategies influence the expression of homing molecules on protective CD4+ T 
cells following vaccination. A vaccine that maximally primes pathogen-specific T cells to express 
critical homing molecules following immunization will promote more efficient “pulling” of 
protective cells to the genital mucosa, where they can develop into memory cells. Ultimately, 
enhanced T cell recruitment and retention in the genital mucosa may increase the protective 
capacity of vaccination. In order to examine how homing molecule expression on T cells is 
regulated, investigators must examine all aspects of T cell priming, including initial activation. 
Interactions between distinct antigen presenting cells and naïve T cells have been shown to 
influence the expression of homing molecules on the surface of antigen-specific T cells during 
priming. Previous studies showed that the activation of naïve T cells by dendritic cells cultured 
with intestinal tissues imprints T cells differently than dendritic cells alone. Co-culture of T cells 
with intestinal DCs induced a homing profile on activated T cells that promoted trafficking to the 
intestines through the upregulation of CCR9 and α4β7 (23, 24). Unlike APC populations from 
the intestine, the influence of distinct genital mucosa resident APC populations on the induction 
of homing molecules on Chlamydia-specific T cells remains almost entirely unexplored. Future 
studies will need to examine how initial priming events can enhance or inhibit the upregulation 
of CXCR3, CCR5, and α4β1 on Chlamydia-specific T cells and evaluate how various vaccine 
strategies specifically alter these interactions. Once APC populations that positively influence T 
cell recruitment to the infected genital mucosa are identified, we can then dissect these 
interactions to elucidate the mechanisms responsible for changes in homing receptor 
expression. Ultimately, identifying vaccine compositions that promote the enhanced expression 
of homing markers that are specific for the genital tract may improve the efficacy of protection 
afforded by immunization. 
Even though the data presented in this dissertation demonstrate the protective role of 
CD4+ T cells during natural infection of mice, human immunity to C. trachomatis appears to be 
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less robust, resulting in limited protective memory. In human disease, the absence of protective 
immunity is not due to a lack of CD4+ T cell activation or homing to the genital tract, but rather it 
is the result of a failure to maintain a stable long-lived memory pool that can protect from 
reinfection (25). The underlying mechanisms that lead to this deficit in memory potential in 
humans are not understood and remain to be investigated experimentally. Future studies will 
need to shift their focus from primary infections to the dissection of how initial activation events, 
homing receptor expression, and the genital tract environment influence the memory potential of 
Chlamydia-specific CD4+ T cells differently in humans and mice. As described above, one major 
difference between humans and mice is the robust induction of IDO following IFNγ stimulation in 
human epithelial cells. While IDO is thought of as a host-mechanism to restrict infection, the 
metabolite byproducts of the IDO response may also have detrimental impacts on CD4+ T cells 
(26). High levels of kynurenines have been shown to directly impact the CD4+ T cell response to 
Mycobacterium tuberculosis during lung infections. During M. tuberculosis infection, mice that 
are unable to induce IDO expression develop an exacerbated Th17 response, a response that 
is directly inhibited by kynurenines (27). Recent work in cancer biology further supports the 
immunosuppressive role of these molecules by showing that tumors can upregulate expression 
of IDO and kynurenine metabolites in order to induce tolerance and prevent T cell-mediated 
tumor clearance and memory development (26, 28). A similar situation may occur in the genital 
tract during C. trachomatis infections. I hypothesize that high expression of IDO has a two-
pronged effect that promotes C. trachomatis survival. The first effect of IDO expression, as 
discussed previously, is the induction of a quiescent form of C. trachomatis that survives 
tryptophan depletion. The second and currently unexplored effect of IDO expression, is the 
direct immunosuppressive and tolerogenic influences that kynurenines, IDO derived 
metabolites, have on CD4+ T cells. Infection with C. trachomatis induces the recruitment of IFNγ 
secreting CD4+ T cells to the genital mucosa, which in turn induces IDO expression, increases 
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the levels of kynurenines, and depletes tryptophan stores. In response to tryptophan depletion, 
C. trachomatis differentiates into the well-described quiescent state, “tricking” the immune 
system into the perception of clearance. At the same time, high levels of kynurenines may 
directly inhibit the development of a robust Th1 response, similar to what has been described for 
other pathogens at other mucosal sites. Future studies are needed to test these hypotheses and 
to determine what impact high IDO expression and high kynurenine levels have on CD4+ T cell-
mediated protection against C. trachomatis in the murine genital mucosa. Taken together, while 
great progress is being made in the development of animals models of C. trachomatis and in 
understanding protective immunity in the genital mucosa of mice, we must now turn our 
attention to gaining a better understanding of what leads to robust memory induction and how 
infection with C. trachomatis alters immune development.  
 
Chlamydia infection alters host cells to promote growth and evade immunity 
     C. trachomatis is superbly adapted to replicate in human cells and persist over time in 
human hosts (1). While C. trachomatis has evolved mechanisms that alter immune 
development, characterizing these virulence mechanisms has remained challenging. On one 
hand, C. trachomatis is unable to evade or manipulate host processes unique to mice, such as 
the IRG response to IFNγ stimulation (19). On the other hand, infections of mice with C. 
trachomatis may also mask immune evasion strategies that are present in humans but not mice, 
such as the induction of quiescence under low tryptophan levels following IDO induction (20). 
Therefore, in vivo mouse studies alone are not sufficient to fully characterize the virulence 
strategies employed by C. trachomatis in humans. In order to understand the strategies used by 
C. trachomatis to acquire nutrients and evade immune clearance, we must characterize how 
infection with C. trachomatis directly alters human cells using in vitro or ex vivo models. I 
hypothesized that understanding the mechanisms used by C. trachomatis to promote 
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intracellular growth may help us to better find strategies to drive bacterial clearance as well as 
lead to the development of host based therapeutics. 
Previous studies have shown that C. trachomatis directly alters host proteins and 
pathways by secreting effector proteins directly into the host cytosol. These virulence factors 
have been shown to impact a wide-variety of host-cell processes, such as NF-κB signaling, 
cytoskeletal structure, cell cycle state, golgi function, and histone methylation (29-32). 
However, the handful of well-studied effectors is only a fraction of the almost 100 proteins 
predicted to be substrates of the type III secretion system, the majority of which have no 
known enzymatic function or host cell target (33). I speculated that large-scale discovery of 
host proteins targeted during infection might give insight into cellular processes manipulated 
by C. trachomatis. In Chapters 5 and 6 of this dissertation I applied two parallel proteomic and 
genomic techniques to broadly identify host proteins whose levels are altered as a result of 
infection. The first approach combined quantitative mass spectrometry, using SILAC and 
microarray transcriptional analysis, to identify host proteins that are altered following infection. 
Using this system I determined that the vast majority of these changes did not appear to result 
from changes in transcription. As a complimentary approach, I used the GPS screening 
platform to probe the human ORFeome collection for host proteins that whose stability was 
altered following infection. SILAC and GPS are inherently different screening platforms that 
independently may not achieve the global depth that is possible when they are used together. 
A strength of SILAC is its ability to assess changes in protein abundance with exceptional 
quantitative precision at endogenous levels of expression, providing us with a method to 
examine changes to proteins at physiological levels on a large scale. However, the 
effectiveness of SILAC has been limited because its protein abundance measurements reflect 
the combined influences of transcription, protein synthesis, and post-translational effects. Its 
performance has also been restricted due to incomplete proteome coverage, though ongoing 
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technological improvements are continually increasing the depth of its reach. GPS 
complements these shortcomings by assessing a larger number of host proteins (many of 
which weren’t identified in SILAC), and examines each ORF independently of transcriptional 
regulation. Furthermore, because GPS uses intact cells it prevents non-specific protease 
activity driven by CPAF, which is characteristic of Chlamydia infected cells (34).  
When I applied SILAC and GPS to identify host proteins that were altered during C. 
trachomatis infection, I found that almost 1,000 total host proteins were altered. Bioinformatic 
analysis on both datasets revealed host processes that were enriched among the altered host 
proteins from the screens. In both the SILAC and the GPS screens, we found a strong 
enrichment of host genes involved in Golgi Apparatus function, host transcriptional regulation, 
and cyotosolic trafficking networks. It was not surprising to identify the Golgi proteins as 
altered during C. trachomatis infection, as several studies have examined the fragmentation of 
Golgi stacks that occurs as intracellular bacterial replication progresses (31). Interestingly, 
bioinformatic analysis of both screens uncovered several host processes that have not been 
previously implicated during C. trachomatis infection. Among these annotated clusters were 
proteins involved in microtubule formation, mitochondrial function, protein degradation, protein 
translation and RNA splicing. Surprisingly, there was also a strong enrichment of genes 
involved in nucleus structure and in transcription factors, suggesting that C. trachomatis 
infection broadly alters host cell processes. It will be important for new studies to examine 
whether secreted bacterial effectors directly mediate the specific changes in host cell proteins 
that occur during C. trachomatis infection. One approach to identify these host-pathogen 
interactions is to take advantage of the GPS reporter cell lines that exhibited altered protein 
stability during infection with C. trachomatis. Using these reporter cell lines to identify 
individual effector proteins that can recapitulate the protein stability changes that are seen 
during infection may be a powerful screening tool. As a proof-of-principle for these 
approaches, I have recently executed a small-scale screen (described in Appendix B) where I 
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discovered that the Chlamydia protein CrpA destabilizes the host protein BNIP3L in order to 
alter the host cell response. These types of analyses can now be executed with a broader 
panel of Chlamydia effector and host proteins to identify potential host-pathogen interactions 
that could then be targeted to disrupt Chlamydia intracellular development.   
One of the more intriguing findings from the SILAC and GPS experiments is that a 
large number of host protein levels are altered independent of changes in host transcription. In 
the SILAC analysis, I coupled quantitative proteomic screening with transcriptional array 
analysis and found that over 90% of the protein changes identified in the SILAC analysis 
occurred without concomitant changes in mRNA expression. Furthermore, changes identified 
using the GPS screening platform were entirely independent of changes in transcriptional 
regulation, as all the proteins were expressed off of a CMV promoter (35). Together these 
findings suggest that C. trachomatis infection broadly alters host proteins independent of 
changes in host transcription. While the mechanisms driving the differential changes in mRNA 
and protein level is not entirely clear, I have uncovered two potential mechanisms that may 
promote this discordance. First, I identified that C. trachomatis infection of human cells inhibits 
the translation efficiency of host ribosomes. By inhibiting translation, Chlamydia can prevent 
the accumulation of pro-inflammatory cytokines and can generate a larger pool of free amino 
acids, which are needed for the pathogen to survive in cells. In fact, in the gain-of-function 
screen described in Chapter 5, I found that overexpression of the elongation factor EEF1D 
prevents efficient C. trachomatis replication. These data indicate that alterations of host 
translation are required for C. trachomatis intracellular growth. The second mechanism that 
may drive differences in host protein and mRNA levels is a direct manipulation of the 
ubiquitin/proteasome system. In the SILAC screen, I found that the host ubiquitin ligase 
adaptor Cul4a was strongly destabilized during C. trachomatis infection. Loss of individual 
ubiquitin networks likely lead to distinct changes in host proteins that would not be found by 
examining transcriptional analysis alone. Furthermore, Chlamydia encodes two 
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deubiquitinating enzymes that are secreted into the host cytoplasm during infection that can 
directly alter ubiquitination in the host (36). Manipulating the ubiquitin landscape in host cells 
would allow C. trachomatis to toggle levels of a broad range of host proteins in infected cells 
to the benefit of the pathogen. More broadly speaking, decoupling transcription and translation 
in host cells may allow C. trachomatis to prevent robust activation of specific immune 
pathways that become transcriptionally activated during infection that may be detrimental to 
intracellular growth of the pathogen. It is also possible that inhibition of host translation 
ensures that there are adequate levels of the nutrients needed by C. trachomatis to survive. 
Future work will need to dissect these individual mechanisms and to identify potential host-
pathogen interactions that drive these processes. 
Together GPS and SILAC identified host proteins that are directly altered by C. 
trachomatis during infection. These screens identified many host proteins that are altered in 
stability following infection, but they did not address the biological impact of the individual host 
protein alterations. I hypothesized that if prevention a specific protein from being altered by C. 
trachomatis inhibited growth, then that protein might represent a potential choke point in the 
host cell that could be targeted to restrict infection. To identify the changes that are required 
for growth, we conducted an overexpression screen for host proteins that were destabilized by 
infection and a siRNA screen for those host proteins that were stabilized by infection. This is 
the first large-scale overexpression screen used to identify pathogen-induced changes that 
are required for the growth of a pathogen in mammalian cells. The proteins that we identified 
are involved in a wide-range of host cell functions, suggesting that C. trachomatis alters host 
cells broadly. Future studies will be conducted to individually characterize how these proteins 
alter C. trachomatis intracellular growth. To gain insight into potential mechanisms by which C. 
trachomatis growth is altered, I grouped hits into common pathways or protein networks. For 
example, I identified that several hits identified in the loss-of-function screen were related to 
the AP-1 transcription complex. AP-1 signaling is known to alter cellular processes, immune 
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activation and cellular survival programs (37). Several bacterial pathogens have been shown 
to manipulate these pathways to alter immune responses and intracellular survival. In fact, 
one recent study identified that Salmonella infections directly alter host transcription in a type 
III secretion system dependent manner, including the activation of AP-1 components, in order 
to allow intracellular development late during infection (41). My mechanistic analysis 
presented in Chapter 6 identified that AP-1 activation occurs 24 hours following C. trachomatis 
infection, and that AP-1 activation is required for efficient intracellular growth in vitro and in 
vivo. It currently remains unknown precisely which AP-1 targets are needed for Chlamydia 
replication and what underlying mechanisms drive AP-1 activation. However, it is interesting 
that C. trachomatis activates AP-1 in host cells when this pathway is also implicated in the 
inflammation in response to Chlamydia infection (37). It is tempting to speculate that 
Chlamydia manipulates AP-1 activation and other host signaling cascades to not only promote 
intracellular growth, but also to directly alter the host immune response. It is possible that the 
high levels of inflammation induced by C. trachomatis may lead to ineffective T cell responses, 
directly linking changes in infected epithelial cells to alterations in host immunity. Current work 
in our lab is investigating the interactions between infection induced inflammation and T cell 
protection in order to address these outstanding questions. Ultimately, it will be important to 
examine many of the host proteins and pathways identified as altered during C. trachomatis 
infection in the SILAC or GPS screens in an in vivo setting, in order to determine their 
influence on protective immunity in the genital mucosa.  
 
Using proteomic approaches to characterize novel host-pathogen interactions    
In Chapters 5 and 6 of this dissertation, I showed that C. trachomatis dramatically 
alters the proteomic landscape of host cells during infection. Previous studies have used 
quantitative proteomic techniques to study host interactions with bacterial pathogens (38, 39). 
While these studies were successful in identifying some host factors altered during infection, 
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the proteome coverage was limited (1000-2000 total host proteins) compared to our current 
study (>10,000 total host proteins). With the success of small-scale studies examining 
Salmonella, combined with the extensive study presented here, investigators should have a 
renewed interest in understanding the impact of intracellular pathogens directly on host cell 
proteins. Investigators studying varying aspects of mammalian cell biology have commonly 
used large-scale proteomic and ORFeome-based screens to understand how global dynamics 
change following specific perturbations (35). Our study is the first to take advantage of the 
human ORFeome as a resource to understand bacterial pathogenesis. By coupling ORFeome 
screens with quantitative mass-spectrometry we achieved over five times greater coverage 
than previous studies focused on the effects that bacterial pathogens have on the human 
proteome.  
It is not hard to imagine several applications of these proteomic approaches to 
characterize unknown host-pathogen interactions. First, several other bacterial pathogens 
encode secretion systems that inject virulence determinants into host cells to manipulate host 
proteins. For example, among others, Salmonella typhimurium and Shigella flexneri encode 
ubiquitin modifying proteins that are secreted into the host cell during infection (40). 
Investigators can now use the approaches described in this dissertation to compare how 
infection directly alters host proteins during each bacterial infection. Using either GPS or 
SILAC, investigators can also begin to identify host proteins whose levels are directly 
mediated by bacterial effectors, by comparing changes to the proteome that occur during 
infection with wild-type bacteria or bacterial lacking specific virulence loci, such as type III or 
type IV secretion systems. In these screens, the proteins that shift following wild-type 
infection, but not during infection with virulence mutants, are the proteins that are likely to be 
directly targeted by secreted bacterial effectors. I anticipate that this screening approach 
would uncover far fewer total altered proteins, but will provide more targeted identification of 
specific host-pathogen interactions than screens that only compare changes in infected and 
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uninfected cells. Unfortunately, because targeted genetics remains difficult in C. trachomatis, 
this virulence mutant screen would still be challenging. In the absence of genetic techniques, it 
is possible to use a gain-of-function approach to identify the host targets of individual virulence 
determinants. In a gain-of-function approach, individual bacterial effectors or control vectors 
would be expressed in host cells and the host proteins that are altered would be compared 
between the two conditions. For example we can use the GPS screening platform to identify 
substrates of bacterial derived ubiquitin modifying proteins ChlaDub1 and ChlaDub2, which 
are encoded by C. trachomatis (36). Together, the experimental approaches described in this 
dissertation provide a blueprint for cataloging host proteins and pathways that are altered by 
pathogens. By screening a broad range of bacterial pathogens, we could begin to identify 
potential host proteins that are targeted by several pathogens. These common pathways 
would reveal host targets that are particularly ripe for the development of host-based antibiotic 
therapies that could prevent pathogen survival and the dissemination of disease. 
 
Summary 
Overall, the work described in this dissertation elucidated critical mechanisms that drive host 
immunity, as well as bacterial virulence strategies that directly alter the host during infection with 
C. trachomatis. The next step in developing a broadly protective vaccine that promotes 
immunity and prevents pathology will require the integration of both immunology and cellular 
microbiology, in a fashion similar to the approaches described here. By combining these 
approaches we will be able to develop a vaccine that not only activates the proper protective 
cellular populations following immunization, but also prevents immune evasion mechanisms that 
are employed by C. trachomatis during infection. Ultimately, these approaches can be applied to 
a wide range of pathogens that remain problematic worldwide to develop novel therapeutic 
strategies that can prevent infection altogether.	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Appendix A: A Luman/CREB3–ADP-ribosylation factor 4 
(ARF4) signaling pathway mediates the response to Golgi 




Appendix A is the result of an exciting collaboration with Dr. Jan Reiling a post-doctoral fellow in 
the laboratory of David Sabatini at the Whitehead Institute. Initially, Jan characterized a host cell 
response to Golgi stress that involved the host protein ARF4 that he discovered using a haploid 
cell line gene trap screen. He found loss of ARF4 prevented the disruption of the Golgi complex 
using pharmaceutical compounds. Golgi disruption is a major virulence mechanism used by 
several intracellular pathogens to subvert host responses and acquire nutrients needed for 
survival. We tested the interesting hypothesis that blocking a general Golgi stress pathway in 
cells may also prevent pathogens from manipulating Golgi function. We found this to be the 
case for two pathogens Shigella flexneri and Chlamydia trachomatis. What follows in Appendix 
A is the entire manuscript that is now in press with Nature Cell Biology. The majority of the 
manuscript (Figures A1-A11) were experiments conducted almost entirely by Dr. Jan Reiling 
with small contributions by me. I then repeated the same mechanistic experiments and workflow 
used by Jan to characterize Golgi stress responses to examine phenotypes of intracellular 
bacterial pathogens, which is summarized in Figures A12 and A13.  
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INTRODUCTION  
The processing, sorting and transport of proteins and lipids in the Golgi to their destined 
intracellular site of action is of fundamental importance to the maintenance and functions of 
subcellular compartments. The Golgi fulfills several other functions beyond regulation of 
vesicular transport of cargo such as serving as an important signaling platform where different 
stimuli converge and by bringing multiple factors together(1-5). Moreover, correct Golgi 
positioning is essential for several directed cell movements including wound healing, secretion 
or maintenance of cell polarity(6, 7). 
 Brefeldin A (BFA) was first described as a molecule with antiviral, antibiotic, and 
antifungal activity and is used as pharmacological tool to interrogate vesicular transport 
processes(8). BFA also showed anticancer effects against several human tumor cell lines and 
was explored as lead chemotherapeutic compound(9-12). BFA treatment of cells inhibits ER-
Golgi transport, impedes protein secretion, and disperses the Golgi. 
 The ADP-ribosylation factors (ARFs) are evolutionarily conserved and ubiquitously 
expressed guanosine triphosphatases (GTPases), which belong to the Ras superfamily of small 
G proteins. They fulfill critical roles in the secretory pathway for transport of cargo between ER 
and Golgi or between different Golgi cisternae and in the endocytic system by recruiting coat 
proteins, activating lipid-modifying enzymes, and by regulating the cytoskeleton dynamics(13, 
14). The effects of BFA are largely ascribed to the inhibition of ARF small G protein-guanine 
nucleotide exchange factor (GEF) complexes. BFA acts as uncompetitive inhibitor by binding in 
a hydrophobic cavity formed between ARF-GDP and a subset of GEFs thereby trapping the 
interaction partners in an unproductive conformation, which prevents exchange of GDP for 
GTP(15). The BFA-sensitive group of large GEFs includes GBF1, BIG1 and BIG2 that exert 
their functions at distinct sites throughout the Golgi complex. 
 Although there is substantial degree of sequence homology between different ARFs, the 
family of five small ARF G proteins found in humans is further divided into three classes based 
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on amino acid similarity: class I is composed of ARF1 and ARF3, ARF4 and ARF5 belong to 
class II, and class III contains a sole member, ARF6. A further distinctive feature is their 
subcellular localization. With the exception of ARF6, the most distantly related ARF that is 
present at the plasma membrane and on endosomes(16, 17), the other ARFs are mainly 
localized at the ER-Golgi interface, with ARF1, 4 and 5 found predominantly at the early Golgi 
and ERGIC, and ARF3 at the trans-Golgi and trans-Golgi network (TGN). ARFs also differ in 
their abundance, e.g. ARF1 and ARF3 are expressed 3-10-fold higher than ARF4-6(18). The 
high sequence conservation between the class I and II ARFs (>80%), their overlapping 
biochemical activities upon overexpression, and their similar expression pattern has hampered 
progress to unambiguously assign defined roles to the individual ARFs.  
 Here, we conducted a large scale insertional mutagenesis screen in a near-haploid 
human chronic myeloid leukemia cell line to identify genes essential for BFA-induced apoptosis 
and thereby uncovered C5orf44/TRAPPC13, and, unexpectedly, ARF4. Despite the previously 
reported redundancy between different ARF members, our study uncovers a role for ARF4 in 
response to BFA not shared with other ARF isoforms. We functionally dissected the mechanism 
of BFA resistance in ARF4-depleted cells and demonstrate that this occurs through upregulation 
of other ARF members such as ARF1 and ARF5, and also requires GBF1. Furthermore, we 
uncovered a signaling module involving the CREB3/Luman transcription factor and ARF4 whose 
expressions correlate with Golgi integrity and might be part of a Golgi stress response. The 
physiological importance of these results is indicated by additional findings revealing that ARF4 
is critical for pathogenicity of Chlamydia trachomatis and Shigella flexneri, which infect millions 
each year.  
RESULTS 
To identify genes involved in BFA-induced toxicity, we employed a gene trap (GT)-based 
insertional mutagenesis approach using the near-haploid KBM7 cell line(19, 20). A 
heterogeneous population of approximately 100 million cells containing random knockout 
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mutations was assessed for their ability to resist cell death induced by chronic (3 weeks) BFA 
treatment. BFA-resistant GT cells were pooled at the end of the experiment, their DNA isolated, 
and the individual insertions mapped to the genome using deep sequencing(21). Two genes 
were enriched for GT insertions and associated with highly significant p-values (Figure A-1): 37 
GTs mapped to ARF4 (p<8.39x10-110) and 12 to C5orf44/TRAPPC13  (p<7.86x10-29). For the 
remainder of this article we will focus on ARF4, and findings related to C5orf44/TRAPPC13 will 
be described elsewhere.  
 Using several lentivirally-transduced shRNA hairpins targeting ARF4, resistance to BFA 
was recapitulated in multiple cell lines including A549, HeLa, HT29, U251, PANC1, PC3, 
DU145, 786-0, MCF7 and MDA-MB231, thereby revealing an essential, conserved role for 
ARF4 in mediating BFA susceptibility (Figure A-1 and data not shown). Loss of ARF4 did not 
significantly alter proliferation or cell cycle phases relative to control cells (data not shown). To 
elucidate whether loss of ARF4 protects against other Golgi-disrupting agents, cells were 
treated for several days with Golgicide A (GCA) or Exo1. Similar to BFA treatment, ARF4 KD 
cells were largely protected from undergoing apoptosis upon GCA or Exo1 exposure in 
comparison to control cells (Figure A-1C). ARF4-depleted cells were, however, not resistant to 
other ER stress inducers including Tunicamycin, Thapsigargin, or A23187 pointing to a specific 
function of ARF4 in the secretory pathway (Figure A-2).  
 The ARFs may act pairwise or in a sequential manner to reinforce or diversify secretory 
transport processes, because earlier RNA interference (RNAi) studies revealed that only 
pairwise KD of different ARF isoforms caused aberrations in the secretory pathway(22-24). The 
finding that ARF4 loss alone was sufficient to render cells BFA-resistant was therefore not 
anticipated and hinted at a discrete role of ARF4 not shared with other ARFs. Our screen 
recovered GT integrations only in ARF4 but not in any other ARF locus. To rule out the 
possibility that all ARFs but ARF4 were false negatives either due essentiality of the other ARFs  
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Figure A-1. Loss of ARF4 provides resistance to several Golgi-disrupting agents 
(a) Mutagenized KBM7 cells were grown for 3 weeks in the presence of 50 ng/mL (180 nM) BFA 
after which genomic DNA of the surviving cells was isolated, and the GT insertion sites 
determined by deep sequencing and alignment to the genome. The number of independent 
insertions per gene was determined (represented by the circle size) and compared with that of 
an unselected mutagenized cell population from which enrichment scores (p-values) were 
derived (y axis). GT insertions were ordered along the x axis based on their chromosomal 
position. The two genes that were most enriched compared with an untreated control dataset 
were ARF4 (37 GTs; p<8.39x10-110) and C5orf44/TRAPPC13 (12 GTs; p<7.86x10-29). 
(b) Viability of several cancer cell lines infected with control or ARF4 hairpins in response to 
BFA. Survival ratio was calculated by dividing cell numbers of BFA-treated cells by their 
corresponding counterparts under untreated conditions (with the exception of U251 cells whose 
viability was measured using the CellTiterGlo (CTG) assay). Shown are the means and S.D. of 
ARF4 KD and control cells and are examples of multiple representative experiments with n=2 
for each condition and genotype with the exception of U251 ARF4 KD and their respective 
control cells for which n=10. Average controls refers to the averaged mean survival ratio of two 
to four different control hairpin-infected cell lines (shLUC, shRFP, shGFP) whose survival ratio 
is shown as the mean and S.E.M.  Treatment duration, BFA concentrations, and p-values are as 
follows: HeLa: 3 days 30 ng/mL BFA treatment, p<0.04 for both ARF4 shRNAs; HT29: 5 days 
30 ng/mL BFA treatment; p<0.033 for both ARF4 shRNAs; U251: 3 days 30 ng/mL BFA 
treatment, p=1.06x10-14 (for shARF4#1) and p=5.72x10-23 for shARF4#2); A549: 3 days 40 
ng/mL BFA treatment, p<0.005 for both ARF4 shRNAs. Significance was determined using 
student’s 2-tailed t-test (1-tailed for HT29 KD cells). 
(c) Survival ratios of control and ARF4-depleted cells in response to BFA, Exo1 and GCA 
treatment as determined by counting surviving cells under treated and untreated conditions. 
Concentrations of compounds used were 20 ng/mL BFA, 2 µM GCA or 75 µM Exo1, treatment 
duration was 3 days. P-values are as follows (n=3): 2 µM GCA: p<0.0003 for both ARF4 
shRNAs; 20 ng/mL BFA: p<0.018 for both ARF4 shRNAs; 75 µM Exo1: p<0.00025 for both 
ARF4 shRNAs. 







Figure A-2. Effect of BFA and other compounds on ARF4 and ARF5 knockdown cells 
(a) ARF4 knockdown validation of HT29 and A549 cells infected with ARF4 hairpins. 
(b) U251 cells lentivirally-transduced with control or ARF4 shRNAs were seeded in 96-well 
plates and treated for 3 days with or without indicated drugs before assessing cell viability using 
the CTG assay. ARF4 KD cells are protected against BFA and GCA but not against TM, TG, or 
A23187 compared with control cells. Drug concentrations used and abbreviations are: 30 ng/mL 
Brefeldin A (BFA), 3 µM Golgicide A (GCA), 500 ng/mL Tunicamycin (TM), 5 nM Thapsigargin 
(TG) and 1 µg/mL A23187. 
(c) ARF4 or ARF5 depletion in HeLa cells causes resistance and hypersensitivity to BFA, 
respectively. Cells were left untreated or treated for 3 days with 7.5 ng/mL BFA, and the survival 
ratio was calculated by counting the number of surviving cells in the presence and absence of 
BFA. It is likely that the ARF4 antibody used for Western blotting also weakly recognizes ARF5 
which is 90% identical to ARF4 (full length ARF4 was used as immunogen for antibody 
production) as there seems to be a slight ARF4 signal reduction upon ARF5 depletion in this 
particular cell line. 
(d) KD of ARF5 in PANC1 cells shows that its loss makes cells more BFA-sensitive similar as in 
(c). Treatment duration was 4 days and 40 ng/mL BFA was used. Viability score was calculated 
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or potential limitations associated with our screening approach such as insertion site 
preferences of the retroviral GT vector, we depleted several cell lines individually of each ARF 
family member by transduction with lentiviral hairpins. Reassuringly, when we knocked down 
ARF5, the other class II ARF, in HeLa or PANC1 cells, no BFA-resistance was observed. 
Instead, these cells were more sensitive to BFA than controls (Figure A-2C and 2D). Lentivirus-
mediated depletion of ARF1 using multiple independent hairpins caused lethality in A549, HeLa, 
MCF7, PC3, HEK293T and PANC1 cells indicating that ARF1 function is essential (data not 
shown). We therefore repeated the infection with a several-fold lower virus titer to generate cells 
with reduced ARF1 expression yet compatible with survival. Reminiscent of ARF5 loss of 
function cells, ARF1-depleted cells were hypersensitive to BFA treatment. Therefore, loss of 
ARF4 protects against whereas loss of ARF1 or ARF5 sensitizes to BFA suggesting a unique 
function for ARF4 in BFA-resistance.  
 Given the protection of ARF4 KD cells from the cell-lethal effects of lower BFA 
concentrations, Golgi morphology was assessed next by immunofluorescence (IF). No obvious 
difference was detected between control and ARF4 KD cells under untreated conditions when 
stained for Giantin, GM130, or GBF1 (Figure A-3A and Figure A-4A). BFA treatment of cells 
infected with control hairpins promoted a diffuse appearance of the Golgi markers throughout 
the cytoplasm indicative of Golgi disassembly. Strikingly, most cells depleted of ARF4 displayed 
a normal Golgi morphology after BFA application similar to Golgi staining pattern in untreated 
conditions (Figure A-3 and Figure A-4B). In agreement with these results, general protein 
secretion was not inhibited by BFA in cells lacking ARF4 compared with control cells (Figure A-
3B). Moreover, Hemagglutinin (HA) glycan maturation of cells infected with influenza A virus or 
class I MHC receptor trafficking was blocked in BFA-treated control cells but not in ARF4 KD 
cells (Figure A-3C and Figure A-4C). Thus, the integrity and functionality of the Golgi and 
secretory pathway following treatment with low BFA concentrations are preserved in ARF4-
depleted cells. Under acute short-term treatment with high BFA  
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Figure A-3: ARF4 depletion preserves Golgi morphology and protein trafficking upon 
BFA treatment 
(a) Representative IF images of one control and two ARF4 KD A549 cell lines reveal that ARF4 
function is critical for Golgi dispersal upon BFA treatment as assessed by staining for the Golgi 
and ERGIC markers GBF1 and Giantin. Cells were treated with 20 ng/mL BFA for 29 hours. 
(b) HeLa cells infected with either of two control (shLUC and shRFP) or ARF4 hairpins were 
metabolically labeled for 4 hours, and the amount of total proteins secreted into the culture 
media was assessed by SDS-PAGE. In the presence of 50 ng/mL BFA secretory trafficking 
persists in cells without ARF4 but not in the control cells. 
(c) Control or ARF4-depleted cells were infected with influenza A virus at low pH. Influenza-
derived Hemagglutinin A (HA)-trafficking through the secretory system was analyzed after a 
pulse of radioactive-labeled Met/Cys followed by a chase with cold Met/Cys. The results show 
that HA glycan-processing is not disrupted in the presence of BFA in cells without ARF4. HA0 is 
the full length HA that forms in the ER and trafficks through the Golgi. HA1 refers to HA that has 
reached the cell surface and is cleaved by Trypsin added to the chase media. See Methods 
section for further details. 
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Figure A-4. Protection against BFA treatment upon loss of ARF4 in HeLa cells 
(a, b) Golgi morphology is preserved in ARF4-depleted cells but not control cells upon treatment 
with low BFA concentrations. Shown are IF images of cells stained for the cis-Golgi marker 
GM130 and DNA (Hoechst). BFA treatment fragments the Golgi complex in control but not in 
ARF4 KD cells. (a) Cells left untreated, and (b) cells treated for one hour with 40 ng/mL BFA. 
(c) Pulse/chase labeling experiment following MHC class I receptor trafficking (revealed by 
immunoprecipitation with the W6/32 antibody) with or without BFA treatment demonstrates that 
a functional secretory pathway persists in ARF4 KD HeLa cells despite the presence of 50 
ng/mL BFA.  
(d) Short term treatment with a high BFA dose of A549 cells transduced with indicated hairpins 
disperses the Golgi both in control and ARF4 KD cells. 
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concentrations, however, GBF1 staining appeared dispersed in ARF4 KD cells similar to 
controls indicative of a disrupted Golgi (Figure A-4D).  
 Compensatory ARF upregulation in cells with downregulated ARF4 function 
Expression of activated forms of ARF1 or Rab1 and increased GBF1 or BIG2 expression were 
described to protect against Golgi disintegration upon BFA application(25-29). However, no 
obvious alterations in expression levels of GBF1, BIG1 and BIG2, several Golgi-matrix proteins 
(GM130, GRASP65, Giantin, Golgin-84), or Rab1b were detected under basal conditions in 
ARF4 KD protein lysates (Figure A-5A and 5B). The ARF1 monoclonal 1D9 antibody is a pan-
ARF antibody recognizing ARF1, ARF3, ARF5, ARF6, and to lesser extent ARF4. Using this 
antibody, increased expression was observed in multiple cancer cell lines including U251, PC3, 
DU145, HT29, 786-0, MDA-MB231, PANC1, and HeLa cells (Figure A-5A-C). We also tested a 
panel of additional ARF antibodies that discriminate ARF isoforms. Enhanced ARF1, ARF3, and 
ARF5 expression but not ARF6 was detected upon ARF4 loss (Figure A-5A and 5B). To assess 
whether increased ARF levels translated into activity changes, an ARF-pull-down assay was 
employed(30). In agreement with the observed pan-ARF expression changes, ARF activity 
increased 1.5-2 fold in untreated or BFA-treated HeLa and PC3 ARF4 KD cells compared with 
control cells (Figure A-5A and 5B). 
 Based on these findings, we surmised that increased ARF1, ARF3 and ARF5 expression 
might play causative roles in ARF4-depleted cells levels endowing them with the capacity to 
withstand BFA toxicity. Accordingly, stable overexpression of either ARF1 or ARF5 alone but 
not ARF4 was sufficient to enhance cellular survival in the presence of BFA (Figure A-7). We 
next asked whether blocking ARF1, ARF3, or ARF5 function in cells without ARF4 might 
reverse BFA resistance. To test this we re-infected stable ARF4 KD or control cells with 
lentiviral ARF1, ARF3, or ARF5 hairpin vectors carrying different antibiotic markers to select for 
double-KD (DKD) cells. ARF1 ARF4 DKD and control cells were then grown in the presence or 
absence of BFA for several days, and their survival ratio was calculated. Strikingly, while ARF4  
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Figure A-5. Compensatory upregulation of other ARF family members in ARF4 
knockdown cells 
(a-c) Several cancer cell lines were transduced with lentiviral control hairpins or shRNAs against 
ARF4, and cell lysates were probed with the indicated antibodies. 
(a, b) Stable hairpin-control or ARF4 KD PC3 (a) or HeLa (b) cells were analyzed for total ARF-
GTP levels in the absence or presence of 20 ng/mL BFA (24 hours treatment) using a GST-
VHS-GAT pull-down assay. In this assay, increased ARF binding to VHS-GAT, a truncated 
GGA3 form and ARF-substrate that is bound only when ARFs are GTP-loaded, serves as proxy 
for ARF activity. A representative example of a quantification of ARF-GTP levels in HeLa cells is 
shown (n=2; note that we omitted the shRFP control in the bar graph for this particular analysis. 
AU= arbitrary units). The corresponding protein lysates for the samples used in (a) and (b) were 
tested with indicated antibodies. 
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Figure A-6: ARF3 function in ARF4-deleted cells is not critical to confer BFA resistance 
A549 cells simultaneously depleted for ARF3 and ARF4 display the ARF4 single KD phenotype 
indicating a negligible role of ARF3 for BFA resistance upon loss of ARF4. Cells were treated for 
3 days with 20 ng/mL BFA or left untreated, and surviving cells were counted in both conditions 
to calculate the survival ratios. Western blotting confirms KD of ARF3 and ARF4 in these cells. 
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KD cells re-infected with shLUC or shRFP hairpins were BFA-resistant, ARF1 ARF4 DKD cells 
displayed up to 60% lower survival comparable to cells that had been successively infected with 
two innocuous hairpins (i.e. vector control + shLUC or shRFP) (Figure A-7B). We also found 
that ARF4 ARF5 DKD cells had a significantly lower survival ratio compared with ARF4 KD cells 
re-infected with control hairpins (Figure A-7C). Unlike ARF1 ARF4 or ARF4 ARF5 co-depletion, 
survival of BFA-exposed ARF3 ARF4 DKD cells did not differ from ARF4 KD cells infected with 
control hairpins suggesting that BFA protection against BFA occurs at the early Golgi but not at 
the TGN where ARF3 localizes(31) (Figure A-6). GBF1 acts as a GEF for several ARF isoforms 
including ARF1, ARF4, and ARF5 and is the rate-limiting factor to control their activity at the 
ERGIC and early Golgi(32). Downregulation of GBF1 therefore inhibits ARF activity, and GBF1 
depletion should be functionally equivalent to ARF1 and ARF5 loss. Cells infected with both a 
control and a GBF1 hairpin showed a similar survival ratio as cells  
infected with control hairpins upon BFA treatment, unlike ARF4 LUC DKD cells that were largely 
resistant to BFA. Strikingly, ARF4 GBF1 DKD cells were BFA-sensitive and displayed the same 
survival as single GBF1 KD cells (Figure A-7D). In summary, resistance of ARF4-depleted cells 
is abrogated upon ARF1, ARF5, or GBF1, but not ARF3 co-depletion, demonstrating that BFA 
resistance following ARF4 loss depends on compensatory accumulation of other ARF isoforms 
or GBF1. When DKD protein lysates were analyzed for ARF4 expression, we found that loss of 
ARF1 or GBF1 entailed the re-emergence of ARF4 expression both in vector control and ARF4-
haripin infected cells indicative of a coordinate regulation of their expression (Figure A-7).  
Golgi stress causes ARF4 induction mediated through CREB3/Luman 
During this study we made the observation that most of the analyzed cancer cell lines 
upregulated ARF4 levels upon BFA treatment (Figure A-9A). In addition, treatment with GCA, 
Exo1 or Monensin enhanced ARF4 expression independent of general ER stress induction 
since GRP78 or CHOP levels were unchanged in Exo1 treated cells, and Tunicamycin or  
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Figure A-7: BFA resistance of ARF4-depleted cells depends on ARF1, ARF5 and GBF1 
(a) Stable overexpression of C-terminally tagged ARF1 or ARF5 but not ARF4 in A549 cells 
increases viability of BFA-treated cells. Treatment duration was 3 days, and cell viability was 
assessed by the CTG assay measuring 12 wells of each genotype and condition. At a 
concentration of 20 ng/mL but not 40 ng/mL BFA ARF4 overproduction slightly sensitized to the 
drug (p=0.015) despite its weak expression. P-values (for both BFA concentrations) are 
p<1.8x10-11 and p<4x10-5 for ARF1 and ARF5 overexpression, respectively. 
(b) A reduction of ARF1 function in ARF4 KD A549 cells negates BFA resistance observed in 
ARF4 single KD cells as determined by coulter counter measurement (p-values of BFA-treated 
samples (compared with the mean of the two average survival ratios of shLUC shARF4 and 
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Figure A-7 (Continued) shRFP shARF4 DKD controls) are: shARF4 shARF1#1: p<0.046; 
shARF4 shARF1#2: p<0.017; shARF4 shARF1#3: p<0.005). 
(c) ARF4 ARF5 co-depletion makes A549 cells significantly less resistant to BFA in comparison 
to DKD controls. P-values are (compared to the averaged cell number ratios of shLUC and 
shRFP under BFA-treated conditions): p<0.0066 (ARF5#1) and p<0.014 (ARF5#2). 
(d) Removing GBF1 function makes ARF4 KD cells as sensitive to undergo apoptosis upon BFA 
treatment as GBF1 single KD cells. P-values for ARF4#1 DKD cells (BFA treatment): p<0.0066 
(GBF1#1); p<0.0065 (GBF1#3). P-values for ARF4#2 DKD cells: p<0.03 (GBF1#1); p<0.02 
(GBF1#3). Western blot analysis of co-depleted cells are presented to confirm KD of the 
indicated proteins. Note the upregulation of ARF4 levels in ARF1- or GBF1-deprived cells. 





Figure A-8. Effect of Golgi stress treatments and CREB3 expression on ARFs and ARF-
GEFs  
(a) Shown are quantitative real-time PCR analyses of BFA treated and vehicle treated cells 
(treatment duration was 29 hours, and cells were either vehicle-treated or with 20 ng/mL BFA). 
P-values (student’s 2-tailed t-test) are as follows: for GBF1, p<0.01 and p<0.004 (A549 and 
HeLa, respectively); BIG1, p<0.05 and p<0.009 (A549 and HeLa, respectively); BIG2, p<0.001 
and p<0.004 (A549 and HeLa, respectively). 
(b) HeLa and A549 cells were co-treated with BFA and two different doses of the protein 
synthesis inhibitor Cycloheximide (CHX) for 29 hours with the indicated concentrations. 
(c) Stable Flag-CREB3 and control (Flag-γTubulin) protein-expressing HeLa cells were left 
untreated or treated for 24 hours with 10 ng/mL BFA before cell lysis, and the lysates tested for 
ARF isoforms and ER stress marker expression by immunoblotting. 
(d) A549 cells infected with control or CREB3 hairpins were treated for 24 hours with several 
Golgi stressors and the lysates probed with the indicated antibodies after SDS-PAGE. Note 
ARF1 induction upon CREB3 downregulation. 
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Thapsigargin had minimal effects on ARF4 levels (Figure A-9B and 9C). Interestingly, 
Thapsigargin treatment was reported to induce Golgi fragmentation, which might explain the 
slightly increased ARF4 levels(33). To test if ARF4 upregulation could be prevented by 
antagonizing BFA-induced Golgi dispersal, cells were simultaneously treated with BFA and H-
89 or Forskolin, respectively. H-89 is a non-selective, cell permeable protein kinase inhibitor that 
sustains Golgi morphology and ARF1-GTP levels in the presence of BFA, and Forskolin acts 
through a BFA-detoxification mechanism and accordingly renders cells less susceptible to 
BFA(2, 34, 35). Indeed, H-89 or Forskolin mitigated ARF4 upregulation in a dose-dependent 
manner when co-treated with BFA, which was paralleled by UPR marker expression (Figure A-
9D and 9E). ARF4 levels therefore correlate with Golgi integrity with low ARF4 expression under 
basal conditions but increased levels following certain stress conditions impinging on Golgi 
homeostasis.  
 Quantitative real-time PCR analysis revealed that ARF4 is transcriptionally induced  
upon BFA treatment (Figure A-11A). Although all other ARFs trended towards increased 
expression following BFA exposure, only ARF1  reached significance, however, to a lower 
magnitude than ARF4. In addition to the ARFs, transcript levels of the three GEFs BIG1, BIG2, 
and GBF1 became upregulated in the presence of BFA (Figure A-8A). As shown earlier for 
GBF1, we also saw a concomitant increase in protein levels following BFA treatment. This 
increase was prevented by co-treatment of Cycloheximide and BFA (Figure A-8B). This 
indicates that ARF4 expression is controlled via new mRNA and protein production. 
It was reported that phorbol 12-myristate 13-acetate (PMA) treatment induces ARF4 
expression, in a manner dependent on sLZIP, a CREB3 (also called Luman or LZIP) isoform 
lacking the transmembrane domain(36). CREB3 is a basic leucine zipper (bLZIP) ER-bound 
transcription factor that is proteolytically cleaved following activation in the Golgi apparatus by 
site-1 protease (S1P) and site-2 protease (S2P), then enters the nucleus where it binds as a 
homodimer to canonical cAMP-response elements (CRE) to enhance transcription of its  
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Figure A-9: Golgi stress causes ARF4 upregulation 
(a) Several cancer cell lines were cultured with or without 20 ng/mL BFA for 29 hours before cell 
lysis, and protein extracts were analyzed with the indicated antibodies. Note the induction of 
ARF4 and GBF1 levels in the presence of BFA. 
(b) A549 cells were left untreated or exposed to 40 ng/mL BFA, 5 µM GCA, 75 µM Exo1 or 10 
µM Monensin for 29 hours revealing increased ARF4 expression. 
(c) Immunoblots showing ARF4 and ER stress marker expression of HeLa and A549 cells 
treated for 29 hours with following compounds and concentrations: lane 1: untreated, lanes 2 
and 3 Brefeldin A (BFA; used at 10 ng/mL= 36 nM and 50 ng/mL= 180 nM); lanes 4-6: 
Tunicamycin (TM; used at 100 ng/mL (119 nM), 500 ng/mL (597 nM) and 2 mg/mL (2.39 µM); 
lanes 7-9: Thapsigargin (TG; used at 10 nM, 100 nM and 500 nM); lane 10: Golgicide A (GCA; 
used at 5 µM). 
(d, e) Co-treatment of A549 or HeLa cells with BFA and increasing amounts of H-89 or 
Forskolin, two compounds that antagonize BFA-induced Golgi dispersal, mitigates upregulation 
of ARF4 and UPR parameters.  
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Figure A-10. Involvement and regulation of CREB3 and S1P in Golgi stress-induced ARF4 
induction 
(a) Lentivirally-transduced HeLa cells stably expressing Flag-CREB3 were left untreated or 
treated for 23 hours with 20 ng/mL BFA, 5 µM GCA, 75 µM Exo1 or 10 µM Monensin before 
fixation and immunofluorescent staining to assess CREB3 localization and Golgi morphology. 
(b) Simultaneous treatment for 28 hours of A549 cells with 10 ng/mL BFA and either of two 
different serine protease inhibitors, AEBSF or PF-429242 mitigates ARF4 upregulation in a 
dose-dependent manner. 
(c) Pharmacological inhibition of S1P in the presence of several Golgi stress agents decreases 
ARF4 expression compared with BFA only-treated HeLa cells. Treatment duration was 29 hours 
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targets(37). How ARF4 levels are regulated upon BFA treatment is unknown. To test if BFA-
induced ARF4 expression requires CREB3, several cell lines were infected with CREB3 hairpins 
to deplete CREB3. Upon BFA treatment CREB3 KD A549 cells displayed substantially reduced 
ARF4 levels paralleled by GRP78 and CHOP downregulation compared to control cells  (Figure 
A-11B). Similar results were obtained in PC3, PANC1, or MDA-MB231 cells demonstrating that 
CREB3 is a conserved mediator of the cellular response to BFA (Figure A-11C). Further 
strengthening this link, we found that CREB3 downregulation promoted ARF1 induction (Figure 
A-8D). Hence, CREB3 KD mirrors loss of ARF4 function. Akin to BFA treatment, CREB3 is also 
required for ARF4 induction in response to GCA, Exo1 and Monensin (Figure A-8D). These 
treatments also activated and redistributed ER-localized CREB3 into the nucleus (Figure A-
10A). Moreover, proteolytic activation of CREB3 and ARF4 upregulation is dependent on S1P, 
because S1P inhibitors (AEBSF and PF-429242) lower CREB3 stabilization and ARF4 
expression in response to BFA, GCA, Exo1 and Monensin (Figure A-10B and 10-C). Western 
blot analysis also revealed that in the presence of BFA CREB3 levels increase beyond the 
weakly detectable levels observed under basal conditions presumably due to inherent 
instability(38, 39) (Figure A-11B and 11C). To assess whether loss of CREB3  alters cellular 
BFA susceptibility, we cultured the KD cells in the absence or presence of the drug. Similar to 
ARF4-depletion, CREB3 KD cells showed enhanced resistance to BFA relative to control cells 
(Figure A-11D). Next, we monitored the effects of CREB3 overexpression on ARF4 levels and 
BFA sensitivity by establishing stable cell lines overexpressing epitope-tagged CREB3. Despite 
only modest CREB3 overexpression levels, ARF4 induction was readily discernable while other 
ARF isoforms were slightly but reproducibly downregulated (Figure A-11E). CREB3 
overexpression sensitized cells to undergo apoptosis in response to BFA correlating with higher 
ARF4 levels and concomitant decrease in the amount of other ARFs (Figure A-11F). 
 
	   242 
 
Figure A-11: CREB3/Luman mediates ARF4 induction upon Golgi stress 
(a) A549 or HeLa cells were vehicle-treated (0.04% ethanol) or treated with 20 ng/mL BFA for 
29 hours, and ARF mRNA levels were assessed by quantitative real-time PCR and normalized 
to 36B4 mRNA expression. Data points are represented as mRNA fold induction compared with 
vehicle-treated samples. Error bars denote S.D. values, and p-values are as follows (student’s 
2-tailed t-test): p=0.019 and 0.0003 for ARF4, and p=0.0015 and 0.01 for ARF1 (A549 and 
HeLa, respectively). All other p-values were not significant. 
(b, c) Lentiviral-mediated KD of CREB3 in A549 (b), PC3, PANC1, or MDA-MB231 (c) in the 
presence of BFA reduces ARF4 expression relative to control hairpin-infected cells. BFA 
concentrations used were 20 ng/mL except for PANC1 (40 ng/mL), and treatment durations 
were 29 hours (A549 cells), 27 hours (PC3), 22 hours (PANC1), or 30 hours (MDA-MB231). 
 
 


















Figure A-11 (Continued) (d) shRNA-mediated CREB3 downregulation increases viability of 
BFA-treated A549 or PC3 cells in comparison to control cells. All p-values (n=2) for A549 and 
PC3 cells (20 ng/mL BFA) are < 0.05. 
(e) Stable CREB3 overexpression is sufficient to elevate endogenous ARF4 levels in PANC1 or 
HEK293T cells. Upon overexpression, two bands could be detected by Western blotting when 
antibodies against the Flag-epitope or endogenous CREB3 were used. The predominant band 
detected in most cell lines when probed for endogenous CREB3 is the upper band 
(approximately 50 kDa, corresponding to the full length form), and a lower band (approximately 
35-40 kDa) is occasionally discernable and might represent S1P/S2P-mediated cleavage 
products(40). * denotes unspecific band. 
(f) Increased BFA susceptibility of stable cell lines overexpressing CREB3. P-values for PANC1 
and HEK293T cells: p=0.04 for both (using 30 ng/mL BFA) and p=0.0005 or p=0.001, 
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We wondered whether the increased BFA sensitivity of ARF1 or GBF1 KD cells and 
reemergence of ARF4 expression in these cells (Figure A-7) might be associated with altered 
CREB3 localization. To this end A549 GBF1 or ARF1 KD and control cells were transfected with 
a Flag-CREB3 overexpression vector and CREB3 localization tested by immunostaining. Similar 
to BFA treatment, ARF1 KD or GBF1 KD resulted in CREB3 accumulation in the nucleus 
presumably caused by partial Golgi fragmentation providing a possible explanation for 
enhanced ARF4 expression. 
Loss of ARF4 protects against propagation of several pathogens  
While BFA chemically induces Golgi dispersal, two intracellular bacterial pathogens, Chlamydia 
trachomatis and Shigella flexneri, naturally subvert host trafficking pathways to acquire lipids 
and disrupt cytokine secretion by inducing Golgi fragmentation(41). We hypothesized infection-
mediated Golgi disruption was similar to BFA treatment, and therefore ARF4 KD cells may 
prevent efficient pathogen growth. When we tested the effects of Chlamydia infection on ARF4, 
no appreciable upregulation was detected in control cells. A slight boost in ARF4 expression 
was detected in ARF4 KD cells (Figure A-13). We wondered whether the life cycle of either 
Chlamydia or Shigella might be affected by ARF4 loss since its depletion protected against 
chemically-induced Golgi disruption. We infected control and ARF4 KD HeLa cells with 
Chlamydia or Shigella, and growth was assessed at various time points after infection. For both 
pathogens no significant replication level differences between control and ARF4-deprived cells 
were detected early, indicating that invasion of ARF4-depleted cells is not disrupted. However, 
we noted defects in persistence/growth for both pathogens late during infection. 48 hours post-
infection Chlamydia replication was reduced by about 40-60% with two independent hairpins 
against ARF4 using a quantitative PCR assay (Figure A-12A). Because Chlamydia must 
complete a biphasic lifecycle to invade new host cells, we examined the production of infectious 
progeny in control or ARF4-deprived cells and found depletion inhibited the production of  
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Figure A-12: ARF4 loss protects against several intracellular pathogens 
(a, b) Intracellular replication and infectivity of C. trachomatis is inhibited upon loss of ARF4 in 
HeLa cells. (a) Quantitative PCR analysis of cells infected with C. trachomatis shows a 
significant decrease of bacterial genomes present after 48 hours but not after 12 hours in ARF4 
KD cells relative to controls. (b) Representative IF images of wild type HeLa cells infected with 
C. trachomatis progeny produced from shRFP or ARF4 hairpin-infected cells reveal significant 
differences in infectivity. C. trachomatis inclusions are represented in green (stained for C. 
trachomatis major outer membrane protein (MOMP)), and cells were counter-stained with Evans 
Blue. The right upper panel shows inclusion forming unit (IFU) quantification. The lower right 
graph displays a quantification of cellular NBD-ceramide labeling demonstrating a lower 
fluorescent ceramide content in control cells relative to shARF4 cells (AU= arbitrary units). Cells 
were pulsed for one hour with NBD-ceramide. Six biological replicates were measured per 
genotype, p<0.05 (one-way ANOVA) and the experiment was performed twice. Bar graphs 
depict average values, and error bars correspond to S.D. 
 (c) Increased ARF4 expression enhances growth of C. trachomatis. HeLa cells were analyzed 
for inclusion formation 48 hours post-infection, p<0.05 using one-way ANOVA. Two 
independent experiments yielding qualitatively similar results have been performed using six 
biological replicates of each genotype. 
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Figure A-12 (Continued) (d) Decreased S. flexneri growth upon ARF depletion. Cells were 
infected with S. flexneri and treated with Gentamicin. The cells were then lysed at various time 
points after and dilution plating was used to count the number of bacterial colonies present 
(CFU=colony forming units). In (a-c) one-way ANOVA was used to calculate the p-values. All p-
values comparing the individual controls and the two different shARF4 hairpins were p<0.05. 
Results are representative of at least two independent experiments with three to six biological 




Figure A-13: Resistance of ARF4 KD cells to C. trachomatis and S. flexneri is mimicked 
by CREB3 loss of function and depends on ARF5 and GBF1 
(a) HeLa cells transduced with lentiviral control or ARF4 hairpins were infected with C. 
trachomatis, and cells were lysed 30 or 36 hours after infection. Blots were probed with 
indicated antibodies. Ctr. HSP60 refers to C. trachomatis HSP60. 
 

















Figure A-13 (Continued) (b) HeLa ARF4 KD and control cells were infected with Chlamydia, 
and 30 hours post-infection cells were fixed and stained for Chlamydia HSP60 (red), GM130 
(green) and DNA (blue). Arrows point to Chlamydia-infected cells and the effects on the Golgi 
apparatus. 
(c) HeLa DKD cells were infected with C. trachomatis and bacterial progeny tested for their 
ability to form inclusions in wild type HeLa cells (48 hours post-infection). Statistically significant 
differences using one-way ANOVA, were observed between ARF4 DKD control cells and ARF4 
GBF1; 4 biological replicates were measured per genotype. The graphs show the means ± SD. 
(d) Immunoblots of cell lysates from HeLa DKD cells used in (c). 
(e) Loss of CREB3 impairs S. flexneri growth (gentamicin protection assay was done 20 hours 
post-infection) and inhibits C. trachomatis reproduction (analysis done 40 hours post-infection). 
Both experiments have been repeated twice with n=3-4 and  p≤0.05 using Student’s t-test or 
one-way ANOVA test. Shown are the means ± SD.   
(f) Western blot analysis of HeLa CREB3 KD cells used for S. flexneri and C. trachomatis 
infection as shown in (e). Cell lysates were derived from both untreated cells and cells treated 
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inclusion-forming units (IFU) (Figure A-12B). We noted that 8 hours following Shigella infection 
there was a two-fold reduction in intracellular bacteria in shARF4 cells, a phenotype that 
became even stronger after 20 hours when intracellular persistence was reduced about 70-100-
fold (Figure A-12D). Both Shigella and Chlamydia directly target ARF1-dependent pathways 
during infection(42). We also examined the growth of the pathogen Salmonella enterica serovar 
typhimurium that does not fragment the Golgi during intracellular replication. However, no 
survival defect was observed in ARF4-depleted cells compared to control cells (data not 
shown). This shows that restriction of both Chlamydia and Shigella, two pathogens with distinct 
intracellular lifestyles, may be due directly to defects in Golgi fragmentation and not pleiotropic 
effects of ARF4 depletion. 
We further examined the mechanisms driving resistance to Chlamydia infection following 
a reduction in ARF4 levels. One requirement for Chlamydia propagation is sphingomyelin, which 
is synthesized from ceramide produced in the ER, and actively acquired by the bacteria(43). 
Blocking Golgi fragmentation in infected cells via chemical inhibition prevents efficient uptake of 
ceramide into the inclusion(41). We assessed the consequences of adding fluorescent NBD-C6-
ceramide to control and ARF4 hairpin-infected HeLa cells. The results show a significant 
reduction of intracellular ceramide accumulation upon loss of ARF4 (Figure A-12B) raising the 
possibility that sphingolipid transfer to the inclusion may be compromised. Using IF microscopy 
we assessed Golgi morphology of Chlamydia-infected cells. GM130 staining presented more 
discernable and pronounced in ARF4 KD cells with a more compact and dense appearance, 
whereas shRFP cells displayed a thinner structure and more dispersed Golgi elements 
(ministacks) (Figure A-13B). Complementary to the ARF4 loss of function phenotype, ARF4 but 
not ARF1 or ARF5 overexpression enhanced Chlamydia replication (Figure A-12C). 
Previous work showed that loss of ARF1 or GBF1 enhances Chlamydia infection 
suggesting that enhanced ARF activity limits replication(44, 45). We hypothesized that the 
compensatory increase in ARF1 and/or ARF5 may underlie the resistance of ARF4 KD cells to 
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Chlamydia growth, similar to BFA resistance. To test this we established the corresponding 
DKD HeLa cells and examined whether increased resistance to Chlamydia is affected in cells 
co-depleted of ARF4 and other ARF isoforms or GBF1. Since we were not able to establish 
ARF1 ARF4 DKD HeLa cells due to lethality, our analysis was restricted to the remaining ARF4 
DKD combinations. In line with our earlier results, the absence of both GBF1 and ARF4 
enhanced the production of infectious Chlamydia compared with control ARF4 DKD cells 
(shARF4 shGFP and shARF4 shRFP). Combinatorial loss of both ARF4 and ARF5 led to a 
slight recovery of bacterial growth, but not to the levels of GBF1, suggesting an important role of 
ARF1 in bacterial growth. ARF3 depletion was without effect (Figure A-13C and 13D). These 
data show that bacterial restriction in ARF4 KD cells is driven by the compensatory upregulation 
of other ARFs similar to BFA treatment. 
Since CREB3 regulates ARF4 expression and sensitivity to BFA (Figure A-12), we also 
assessed its effects on the survival of Chlamydia and Shigella. HeLa CREB3 KD cells were 
subjected to the same pathogen infection assays as described above. We found that these cells 
were several-fold more resistant to both pathogens relative to controls (Figure A-13E). 
Interestingly, under basal conditions we noted higher expression of ARF1 in CREB3 KD cells, 
consistent with the upregulation and pathogen restriction seen in ARF4 KD cells (Figure A-13F). 
Thus, these data suggest that a CREB3-ARF4 signaling pathway mediates the survival 
response to a number of pharmacological Golgi-perturbing agents and certain Golgi-
fragmenting pathogens.  
 
Discussion 
We have identified ARF4, one of the five human members of the ARF family of small G proteins, 
in a loss of function viability screen in human cells for genes providing resistance to BFA. The 
ARF family members are regarded as providing overlapping functions such that depletion of any 
single ARF does not cause discernable secretory trafficking pathway alterations. Volpicelli-
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Daley et al. (2005) used siRNA treatment of HeLa cells to deplete ARFs individually or in 
pairwise combinations, but no effects on the levels of other ARF isoforms were reported. We, 
however, found increased expression of other ARFs upon lentiviral-mediated downregulation of 
ARF4. A possible explanation could be differences in the ARF KD levels achieved in each 
respective study. Here, we have shown that ARF4 KD is sufficient to make cells resistant to 
BFA, GCA or Exo1, which is the opposite phenotype compared with ARF1- or ARF5-depleted 
cells. Cells lacking ARF4 preserve Golgi integrity and function even in the presence of BFA, and 
we found upregulated ARF1, ARF3 and ARF5 levels accompanied by increased pan-ARF 
activity in these cells. Furthermore we discovered that BFA exposure increased the levels of 
GBF1, BIG and BIG2. Altogether, these findings suggest that the combination of enhanced ARF 
and ARF-GEF levels in ARF4-depleted cells enables them to cope with toxic BFA 
concentrations allowing to sustain secretory pathway activity and hence survival in the presence 
of the drug. In agreement with this model, downregulation of ARF1, ARF5, and GBF1, but not 
ARF3, in ARF4 loss of function cells restored BFA sensitivity.  
 In addition to conferring resistance to several Golgi-disassembling agents, we found that 
ARF4 and CREB3 depletion protected against intracellular growth of two pathogenic bacteria, 
C. trachomatis and S. flexneri that cause Golgi fragmentation upon infection. It is likely that 
intracellular trafficking pathways important for bacterial nutrient supply or to escape host 
defense mechanisms are impaired in these cells(41, 46). For Chlamydia, transport of 
sphingolipids or cholesterol into the inclusion, which depends on Golgi fragmentation, could be 
inhibited upon loss of ARF4(41). Chlamydia and Shigella infect millions every year yet no 
effective vaccine is available(47-50). In light of the increased occurrence of antibiotic resistant 
Chlamydia and Shigella strains and the fact that cells without CREB3 or ARF4 restrict bacterial 
growth, inhibitors that target CREB3/ARF4 functions may become a new treatment option to 
combat a subset of intracellular infections. Altogether, these results suggest that inhibition of 
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ARF4 or CREB3 could prove beneficial in several disease settings to restrict the pathogenicity 
of intracellular pathogens.  
 A further unanticipated finding of this study was that incubation of cells with BFA induced 
ARF4 expression through CREB3. CREB3 belongs to a family of bZIP ER membrane-bound 
transcription factors that also includes OASIS (CREB3L1), BBF2H7 (CREB3L2), CREBH 
(CREB3L3) and CREB4 (CREB3L4/AIbZIP/Tisp40). This family is also related to ATF6α/β, one 
of the three major proximal ER stress transducers, and furthermore shares the same 
mechanism of activation. The functions of CREB3 are ill defined, and whereas several other of 
the five CREB3-like transcription factors are activated in response to ER stress and contribute 
to diversification of the UPR in a cell-type specific manner, there is some debate whether 
CREB3 is induced under ER stress conditions(40, 51-55). ARF1 or GBF1 depletion by RNAi 
caused ARF4 levels to rise indicating that their levels are coordinately regulated. GBF1 
depletion causes relocation of S2P from the Golgi to the ER(56), and we demonstrate that 
inhibition of S1P alleviates CREB3 and ARF4 induction elicited by BFA treatment. Furthermore 
we found that exogenous CREB3 expression in GBF1 KD and ARF1 KD cells leads to its 
nuclear relocation. Presumably full length CREB3 is cleaved by S1P and S2P upon GBF1 or 
ARF1 KD thereby mimicking BFA treatment.  
 We extended the findings made with BFA to three other compounds compromising the 
Golgi – GCA, Exo1 and Monensin – which all increased ARF4 expression suggesting that its 
levels might parallel Golgi integrity or Golgi stress induction. Treatment with these chemicals 
leads to proteolytic CREB3 activation through S1P and S2P followed by its nuclear 
accumulation. What could be the specific Golgi stress stimulus leading to ARF4 induction? GCA 
has a mode of action comparable to BFA by inhibiting ARF1-GBF1 function and potentially other 
ARFs causing COPI vesicle coat dissociation from Golgi membranes(57, 58). The Golgi-
fragmenting effects of Exo1 might be promoted by GTP hydrolysis on all Golgi-localized ARF 
members thereby mimicking reduced ARF activity(59). The cationic ionophore Monensin 
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promotes H+/Na+ exchange, which leads to alkalization of the Golgi lumen causing osmotic 
swelling mainly in late Golgi and post-Golgi/endosomal compartments and a block in 
anterograde and retrograde transport(60-62). Increased ARF4 expression therefore might be 
related to loss of ARF1 from Golgi membranes and/or decreased ARF1 activity leading to 
defects in Golgi integrity. 
 Another question is what the purpose of ARF4 upregulation during Golgi stress might be. 
Whether enhanced ARF4 expression as a result of Golgi stress treatments represents a cellular 
attempt to boost Golgi capacity and thereby to regain sufficient secretory pathway function in 
the presence of BFA, or conversely whether ARF4 induction initiates a so far uncharacterized 
apoptotic program to eliminate cells with irreparable Golgi damage, is not known. It could also 
be that increased ARF4 levels negatively regulate the activities of Golgi-protective ARFs such 
as ARF1. Notwithstanding the precise signaling mechanisms downstream of ARF4, we 
speculate that the Golgi apparatus might actively sense certain stress stimuli and relay a signal 
to the nucleus to induce factors critical for the re-establishment of Golgi homeostasis or to 
trigger pro-apoptotic events if the stress is insurmountable. The proposed signaling pathway 
could therefore be viewed as Golgi stress response comparable to the unfolded protein 
response that is initiated at the ER(63, 64). How Golgi stress might be sensed, and what the 
stress signals are, remains to be further investigated. 
 Golgi fragmentation is a pathological feature of several neurodegenerative diseases 
including amyotrophic lateral sclerosis (ALS), Alzheimer, Parkinson, spinocerebellar ataxia type 
2 (SCA2)(33, 65-67) and is also observed in patients with Niemann-Pick type C (NPC) 
disease(68). In addition, several bacteria and viruses induce Golgi disassembly(69). It is 
therefore possible that these pathologies are associated with Golgi stress induction. Elucidating 
the components acting in this proposed Golgi stress signaling network might thus be valuable in 
identifying novel treatment options for neuronal disorders, cancer, or pathogen-induced disease 
states. 
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METHODS 
General methods. A detailed description of common methods and protocols including 
extraction of DNA and determination of GT insertion sites, proliferation assays, 
immunofluoresecence (IF), and lentivirus production has been described previously(19, 21). 
Briefly, cell viability assays were performed either using a Z2 coulter counter apparatus 
(Beckman Coulter) for direct cell number counts (cells with diameters between 10 and 30 µm 
were counted), or using the CTG assay (Promega). IF pictures were generally acquired with an 
epifluorescence microscope (Zeiss Axiovert 200 M, 63x magnification) equipped with a Zeiss 
AxioCam camera. To acquire the images shown in Supplementary Fig. S6b a Zeiss LSM 710 
NLO Laser Scanning confocal microscope was used. For Western blotting proteins were 
resolved on 4–12% NuPAGE Novex gradient Bis⋅Tris gels (Invitrogen) and transferred onto 
PVDF membranes (Immobilon). IgG-HRP–coupled secondary antibodies (Santa Cruz 
Biotechnology) for immunoblotting were used at 1:5000 in 5% milk/PBS-T for 1 hour incubation 
at room temperature. Proteins bands were visualized with Western Lightning 
chemiluminescence (ECL)/plus-ECL reagent (Perkin-Elmer). 
Cell culture. All cell lines described with the exception of KBM7 cells were grown in standard 
Dulbecco’s medium (DMEM) with 10% heat-inactivated fetal serum (IFS) in the presence of 250 
units/mL penicillin and 250 µg/mL streptomycin. KBM7 cells were grown in Iscove’s modified 
Dulbecco’s medium (IMDM) supplemented with antibiotics. 
Densitometric analyses. Quantification of Western blots presented in Fig. 3b to determine 
normalized ARF-GTP levels was done using ImageJ analysis software (densitometry 
measurement tool). In Fig. 3b, pan-ARF bands were normalized to PAR-4 protein lysate levels, 
which remain unchanged by BFA. 
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Bacterial strains and media. Shigella flexneri serovar 2a WT strain 2457T, Salmonella 
enterica serovar typimurium strain SL1344, and Chlamydia trachomatis serovar L2 434/Bu were 
used in this study and have been previously described(70-72).  
Chlamydia quantitative PCR and Infectious forming unit assays. To assess the levels of C. 
trachomatis present, we used a previously established qPCR method(73). Briefly, we isolated 
nucleic acid from infected cells using the DNeasy kit (Qiagen). Chlamydia 16S DNA was 
quantified by qPCR on an ABI Prism 7000 sequence detection system using primer pairs and 
dual-labeled probes. Using standard curves from known amounts of Chlamydia the levels of 
16S DNA per well was calculated. For IFU experiments control cells or ARF4 KD cells were 
seeded at a density of 5x104 into 24-well plates in triplicate. Cells were infected the following 
day with 5x104 IFU of C. trachomatis for 48 hours. Cells were subsequently lysed and diluted 
1:1000 or 1:10000 and re-seeded into 24- or 96-well plates containing 104 wild type HeLa cells. 
Twenty-four hours following infection, cells were fixed with ice-cold methanol for 30 minutes. 
Cells were washed two times with PBS containing 0.1% Tween. Cells were then stained using 
DAPI and an antibody to C. trachomatis MOMP. Cells were quantified by fluorescence 
microscopy and the mean number of IFU produced by control cells and ARF4 KD cells for each 
well was calculated. 
Gentamicin protection assay. 5x104 control or ARF4 KD cells were seeded in 24-wells plates 
in triplicate. Cells were infected with S. flexneri or S. typhimurium by centrifuging exponential 
phase bacteria diluted in PBS onto semi-confluent monolayers of cells at an MOI of 1:1 at 
700×g for 10 minutes. The cells were subsequently incubated for 20 minutes at 37°C and 5% 
CO2, washed 3 times with PBS, and replaced with media containing gentamicin (25 µg/mL) to 
kill extracellular bacteria. To assess intracellular bacterial number, the cells were then incubated 
for indicated amounts of time in media containing gentamicin, washed 3 times with PBS, and 
lysed in 0.1% sodium deoxycholate/PBS. Cell lysates were then plated on tryptic soy agar 
(TSA) or LB plates, and CFU were counted after overnight incubation at 37°C. 
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NBD C6-ceramide pulse labeling . Control or shARF4 cells were infected with C.trachomatis at 
an MOI of 5 for 20 hours. The media was aspirated and replaced with PBS containing NBD-
Ceramide (Invitrogen) and placed at 37° C for 1 hour. Cells were then washed with PBS and 
replaced with fresh media to allow back exchange of fluorescent ceramide. Five hours following 
pulse, the media was removed and replaced with PBS. Plates were then read using SpectraMax 
M2 plate reader with an excitation/emission of 466/536 nm.  
Virus infections and pulse chase experiments. HeLa cells were grown in 10 cm culture 
dishes and infected with wild type WSN influenza A at an MOI of 0.5 for 4 hours in DMEM 
supplemented with BSA and 1 µg/mL TPCK-treated trypsin. Cells were harvested and 
resuspended in methionine- and cysteine-free DMEM and starved for 45 mins at 37ºC followed 
by a 10 min pulse labeling with [35S]cysteine/methionine (Perkin Elmer) at 0.77mCi/mL and  a 
chase with DMEM containing cold cysteine/methionine for 0, 30 and 60 min. For all 
experiments, 1 µg/mL trypsin was added to the chase media. At indicated time points during 
chase, cell pellets were collected, lysed in buffer containing NP-40 followed by 
immunoprecipitation with flu anti-HA serum.  
Virus fusion with the plasma membrane at low pH. Influenza A in DMEM containing BSA 
and 20 mM MES (pH 5.5) was allowed to bind to HeLa cells (at an MOI of 0.5) for 1 hour at 
room temperature. The binding medium was removed and the cells were incubated for 4 hours 
at 37ºC in DMEM containing BSA and 1 µg/mL of TPCK-treated trypsin. Following infection cells 
were harvested and processed for pulse-chase as described above. 
Trafficking of Class I MHC. HeLa cells infected with control or ARF4 lentiviral hairpins were 
grown in 10 cm dishes. Cells were either vehicle treated or treated with 50 ng/mL Brefeldin A for 
2 hours at 37ºC. Cells (-/+BFA) were harvested and resuspended in methionine- and cysteine-
free DMEM and starved for 45 minutes at 37ºC followed by a 15 min biosynthetic labeling with 
[35S]cysteine/methionine (Perkin Elmer) at 0.77mCi/ml and chase for 0, 30 and 60 minutes 
either in the absence or presence of 50 ng/mL BFA. At indicated time points, cells were lysed in 
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buffer containing NP-40 and subjected to immunoprecipitation using mouse monoclonal W6/32 
anti-HC antibodies, resolved by SDS-PAGE and visualized by autoradiography. 
Assay for total protein secretion. HeLa cells infected with a shLUC control or ARF4 hairpins 
were grown in 10 cm dishes and biosynthetically labeled with [35S]cysteine/methionine (Perkin 
Elmer) at 0.77mCi/ml for 4 hours in DMEM supplemented with inactivated calf serum. Cells 
were either vehicle (ethanol) treated or treated with 50 ng/mL Brefeldin A for 2 hours during the 
course of metabolic labeling. Following BFA treatment, labeling media was replaced with fresh 
media with or without 50 ng/mL BFA. At indicated time points, media was collected, total protein 
precipitated using trichloro acetic acid (TCA) and subjected to SDS-PAGE to resolve total 
secreted proteins. 
Quantitative (Q) real-time PCR. Cells were grown in 6 cm dishes, and mRNA was isolated 
using the RNeasy Plus Mini kit (Qiagen). 1 µg total RNA was used for the reverse transcription 
(RT) reaction using Oligo dT primers and Superscript III (Invitrogen Life Sciences). cDNA was 
diluted 1:15 after RT for subsequent use for Q real-time PCR. SYBR Green PCR master mix 
(Applied Biosystems) was used and reaction volume was 10 µL per q real-time PCR reaction 
(384 well plate run on an ABI 7900 machine). Three biological replicates were analyzed per 
genotype and condition, and two technical replicates were run per biological replicate for 
calculating the mean Ct values.  
VHS-GAT pull-down assay. ARF activity was measured using an ARF pull-down assay 
essentially as described earlier(74). GST-VHS-GAT (VHS-GAT from GGA3) was bacterially 
expressed, and the cell pellet spun down at 4000 rpm-1. The cell pellet was lysed by sonication 
in 20 mL lysis buffer (40 mM Hepes pH 7.4, 150 mM NaCl, 2 mM EDTA, 1 µM DTT and 
protease inhibitor cocktail (Roche) added). The bacterial cell lysate was then centrifuged for 30 
minutes at 20,000 rpm-1, and Glutathione Agarose beads (Thermo Scientific) that had been 
washed two times with PBS and once with bacterial lysis buffer were added to the bacterial 
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supernatant for 1 hour to bind GST-VHS-GAT to the beads. Between 750 µg and 1.5 mg total 
human cell protein extracts (PC3 or HeLa lysed in 1% NP40 lysis buffer) were combined with 60 
µL Glutathione Agarose-GST-VHS-GAT slurry and rotated for 2 hours at 4º C for ARF pull-
down. Immunoprecipitates were washed three times in 1% NP40 lysis buffer before elution in 
50-60 µL 2X sample buffer and boiling for 3 minutes. Eluates were resolved on a 4-12% 
gradient Bis-Tris gel and probed with anti-ARF1(1D9) antibody (pan-ARF). 
Antibodies and reagents. Primary antibodies: mouse anti-GBF1 (BD Transduction 
Laboratories), rabbit anti-Giantin (Abcam), rabbit anti-CREB3 (Abcam), mouse anti-
ARF1(1D9)/pan-ARF (Novus Biologicals), mouse anti-ARF3 (Santa Cruz Biotechnology), rabbit 
anti-ARF4 (Proteintech), mouse anti-ARF5 (Abnova), rabbit anti-ARF6 (Cell Signaling 
Technologies), rabbit anti-Rab1b (Proteintech), rabbit anti-GRP78 (Santa Cruz Biotechnology), 
mouse anti-CHOP (Cell Signaling Technologies), rabbit anti-Golgin-84 (GeneTex), goat anti-
GM130 (Santa Cruz Biotechnology), mouse anti-Ctr. HSP60 (Santa Cruz Biotechnology), rabbit 
anti-GRASP65 (GeneTex), mouse anti-p84 (GeneTex), rabbit anti-GSK3β (Cell Signaling 
Technologies), rabbit anti-BIG1 (Bethyl Laboratories), rabbit anti-BIG2 (Bethyl Laboratories), 
mouse anti-C. trachomatis-MOMP (Fluorescein-conjugated; Biorad). 
Compounds were obtained from following companies: Brefeldin A (Sigma-Aldrich), Golgicide A 
(Santa Cruz Biotechnology), Exo1 (Santa Cruz Biotechnology), H-89 (Santa Cruz 
Biotechnology), Forskolin (Santa Cruz Biotechnology), Monensin (Enzo Life Sciences), AEBSF 
(VWR), PF 429242 (AdooQ BioScience) 
Cloning of CREB3 and ARFs CREB3 was amplified from a HeLa cDNA pool using the primers 
LZIP/SalI and LZIP/NotI, sequence-verified and cloned into pLJM60 yielding N-terminally Flag-
tagged CREB3. EGFPmyc was PCR-amplified using the primers oJR401 and 
oJR402myc/EcoRI and a vector containing EGFP sequence as DNA source. For ARF1myc 
cloning, we used primers oJR447/AgeI and oJR448myc/EcoRI in combination with ARF1-HA 
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cDNA (Addgene plasmid 10830, principal investigator: Thomas Roberts). ARF4myc cDNA was 
PCR-amplified from an A549 cDNA pool using primers oJR403/AgeI and oJR405myc/XbaI. 
ARF5myc cDNA construct was derived from two successive PCR steps: for the first PCR, ARF5 
was amplified out of an A549 cDNA pool with primers oJR439/SalI and oJR440/NotI, for the 
second PCR primers ARF5/AgeI and ARF5myc/EcoRI were used. All PCR products were 
TOPO TA-subcloned and sequence-verified before digestion of the cDNAs and ligation into 
lentiviral expression vectors. 
Transient transfection assays  70,000 GBF1 KD and ARF1 KD or control A549 cells were 
seeded into wells of 12 well cell culture plates and transfected with 100 ng Flag-CREB3 cDNA 
expression vector 24 hours post cell seeding using X-tremeGene 9 transfection reagent 
(Roche). After additional 24 hours, cells were left untreated or treated with 20 ng/mL BFA for 24 
hours before fixation in 4% paraformaldehyde, permeabilization in 0.05% Triton-X in PBS and 
further processing for immunofluorescent staining. 
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Introduction 
Chlamydia trachomatis is predicted to secrete over 100 virulence determinants directly into the 
host cell cytosol where they manipulate host cell functions and promote bacterial survival. In 
Chapters 5 and 6 of this dissertation, I have characterized how the host proteome is changed 
directly throughout infection with C. trachomatis. Using both quantitative mass spectrometry in 
conjunction with gain-of-function screening approaches, I identified hundreds of host proteins 
that are altered in their levels or stability during infection. One question that remains to be 
answered however, is whether any of these changes are directly mediated by individual C. 
trachomatis effectors.  
 As discussed previously, genetic manipulation of C. trachomatis has remained limited, 
with investigators now resorting to EMS-induced mutatgenesis to create loss-of-function strains 
of C. trachomatis. This approach is time consuming and does not guarentee successful 
generation of loss-of-function alleles. An alternative approach to characterize the function of 
unknown effector proteins is to use gain-of-function analyses and individually express 
Chlamydia effector proteins in host cells. This allows investigators to then examine the impact of 
specific virulence proteins on particular host phenotypes. We hypothesized that we could adapt 
the GPS reporter cell lines, that shift in EGFP:DsRed ratio following C. trachomatis infection, to 
identify effector proteins responsible for the underlying host protein alterations. If a particular 
bacterial effector targets a host protein or family of host proteins in the GPS validation screen, 
then the EGFP:DsRed should shift when the effector is expresed independently of infection. 
This approach would allow rapid screening by flow cytometry, to identify the function of effectors 
with unknown function. 
 As a proof-of-principle of this concept, we used this approach to identify host targets of 
two Chlamydia proteins known to have access to the cytosol, CrpA and Cap1. Previous work in 
our lab has described that both of these Chlamydia derived proteins are secreted into the host 
cytosol where they can stimulate CD8+ T cell responses. Unfortunately, while we have 
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characterized the immune response to these effector proteins in great detail, the molecular 
function of each bacterial protein remains entirely uncharacterized. The Experiments that follow 
serve as preliminary data suggesting further use of the GPS screening platform to identify 
individual host protein/bacterial effector interactions, allowing us to better understand 
mechanisms used by Chlamydia to infect and alter host cells for intracellular survival. 
Results 
The Chlamydia effector CrpA destabilizes the host protein BNIP3L  
Both SILAC and GPS identified host proteins that are altered during infection and are 
necessary for normal replication. One shortcoming of these analyses is the lack of insight into 
which, if any, C. trachomatis proteins directly alter host proteins. We speculated that a single 
Chlamydia virulence factor might be able to recapitulate some of the changes in host protein 
stability identified by SILAC and GPS. Previously, our lab has identified two Chlamydia proteins, 
Cap1 and CrpA, that gain access to the host cytosol and stimulate CD8+ T cell responses, but 
their functions remain undescribed (1, 2). Since we created individual reporter constructs for 
over 100 host proteins that are altered following infection (such as those in Chapter 6), we then 
used those constructs to examine whether the expression of either Cap1 or CrpA alone was 
sufficient to recapitulate the EGFP:DsRed ratio shift of individual host-protein reporter lines 
observed when the cells were infected with C. trachomatis.  We transfected vector alone, Cap1, 
or CrpA into host reporter cell lines and 24 hours later examined the EGFP:DsRed ratio by high-
throughput 96 well-plate flow cytometry. We then overlayed the plots and saw a distinct 
destabilization with one host protein, BNIP3L, only in the presence of CrpA (Figure B-1A). 
Unfortunately, we did not see any host proteins shift under any circumstances in the presence of 
Cap1 (Figure B-1B).  
To examine C. trachomatis-induced degradation of BNIP3L we first confirmed that 
BNIP3L is destabilized following infection with C. trachomatis (Figure B-1C). We then tested  












Figure B-1. Gain-of-function screen identifies BNIP3L and BNIP3 as targets of the 
secreted Chlamydia virulence factor CrpA. 
A) A subset GPS hits were tested in 293T cells using flow cytometry. Cells were mock-
transfected (red line) or transfected with CrpA (blue line) for 24 hours. 
B) A subset GPS hits were tested in 293T cells using flow cytometry. Cells were mock-
transfected (red line) or transfected with Cap1 (blue line) for 24 hours. 
C) HeLa cells were mock-infected or infected with C. trachomatis for the indicated timepoints. 
Cells were analyzed by immunoblot for levels of BNIP3L and Tubulin (loading control). 
D) HeLa cells expressing EGFP or CrpA-EGFP were analyzed by immunoblot for levels of 
BNIP3L and Tubulin (loading control).  
E) HeLa cells were mock-infected or infected and transfected with a BNIP3L or DC-BNIP3L. 
Twenty-four hours after infection cells were analyzed by immunoblot for levels of BNIP3L (myc-
tag) and Actin (loading control). 
F) HeLa cells expressing EGFP or CrpA-EGFP were analyzed by immunoblot for levels of 
BNIP3, Puma, BAD and Actin (loading control). 
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whether cells stably expressing the fusion protein, CrpA-EGFP or EGFP alone would alter 
levels of BNIP3L in host cells. We first examined the levels of endogenous BNIP3L.  As 
shown in Figure B-1D, cells expressing CrpA-EGFP had lower levels of monomeric BNIP3L 
and no detectable levels of dimeric BNIP3L when compared to EGFP alone.  These data 
confirm our gain-of-function screen, suggesting that CrpA decreases the levels of BNIP3L in 
host cells.  
BNIP3L contains a putative BH3 domain similar to other pro-apoptotic proteins such 
as BAD and PUMA (3).  To determine whether CrpA-induced degradation of BNIP3L 
depends upon an intact BH3 domain, we deleted the C-terminus of BNIP3L (up to and 
including the BH3 domain) and examined the ability of CrpA to specifically degrade the 
truncated construct. First, we confirmed that expression of a myc-tagged version of full-
length BNIP3L in the presence or absence of CrpA recapitulated our results seen at the 
endogenous levels of expression. Similar to our previous results we observed a significant 
degradation for full-length BNIP3L-myc in the presence of CrpA-EGFP (Figure B-1E). In 
contrast levels of BNIP3LΔC-myc were similar regardless of coexpression with CrpA-EGFP 
or EGFP in the cells (Figure B-1E).  These results suggest that CrpA induces the 
degradation of BNIP3L in a manner that requires the presence of the BH3 domain.  
The observation that CrpA-induced degradation of BNIP3L is sensitive to the presence 
of the BH3 domain led us to speculate that CrpA may also alter the closely related protein 
BNIP3, or more generally alter BH3-containing factors, such as Puma and BAD. We tested 
whether cells stably expressing CrpA-EGFP exhibited lower levels of BNIP3, Puma and Bad 
compared to control cells stably expressing EGFP alone.  Interestingly, levels of Puma and 
BAD were indistinguishable in these cell lines (Figure B-1F) yet the levels of BNIP3 were 
decreased in the presence of CrpA. This observation, that CrpA does not universally degrade 
members of the BH3 family of proteins, suggests that this virulence factor does not be globally 
alter host proteins during infection but may specifically target a host cell process. 
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CrpA alters the cellular response to hypoxia   
Recent work has elucidated a role for BNIP3 and BNIP3L in controlling the balance 
between autophagy and apoptosis under hypoxic conditions (4, 5). These studies showed that 
loss of both BNIP3 and BNIP3L leads to the prevention of autophagy under hypoxia while 
increasing cellular apoptosis. Hypoxia has recently become of interest to those studying C. 
trachomatis, as it now appears that hypoxia has a beneficial effect on C. trachomatis growth 
(6). 
We next examined whether CrpA was able to alter the cellular response to hypoxia. 
Several studies have shown that the basal levels of BNIP3 and BNIP3L in host cells are low 
under normoxic conditions (4, 5). However, shortly after cells sense hypoxia, BNIP3 and 
BNIP3L are strongly induced in a HIF1α-dependent manner. A recent study showed that C. 
trachomatis induces a hypoxic-like response during infection that relies on the transcription 
factor HIF1α and is critical for C. trachomatis induced apoptosis resistance (7). We 
hypothesized that the effect of CrpA on BNIP3 and BNIP3L would be exacerbated under 
simulated hypoxic conditions that occur normally during infection. We treated stable cell lines 
expressing CrpA-EGFP or EGFP alone with cobalt chloride to mimic the hypoxic response 
and examined the cells 6 hours later. We found the levels of both monomeric BNIP3 and 
BNIP3L were strikingly higher in EGFP control cells (Figure B-2A). We also detected a strong 
dimer of BNIP3L following treatment, but never reliably detected BNIP3 dimers. This 
suggested that under hypoxia, as in normoxia, the level of BNIP3 was dramatically lower in 
the presence of CrpA.  Surprisingly, the levels of monomeric BNIP3L were elevated following 
treatment, albeit consistently lower than EGFP controls. However, we never identified the 
dimeric BNIP3L in cells expressing CrpA. Twelve hours post-treatment the results were more 
robust and consistent with our previous findings.  These data suggest that under simulated 
hypoxic conditions, CrpA efficiently removes BNIP3 and BNIP3L from host cells and prevents  
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Figure B-2. CrpA alters the hypoxic response in cells. 
A) HeLa cells expressing EGFP or CrpA-EGFP were subjected to conditions mimicking hypoxia 
using CoCl2 for the indicated amount of time time. Cells were then analyzed by immunoblot for 
BNIP3, BNIP3L and Tubulin (loading control). 
B) HeLa cells expressing EGFP or CrpA-EGFP were placed under normoxia or hypoxia-like 
conditions for 12 hours. Cells were stained with Live/Dead dye (Aqua fixable Dead Cell stain kit) 
and examined by flow cytometry. The graph shows the percent cell death for triplicate samples 
+/- the standard deviation (**p<.01) (n=3). 
C) Left: HeLa cells expressing EGFP or CrpA-EGFP were subjected to normoxia or hypoxia-like 
conditions for 12 hours. Bafilomycin A was then added to the cultures and 20 minutes later the 
cells were analyzed by immunoblot for LC3I and LC3II. Right: Semi-quantitative determination 
of the LC3II/LC3I ratio. The graph shows the mean LC3II/LC3I ratio from triplicate samples +/- 
the standard deviation (*P<.05) (n=2). 
D) HeLa cells expressing EGFP or CrpA-EGFP were infected with C. trachomatis, and 2 hours 
later cells were placed under normoxia or hypoxia-like conditions. Thirty-six hours post-infection 
the levels of C. trachomatis were examined using qPCR of the 16s gene. The graph shows the 
mean levels of C. trachomatis for triplicate samples +/- the standard deviation (**P<.01) (n=3). 
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dimerization of these host proteins. 
A recent study has shown that loss of BNIP3 and BNIP3L simultaneously leads to higher 
levels of cell death. We reasoned that since CrpA removed BNIP3 and BNIP3L following 
hypoxia induction, cells expressing CrpA should also have higher levels of cell death under 
hypoxic conditions. To test this we examined the levels of cell death under normoxic and 
hypoxic conditions in cells expressing CrpA or Control cells. Under normoxic conditions, levels 
of cell death were similar between control cells and cells expressing CrpA (Figure B-2B). 
However following the addition of CoCl2, cells expressing CrpA had two-fold higher levels of cell 
death, while control cells remained relatively unchanged. These data suggest that the removal 
of BNIP3 and BNIP3L by CrpA under hypoxic conditions may serve to inhibit the induction of 
autophagy, but at a cost of higher levels of cell death. To confirm that cells expressing CrpA are 
unable to induce autophagy under hypoxic conditions we examined the levels of the autophagy-
activated protein LC3II. We compared the levels of LC3II in control cells and cells expressing 
CrpA following hypoxia induction. As shown in Figure B-2C control cells had elevated levels of 
LC3II following hypoxia induction while cells expressing CrpA had lower levels of LC3II under 
hypoxic conditions. These data confirm the hypothesis that CrpA prevents the efficient induction 
of autophagy under hypoxia, and biases the cells towards cell death.  
To date it has not been easy to create targeted mutations in C. trachomatis. Therefore it 
is extremely difficult to examine how loss-of-function mutants alter C. trachomatis growth. 
Because of this limitation we examined whether the overexpression of CrpA would alter the 
growth of C. trachomatis under normoxic or hypoxic conditions. We hypothesized that under 
hypoxic conditions, since the overexpression of CrpA pushes the host cell strongly towards cell 
death, C. trachomatis growth may be inhibited due to the loss of its essential intracellular niche. 
We infected cells overexpressing CrpA or control cells with C. trachomatis. 2 hours following 
infection, we induced hypoxic-like conditions by adding media containing CoCl2. Thirty-six hours 
post-infection we examined the levels of C. trachomatis by qPCR. When we compared levels of 
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C. trachomatis in control cells or cells expressing CrpA, we found they were almost identical 
(Figure B-2D). Surprisingly, we found that the presence of CrpA inhibited C. trachomatis growth 
over ten times more than control cells under hypoxic-like conditions.  These data confirm that 
CrpA alters the cellular hypoxic response. Furthermore, when CrpA is overexpressed during 
infection, it can significantly inhibit the ability of C. trachomatis to grow under hypoxic-like 
conditions. 
Discussion 
One question that our screens alone do not answer is which host protein alterations 
are directly caused by C. trachomatis effectors and which are induced indirectly. Here we 
found that the C. trachomatis effector CrpA destabilizes the host proteins BNIP3L and BNIP3. 
CrpA did not alter any other BH3 domain proteins we examined, suggesting that CrpA directly 
targets BNIP3 and BNIP3L.  
 Recent work has characterized BNIP3 and BNIP3L as critical mediators of the balance 
between autophagy and cell death under hypoxic conditions (5). Loss of BNIP3 and BNIP3L 
prevents hypoxia-induced autophagy in cells and promotes apoptosis. Genital strains of C. 
trachomatis infect the upper genital tract where oxygen levels are less than 5%. One group 
recently showed that hypoxia protects C. trachomatis from IFNγ-mediated growth restriction 
that would occur under normoxia (6). Furthermore, a recent study examining host factors 
required for C. trachomatis-induced prevention of apoptosis showed that HIF1α is activated in 
cells as early as 12 hours post-infection (7). Two proteins that are strongly upregulated in 
response to HIF1α activity are BNIP3 and BNIP3L. Here we show that the C. trachomatis 
effector CrpA alters the protein levels of both BNIP3 and BNIP3L, and that this effect is 
exacerbated under hypoxia-like conditions. The loss of BNIP3 and BNIP3L in hypoxic 
conditions prevents the efficient induction of autophagy, where autophagy is a factor 
restricting C. trachomatis growth (8). By preventing autophagy during hypoxia, cells would be 
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pushed towards death by apoptosis. However, it has been clearly demonstrated that C. 
trachomatis has factors which prevent apoptosis and necrosis during infection (9). Our data 
here show that overexpression of CrpA during infection leads to significantly reduced C. 
trachomatis growth under hypoxia-like conditions. We speculate that the overexpression of 
CrpA overwhelms the C. trachomatis effectors that normally prevent cell death. Unfortunately, 
we are not currently able to examine how the loss of CrpA would alter the growth of C. 
trachomatis during hypoxia. While several recent advances have been made in the genetic 
manipulation of C. trachomatis, it is still unclear whether a mutant C. trachomatis lacking CrpA 
can be constructed (10-12).  
In the absence of loss-of-function mutants, our current study highlights the potential 
use of gain-of-function analyses to identify effector-host substrate pairs and to identify specific 
host pathways manipulated during infection. With the function of the majority of C. trachomatis 
effectors unknown, the catalog of altered proteins we have generated now allows for testing 
individual effectors for their ability to recapitulate an alteration we found occurring during 
infection. While this study has identified a large number of protein alterations, it is almost 
certainly incomplete. Here we have examined the stability of individual proteins and identified 
changes in host protein levels following infection. Many effectors however, may not directly 
alter host protein stability. In these cases our current list of altered proteins would not include 
the host substrate. Our study must also be refined to identify host protein alterations that are 
directly caused by C. trachomatis and those that are a result of indirect causes. There is also 
a need to develop screens able to identify other post-translational modifications induced by C. 
trachomatis. Major advances in proteomics have allowed systems-level understanding of 
changes in phosphorylation, ubiquitination, and lysine acetylation, and similar screens could 
be used to identify the individual C. trachomatis effectors driving those changes (13-15). 
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Appendix C: Supplementary Tables Associated with Chapters 5 and 6 
 
Table S5-1 SILAC Dataset 
 
Worksheet 1   SILAC data 4 hours post-infection 
 
Worksheet 2  SILAC data 14 hours post-infection 
 
Worksheet 3  SILAC data 24 hours post-infection (Replicate #1) 
 
Worksheet 4  SILAC data 24 hours post-infection (Replicate #2) 
 
Worksheet 5  24 hour SILAC Replicate overlap analysis 
 
Worksheet 6  Transcriptional microarray data 
 
Table S5-2  DAVID analysis of enriched host protein networks from 
SILAC data 
 
Table S5-3  Gain-of-Function Screen dataset 
 
Worksheet 1  Gain-of-function screen data for experimental proteins.  
 
Worksheet 2  Gain-of-function screen data for control proteins 
 
Table S6-1 GPS validation summary, Screen data, and Probe info  
 
Worksheet1  GPS screen Validation summary  
 
Worksheet 2  Merged GPS data for each probe to positive hits in GPS screen  
 
Worksheet 3  Raw GPS Screen Data 
 
Worksheet 4   Sequence information for each probe present in the 
library/microarrays. 
 
Table S6-2  Bioinformatics analysis summary. 
 
Worksheet 1  DAVID analysis of stabilized proteins in the GPS screen 
 
Worksheet 2  DAVID analysis of destabilized proteins in the GPS screen. 
 
Table S6-3  Log2 Ratios for growth in Loss-of-Function screen 
(Experimentals and Controls) 
 
Worksheet 1  siRNA screen full data (experimentals) 
 
Worksheet 2  siRNA Controls 
 
Table S6-4  Customized Macro for plotting GPS histograms 
